



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> :  C12N 15/00		A2	(11) International Publication Number: <b>WO 99/53047</b>
			(43) International Publication Date: 21 October 1999 (21.10.99)
<p>(21) International Application Number: PCT/US99/08220</p> <p>(22) International Filing Date: 15 April 1999 (15.04.99)</p> <p>(30) Priority Data: 60/081,882 15 April 1998 (15.04.98) US</p> <p>(71) Applicant (for all designated States except US): UNIVERSITY OF SASKATCHEWAN [CA/CA]; 120 Veterinary Road, Saskatoon, Saskatchewan S7N 5E3 (CA).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): REDDY, Police, Seshidhar [CA/US]; Apartment #1, 722 Clopper Road, Gaithersburg, MD 20878 (US). TIKOO, Suresh, Kumar [CA/CA]; 302 102 Edinburgh Place, Saskatoon, Saskatchewan S7H 5J7 (CA). BABIUK, Lorne, A. [CA/CA]; 245 East Place, Saskatoon, Saskatchewan S7J 2Y1 (CA).</p> <p>(74) Agents: BRENNAN, Sean, M. et al.; Morrison &amp; Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).</p>			<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> Without international search report and to be republished upon receipt of that report.</p>
<p>(54) Title: PORCINE ADENOVIRUS TYPE 3 GENOME</p>			
<p>(57) Abstract</p> <p>The complete nucleotide sequence of the genome of porcine adenovirus type 3 (PAV-3) is provided. Methods for construction of infectious PAV genomes by homologous recombination in prokaryotic cells are provided. Recombinant PAV viruses are obtained by transfection of mammalian cells with recombinant PAV genomes. The PAV-3 genome can be used as a vector for the expression of heterologous nucleotide sequences, for example, for the preparation and administration of subunit vaccines to swine or other mammals. In addition, PAV-3 vectors can be used for gene therapy and expression of heterologous polypeptides. PAV-3 genome sequences can also be used for diagnostic purposes, to detect the presence of PAV-3 DNA in a subject or biological sample.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## PORCINE ADENOVIRUS TYPE 3 GENOME

### TECHNICAL FIELD

10 The present invention is in the field of recombinant mammalian viral vectors. More particularly, it concerns recombinant porcine adenovirus vectors for diagnostic and therapeutic purposes, such as vaccines and expression systems.

### BACKGROUND

15 Adenoviruses are double-stranded DNA viruses that have been isolated from a wide variety of avian and mammalian species, including swine. While the majority of adenovirus infections in swine are subclinical, porcine adenovirus (PAV) infection has been associated with encephalitis, pneumonia, kidney lesions and diarrhea. Derbyshire (1992) In: "Diseases of Swine" (ed. Leman *et al.*), 7th edition, Iowa State University Press, Ames, IA. pp. 225-227. Thus, there is a 20 need for vaccines that will provide protection against PAV infection.

25 In addition to their potential ability to provide protection against PAV infection, PAVs could also be used as viral vaccine vectors, if insertion capacity can be determined, and appropriate insertion sites can be defined and characterized. It has been shown that PAV is capable of stimulating both humoral response and a mucosal antibody responses in the intestine of infected piglets.

Tuboly *et al.* (1993) *Res. in Vet. Sci.* **54**:345-350. Thus, recombinant PAV vaccine vectors would be especially useful, as they would be likely to be capable of providing both systemic and mucosal immunity to antigens encoded by native and/or recombinant PAV genomes.

30 Cross-neutralization studies have indicated the existence of at least five serotypes of PAV. Derbyshire *et al.* (1975) *J. Comp. Pathol.* **85**:437-443; and

Hirahara *et al.* (1990) *Jpn. J. Vet. Sci.* **52**:407-409. Previous studies of the PAV genome have included the determination of restriction maps for PAV Type 3 (PAV-3) and cloning of restriction fragments representing the complete genome of PAV-3. Reddy *et al.* (1993) *Intervirology* **36**:161-168. In addition, restriction maps for PAV-1 and PAV-2 have been determined. Reddy *et al.* (1995b) *Arch. Virol.* **140**:195-200.

Nucleotide sequences have been determined for segments of the genome of various PAV serotypes. Sequences of the E3, pVIII and fiber genes of PAV-3 were determined by Reddy *et al.* (1995a) *Virus Res.* **36**:97-106. The E3, pVIII and fiber genes of PAV-1 and PAV-2 were sequenced by Reddy *et al.* (1996) *Virus Res.* **43**:99-109; while the PAV-4 E3, pVIII and fiber gene sequences were determined by Kleiboecker (1994) *Virus Res.* **31**:17-25. The PAV-4 fiber gene sequence was determined by Kleiboecker (1995b) *Virus Res.* **39**:299-309. Inverted terminal repeat (ITR) sequences for all five PAV serotypes (PAV-1 through PAV-5) were determined by Reddy *et al.* (1995c) *Virology* **212**:237-239. The PAV-3 penton sequence was determined by McCoy *et al.* (1996a) *Arch. Virol.* **141**:1367-1375. The nucleotide sequence of the E1 region of PAV-4 was determined by Kleiboecker (1995a) *Virus Res.* **36**:259-268. The sequence of the protease (23K) gene of PAV-3 was determined by McCoy *et al.* (1996b) *DNA Seq.* **6**:251-254. The unpublished sequence of the PAV-3 hexon gene (and the 14 N-terminal codons of the 23K protease gene) has been deposited in the GenBank database under accession No. U34592. The unpublished sequence of the PAV-3 100K gene has been deposited in the GenBank database under accession No. U82628. The sequence of the PAV-3 E4 region has been determined by Reddy *et al.* (1997) *Virus Genes* **15**:87-90.

Adenoviruses have proven to be effective vectors for the delivery and expression of foreign genes in a number of specific applications, and have a number of advantages as potential gene transfer and vaccine vectors. See Gerard *et al* (1993) *Trends Cardiovasc. Med.* **3**:171-177; Imler *et al.* (1995) *Hum. Gene Ther.* **6**:711-721. The ability of these vectors to mediate the efficient expression

of candidate therapeutic or vaccine genes in a variety of cell types, including post mitotic cells, is considered an advantage over other gene transfer vectors.

Adenoviral vectors are divided into helper-independent and helper-dependent groups based on the region of the adenoviral genome used for the insertion of transgenes. Helper-dependent vectors are usually made by deletion of E1 sequences and substitution of foreign DNA, and are produced in complementing human cell lines that constitutively express E1 proteins. Graham *et al.* (1977) *J. Gen. Virol.* **36**:59-74; Fallaux *et al.* (1996) *Hum. Gene Ther.* **7**:215-222; Fallaux *et al.* (1998) *Hum. Gene Ther.* **9**:1909-1917. However, porcine adenoviruses do not replicate in human cell lines; hence these lines are unsuitable for the propagation of E1-deleted PAV vectors.

Though E1-deleted viruses do not replicate in cells that do not express E1 proteins, the viruses can express foreign proteins in these cells, provided the genes are placed under the control of a constitutive promoter. Xiang *et al.* (1996) *Virology* **219**:220-227. Vaccination of animals with adenovirus recombinants containing inserts in the E1 region induced a systemic immune response and provided protection against subsequent challenge. Imler *et al.* (1995) *Hum. Gene Ther.* **6**:711-721; Imler *et al.* (1996) *Gene Therap* **3**:75-84.. This type of expression vector provides a significant safety profile to the vaccine as it eliminates the potential for dissemination of the vector within the vaccinee and therefore, the spread of the vector to nonvaccinated contacts or to the general environment. However, the currently used human adenovirus (HAV) based vectors are endemic in most populations, which provides an opportunity for recombination between the helper-dependent viral vectors and wild type viruses.

To circumvent some of the problems associated with the use of human adenoviruses, non human adenoviruses have been explored as possible expression vectors. All vectors developed to date, except one (Klonjkowski *et al* (1997) *Hum. Gene Ther.* **8**:2103-2115), contain an intact E1 region. Use of such vectors for gene therapy in humans and vaccination in animals is unsafe because they

have the ability to replicate in normal cells, and they retain the oncogenic potential of the E1 region.

Recombinant PAV genomes containing heterologous nucleotide sequences have not yet been described. Similarly, sites where insertion of heterologous sequence would not interfere with the ability of a PAV vector to stimulate an immune response against a determinant encoded by an inserted sequence have not been identified. Consequently, the development of effective recombinant PAV vectors for use in immunization, expression systems and gene therapy, awaits resolution of these issues. Similarly, there is a need for improved adenoviral vectors lacking E1 replication and oncogenic functions, for expression of transgenes in mammalian cells.

#### SUMMARY OF THE INVENTION

The present invention provides the complete nucleotide sequence of the porcine adenovirus type 3 (PAV-3) genome. Nucleic acid sequences that are substantially homologous to those comprising a PAV genome are also encompassed by the invention. Substantially homologous sequences include those capable of duplex and/or triplex formation with a nucleic acid comprising all or part of a PAV genome (or with its complement). As is known to those of skill in the art, duplex formation is influenced by hybridization conditions, particularly hybridization stringency. Factors affecting hybridization stringency are well-known to those of skill in the art. *See, for example, Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual; Hames et al. 1985) Nucleic Acid Hybridisation: A Practical Approach, IRL Press Ltd., Oxford* Accordingly, it is within the skill of the art to identify a sequence that is substantially homologous to a sequence from a PAV genome.

In addition, novel porcine adenovirus (PAV) expression vector systems comprising PAV genome sequences are disclosed herein. The PAV-3 sequence includes regions into which heterologous sequences can be inserted including, but not limited to, the E1, E3 and E4 regions, and the region between E4 and the right

end of the genome. The invention also provides non-essential regions which can be deleted to increase the capacity of a PAV vector for inserted heterologous sequences. These include, but are not limited to, the E3 and E4 regions, and the region between E4 and the right end of the genome. Essential regions, such as E1, 5 can also be deleted, if virus bearing such deletions are propagated in helper cell lines supplying the deleted essential function. Thus, PAV genome sequences can be replaced by one or more foreign genes to generate recombinant PAV vectors expressing heterologous antigenic polypeptides (or antigenic fragments thereof) for the purposes of producing live recombinant virus, subunit vaccines, nucleic 10 acid immunization, or other types of therapy. Multiple heterologous sequences can be inserted into the same, or different, locations in the genome, limited only by the capacity of the virus to accept heterologous sequences. This capacity can be expanded by deletion of viral sequences.

15 In addition, the invention provides PAV transcriptional and translational regulatory sequences which can be used for expression of heterologous genes that have been inserted into the vectors of the invention. Furthermore, the novel sequences of the present invention can be used for diagnostic purposes, to determine the presence of PAV antigens and/or PAV nucleic acids in a subject or biological sample.

20 In additional embodiments, the invention provides compositions providing immunity to PAV infection, through expression of antigenic PAV polypeptides. The invention also provides vectors comprising PAV genome sequences, including sequences encoding various PAV genes as well as PAV regulatory sequences, which are useful for controlling the expression of heterologous genes 25 inserted into PAV vectors.

30 The invention provides defective recombinant PAV vectors that are deleted in their E1 region, as well as helper cell lines providing E1 function, in which such defective vectors can be propagated. Because these defective vectors replicate inefficiently in cells other than the helper cells, they are less likely to stimulate an immune response in a mammalian host. This makes them

particularly suitable for use as vaccine vectors. In addition, since the amount of nucleic acid that can be packaged into an adenovirus virion is limited, deletion of the E1 region expands the capacity of these defective vectors, enabling them to accept larger inserts of heterologous sequence. Additional deletions in other 5 regions of the genome can be used to expand the capacity of these defective vectors still further.

The invention further provides methods for obtaining recombinant PAV vectors. In a preferred embodiment, heterologous nucleotide sequences are introduced, through recombinant DNA techniques, into a bacterial plasmid 10 comprising a defined portion of the PAV genome. The recombinant plasmid, containing heterologous sequences flanked by PAV sequences, is introduced into a host cell in combination with a full-length PAV genome or a plasmid containing a full-length or nearly full-length PAV genome. Within the host cell, recombination between the plasmid and the PAV genome generates a recombinant 15 PAV genome. Alternatively, recombinant PAV genomes can be constructed *in vitro*, using standard techniques in molecular biology and biotechnology.

The invention also provides methods for preparing live recombinant virus and subunit vaccines for inducing protective immune responses to an infectious organism in a mammalian subject. Protective immune responses include humoral 20 (antibody) responses, cell-mediated responses, mucosal responses, or any combination of these. The methods involve insertion, into the porcine adenovirus genome, of heterologous nucleotide sequences encoding one or more protective antigenic determinants of a pathogen. The heterologous sequences are inserted in such a way as to come under the regulatory control of a PAV promoter, or the 25 heterologous sequences are inserted in operative linkage to a eukaryotic transcriptional regulatory sequence. Translation of transcribed heterologous sequences can be controlled by PAV translational regulatory elements, or the heterologous sequence can include non-PAV sequences which regulate its translation.

In another aspect, the invention includes the use of recombinant porcine adenoviruses and recombinant PAV vectors for the expression of a nucleotide or amino acid sequence of interest in a cell system, such as, for example, production of antigen to be used in the preparation of antibodies, or production of antisense 5 RNA.

The invention also includes an expression system comprising a porcine adenovirus expression vector wherein heterologous nucleotide sequences are inserted. The inserted heterologous sequences can comprise one or more regulatory elements for transcription and/or translation, or can be inserted so as to 10 come under the control of PAV regulatory elements. Inserted regulatory elements can be those that are normally associated with the heterologous sequence, or a heterologous sequence can be juxtaposed to and placed in operative linkage with a regulatory element with which it is not normally associated, using standard recombinant DNA techniques. Heterologous sequences can be inserted into a 15 full-length PAV genome, or into a PAV genome which has been deleted in one or more regions. A deletion in the PAV genome can be made to provide a site for insertion of a heterologous sequence, or simply to increase the capacity of the PAV vector to accommodate heterologous sequences inserted at another location.

The invention also provides recombinant PAV polypeptides including, but 20 not limited to, those encoded by the following genes: E1A, E1B, E4, pIX, DBP, pTP, pol, IVa2, 52K, IIIA, pIII, pVII, pV, pX, pVI, and 33K. Such recombinant PAV polypeptides are produced in any eukaryotic expression vector known in the art, into which is inserted a PAV nucleotide sequence according to the invention. Also provided are methods and compositions for recombinant production of 25 heterologous polypeptides and RNAs in a PAV vector. Expression of heterologous polypeptides and RNAs in a PAV vector can be regulated by endogenous PAV regulatory sequences, or by non-PAV sequences. Non-PAV regulatory sequences can be those which normally regulate the heterologous sequence, or they can be sequences that are not normally associated with the 30 heterologous sequence in a regulatory capacity.

Thus, in one embodiment, the invention includes an expression system in which one or more regions of the PAV genome are deleted and replaced with heterologous sequences. In another embodiment, the invention includes a PAV expression system in which heterologous sequences are introduced into the PAV genome without the removal of any PAV sequences. Intergenic regions of the PAV genome comprising regulatory sequences are useful in the practice of the invention for controlling the expression of homologous and heterologous sequences.

The invention also includes recombinant vector systems comprising two or more nucleic acid molecules. In one embodiment, the vector system comprises two plasmids, the first containing a full-length or nearly full-length PAV genome and the second containing a segment of the PAV genome, such as the left end (including the E1 region) or the right end (including the E3 and/or E4 regions). Introduction of heterologous nucleotide sequences into the second plasmid, followed by co-transfection of both plasmids into a suitable host cell, will allow homologous recombination between the two plasmids to generate a viral genome containing inserted heterologous sequences. In another embodiment, the vector system comprises a full-length or nearly full-length PAV genome and a plasmid containing a segment of the PAV genome. Insertion of heterologous sequences into the plasmid, followed by co-transfection and homologous recombination, will generate recombinant PAV genomes as above.

Additional aspects of the invention provide a recombinant PAV comprising a heterologous sequence wherein the heterologous sequence encodes an antigenic determinant of a disease-causing organism; and a recombinant PAV comprising a heterologous sequence wherein the heterologous sequence encodes a foreign gene or fragment thereof. In further embodiments, the invention provides pharmaceutical compositions comprising recombinant PAV for producing an immune response in a mammalian host, the recombinant PAV comprising a heterologous nucleotide sequence encoding a protective determinant of a pathogenic organism. The heterologous sequence is expressed in quantities

sufficient for induction of a protective immune response, either through operative linkage to one or more non-PAV regulatory sequences, or through control by endogenous PAV regulatory sequences. The protective immune response can be humoral, cell-mediated and/or mucosal.

5        The recombinant PAV vectors of the invention will also allow the expression of various therapeutic polypeptides in a wide range of mammalian hosts and are thus useful in the practices of nucleic acid immunization and gene therapy. Exemplary hosts include, but are not limited to, human, equine, bovine, porcine, ovine, caprine, avian, and murine. Those of skill in the art are aware of 10 various therapeutic polypeptides which can be usefully expressed in mammalian hosts. Such therapeutic polypeptides include, but are not limited to, coagulation factors, growth hormones, cytokines, lymphokines, tumor-suppressing polypeptides, cell receptors, ligands for cell receptors, protease inhibitors, antibodies, toxins, immunotoxins, dystrophins, cystic fibrosis transmembrane 15 conductance regulator (CFTR) and immunogenic polypeptides.

10       The invention also provides diagnostic methods and compositions for the detection of PAV nucleic acids and proteins in a cell or biological sample. The PAV nucleotide sequences disclosed herein can be used as hybridization probes to detect PAV nucleic acids. In addition, the PAV nucleotide sequences disclosed 20 herein encode PAV polypeptides, which can be used for the production of antibodies reactive with various PAV antigens. Such antibodies can be used to detect PAV antigens by immunoassay. Alternatively, PAV polypeptides themselves can be used in competitive immunoassays to detect the presence of 25 PAV antigens in a cell or biological sample. PAV polypeptides can be produced by the PAV vectors of the invention, or can be produced in any mammalian expression vector known in the art.

#### BRIEF DESCRIPTION OF THE DRAWINGS

15       **Figure 1** shows the complete nucleotide sequence of the PAV-3 genome 30 (SEQ ID NO: 1).

**Figure 2** shows the transcriptional map of the PAV-3 genome derived from alignment of the sequences of cDNA clones with the genomic sequence, and nuclease protection mapping of viral transcripts. The PAV-3 genome is represented by the thick horizontal line, with the numbers below the line representing PAV-3 map units (*i.e.*, percentage of genome length from the left end). Rightward-reading transcription units are depicted above the line and leftward-reading transcription units are shown below the line.

**Figure 3** shows immunoprecipitation of E1A and E1B proteins from various cell lines.

10 In Figure 3A, proteins in cell lysates were separated by gel electrophoresis, and analyzed by immunoblotting using the DP11 monoclonal antibody, which recognizes the human adenovirus E1A protein. Lane 1: 293 cells (human cells transformed by HAV-5, which express adenovirus E1A and E1B); Lane 2: Fetal porcine retinal cells; Lane 3: VIDO R1 cells; Lane 4: 293 cells.

15 In Figure 3B, proteins in cell lysates were separated by gel electrophoresis, and analyzed by immunoblotting using the DP17 monoclonal antibody, which recognizes the human adenovirus E1B protein. Lane 1: human 293 cells; Lane 2: Fetal porcine retinal cells; Lane 3: VIDO R1 cells; Lane 4: 293 cells.

20 **Figure 4** shows a map of the plasmid pPAV-101.

**Figure 5** shows a map of the plasmid pPAV-102.

**Figure 6** shows a map of the plasmid pPAV-300.

25 **Figure 7** shows proteins labeled after infection of VIDO R1 cells with a recombinant PAV containing the PRV gp50 gene inserted in the E3 region. Labeled proteins were separated by gel electrophoresis; an autoradiogram of the gel is shown. Lane 1: Molecular weight markers of 30K, 46K, 69K and 96K, in order of increasing molecular weight. Lane 2: Mock-infected cells, 12 hours post-infection. Lane 3: PAV-3-infected cells, 12 hours post-infection. Lane 4: cells infected with a recombinant PAV containing the PRV gp50 gene, 12 hours post-infection. Lane 5: cells infected with a recombinant PAV containing the PRV

gp50 gene, 16 hours post-infection. Lane 6: cells infected with a recombinant PAV containing the PRV gp50 gene, 24 hours post-infection.

**Figure 8** provides a schematic diagram of the construction of an E1- and E3-deleted PAV vector with a green fluorescent protein gene insertion.

5

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention provides the complete nucleotide sequence and transcriptional map of the porcine adenovirus type 3 (PAV-3) genome. The sequence comprises a linear, double-stranded DNA molecule of about 34,094 base pairs, as shown in Figure 1 (SEQ ID NO: 1). Previously-determined partial sequences can be aligned with the complete genomic sequence as shown in Table 1.

**Table 1. Alignment of published PAV-3 sequences**

GenBank Accession No.	PAV Gene(s) included within sequence	Reference	Genome coordinates
L43077	ITR	Reddy et al., 1995c	1-144
U24432	penton	McCoy et al., 1996a	13556-15283
U34592	hexon; N-terminal 14 codons of 23K (protease) gene	unpublished	19036-21896
U33016	protease (23K)	McCoy et al., 1996b	21897-22676
U82628	100K	unpublished	24056-26572
U10433	E3, pVIII, fiber	Reddy et al., 1995a	27089-31148
L43363	E4	Reddy et al., 1997	31064-34094

15 Knowledge of the PAV genome sequence is useful for both therapeutic and diagnostic procedures. Regions suitable for insertion and regulated expression of heterologous sequences have been identified. These regions include, but are not limited to the E1, E3 and E4 regions, and the region between the E4 region and the right end of the genome. A heterologous nucleotide

sequence, with respect to the PAV vectors of the invention, is one which is not normally associated with PAV sequences as part of the PAV genome.

Heterologous nucleotide sequences include synthetic sequences. Regions encoding immunogenic PAV polypeptides, for use in immunodiagnostic

5 procedures, have also been identified and are disclosed herein. These include the regions encoding the following PAV proteins: E1A, E1B, E4, pIX, DBP, pTP, pol, IVa2, 52K, IIIA, pIII, pVII, pV, pX, pVI, 33K, pVIII, hexon and fiber (see Table 2). Regions essential for viral replication, such as E1 and E2A, can be deleted to provide attenuated strains for use as vaccines. Nonessential regions, 10 such as parts of the E3 and E4 regions, can be deleted to provide insertion sites, or to provide additional capacity for insertion at a site other than the deleted region. Deletions of viral sequences can be obtained by any method known in the art, including but not limited to restriction enzyme digestion and ligation, oligonucleotide-mediated deletion mutagenesis, and the like.

15 The practice of the present invention employs, unless otherwise indicated, conventional microbiology, immunology, virology, molecular biology, and recombinant DNA techniques which are within the skill of the art. These techniques are fully explained in the literature. See, *e.g.*, Maniatis et al., *Molecular Cloning: A Laboratory Manual* (1982); *DNA Cloning: A Practical Approach*, vols. I & II (D. Glover, ed.); *Oligonucleotide Synthesis* (N. Gait, ed. 20 (1984)); *Nucleic Acid Hybridization* (B. Hames & S. Higgins, eds. (1985)); *Transcription and Translation* (B. Hames & S. Higgins, eds. (1984)); *Animal Cell Culture* (R. Freshney, ed. (1986)); Perbal, *A Practical Guide to Molecular Cloning* (1984); Ausubel, *et al.*, *Current Protocols In Molecular Biology*, John Wiley & Sons (1987, 1988, 1989, 1990, 1991, 1992, 1993, 1994, 1995, 1996); 25 and Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual* (2<sup>nd</sup> Edition); vols. I, II & III (1989).

**Nucleotide Sequence, Genome Organization, and Transcription Map  
of Porcine Adenovirus Type 3 (PAV-3).**

The complete nucleotide sequence of PAV-3 genome is 34,094 base pairs (bp) in length and has a base composition of 31.3% G, 32.5% C, 18.3% A, and 17.9% T. Thus, the sequence of the PAV-3 genome has a G+C content of 63.8%, which is unusually high when compared with the G+C content of many other animal adenoviruses. The genome termini share inverted terminal repeats (ITR) of 144 bp. Reddy *et al.*, 1995c, *supra*. The organization of the genome as determined by analysis of open reading frames (ORFs), nuclease protection mapping, and sequencing of cDNA clones, is summarized in Table 2 and Figure 2.

One important feature of PAV-3 genome is the presence of a short virion associated (VA) RNA gene between the splice acceptor sites of the precursor terminal protein (pTP) and 52 kDa protein genes (Figure 2). Expression of VA genes increases the kinetics of viral replication; thereby providing the potential for higher yields of recombinant gene products using the PAV vectors of the invention. The locations of the signature sequences present upstream and downstream of VA RNA genes indicate the VA RNA gene of PAV-3 is about 126 nucleotides (nt) in length. This is somewhat shorter than most VA RNAs, whose lengths are  $163 \pm 14$  nts, however shorter VA RNAs have also been reported in HAV-10 and CELO virus. Ma *et al.* (1996) *J. Virol.* **70**:5083-5099; and Chiocca *et al.* (1996) *J. Virol.* **70**:2939-2949. The VA RNA genes were not found in the genomes of BAV-3, CAV-1, and OAV. Reddy *et al.* (1998) *J. Virol.* **72**:1394-1402; Morrison *et al.* (1997) *J. Gen. Virol.* **78**:873-878; and Vrati *et al.* (1996) *Virology* **220**:186-199.

In PAV-3 the major late transcript initiates at 17.7 map units (m.u.: an adenovirus map unit is 1% of genome length, starting from the left end of the genome). There are six 3'-coterminal families of late mRNAs, denoted L1 to L6 (see Figure 2). All mRNAs produced from the major late promoter (MLP) contain a tripartite leader sequence (TPL). The first portion of the TPL lies next

to the MLP and is 61 nts long. The second portion lies within the gene coding for pol and is 68 nt in length. The third portion is 99 nts long and is located within the gene coding for pTP. Thus the TPL of PAV-3 is 228 nt long and is derived from three exons located at 17.7, 20.9, and 28.1 m.u.

5 The MLP and TPL sequences can be used for expression of a heterologous sequence in a recombinant PAV vector or in any other adenoviral expression system.

Table 2: Transcriptional and Translational Features of the PAV-3 Genome

Region	Gene	Transcription start site	ATG	Splice donor site	Splice acceptor site	Poly(A) signal	Poly(A) addition site
E1A	229R	heterogeneous	533			1286	1307
	214R		533	1043	1140	1286	1307
E1B	202R	1382	1461			4085	4110, 4112
	474R	1382	1829			4085	4110, 4112
pIX	Pix	3377	3394			4085	4110, 4112
E2A	DBP	17011c	24041c	26949c, 24714c	24793c, 24051c	22560c	22536c
E2B	PTP	17011c	13638c	24949c, 24714c	24793c, 13772c	4075c	4053c
	pol	17011c	13638c	24949c, 24714c	24793†c, 13772†c	4075c	4053c
IVa2	IVa2	5867c	5711c	5699c	5441c	4075c	4053c
E3		27473				28765	28793
E4		33730c				31189c	31170c
L1	52K	6064	10629	9684	10606	13601	13627
	III A	6064	11719	9684	11715	13601	13627
L2	pIII	6064	13662	9684	13662	15698*	15735
	pVII	6064	15170	9684	15139	15698*	15735
L3	pV	6064	15819	9684	15793	18992	19013
	pX	6064	17783	9684	17776	18992	19013
	pVI	6064	18076	9684	18063	18992	19013
L4	Hexon	6064	19097	9684	19096	22544	22567
	Protease	6064	21934	9684	21931†	22544	22567
L5	100k	6064	24056	9684	24056	28765	28793
	33K	6064	26181	9684	26130	28765	29793
	pVIII	6064	27089	9684	26792	28765	28793
L6	Fiber	6064	28939	9684	28910	31143	31164

**Notes:**

\* TTGTTT is present as a polyadenylation signal instead of AATAAA

† The splice acceptor sites for the *pol* and protease genes were determined based on consensus splice acceptor sequences

“c” refers to sequences on the complementary (leftward-reading) strand of the PAV genome.

### Construction of recombinant PAV vectors

In one embodiment of the invention, a recombinant PAV vector is constructed by *in vivo* recombination between a plasmid and a PAV genome. Generally, heterologous sequences are inserted into a plasmid vector containing a portion of the PAV genome, which may or may not possess one or more deletions of PAV sequences. The heterologous sequences are inserted into the PAV insert portion of the plasmid vector, such that the heterologous sequences are flanked by PAV sequences that are adjacent on the PAV genome. The PAV sequences serve as "guide sequences," to direct insertion of the heterologous sequences to a particular site in the PAV genome; the insertion site being defined by the genomic location of the guide sequences.

The vector is generally a bacterial plasmid, allowing multiple copies of the cloned sequence to be produced. In one embodiment, the plasmid is co-transfected, into an appropriate host cell, with a PAV genome comprising a full-length or nearly full-length PAV genomic sequence. The PAV genome can be isolated from PAV virions, or can comprise a PAV genome that has been inserted into a plasmid, using standard techniques of molecular biology and biotechnology. Construction of a plasmid containing a PAV genome is described in Example 2, *infra*. Nearly full-length PAV genomic sequences can be deleted in regions such as E1, E3, E4 and the region between E4 and the right end of the genome, but will retain sequences required for replication and packaging. PAV genomes can be deleted in essential regions if the essential function can be supplied by a helper cell line.

Insertion of the cloned heterologous sequences into a viral genome occurs by *in vivo* recombination between a plasmid vector (containing heterologous sequences flanked by PAV guide sequences) and a PAV genome following co-transfection into a suitable host cell. The PAV genome contains inverted terminal repeat (ITR) sequences required for initiation of viral DNA replication (Reddy *et al.* (1995c), *supra*), and sequences involved in packaging of replicated viral genomes. Adenovirus packaging signals generally lie between the left ITR and

the E1A promoter. Incorporation of the cloned heterologous sequences into the PAV genome thus places the heterologous sequences into a DNA molecule containing viral replication and packaging signals, allowing generation of multiple copies of a recombinant PAV genome that can be packaged into infectious viral particles. Alternatively, incorporation of the cloned heterologous sequences into a PAV genome places these sequences into a DNA molecule that can be replicated and packaged in an appropriate helper cell line. Multiple copies of a single sequence can be inserted to improve yield of the heterologous gene product, or multiple heterologous sequences can be inserted so that the recombinant virus is capable of expressing more than one heterologous gene product. The heterologous sequences can contain additions, deletions and/or substitutions to enhance the expression and/or immunological effect of the expressed gene product(s).

Attachment of guide sequences to a heterologous sequence can also be accomplished by ligation *in vitro*. In this case, a nucleic acid comprising a heterologous sequence flanked by PAV guide sequences can be co-introduced into a host cell along with a PAV genome, and recombination can occur to generate a recombinant PAV vector. Introduction of nucleic acids into cells can be achieved by any method known in the art, including, but not limited to, microinjection, transfection, electroporation, CaPO<sub>4</sub> precipitation, DEAE-dextran, liposomes, particle bombardment, *etc.*

In one embodiment of the invention, a recombinant PAV expression cassette can be obtained by cleaving a wild-type PAV genome with an appropriate restriction enzyme to produce a PAV restriction fragment representing, for example, the left end or the right end of the genome comprising E1 or E3 gene region sequences, respectively. The PAV restriction fragment can be inserted into a cloning vehicle, such as a plasmid, and thereafter at least one heterologous sequence (which may or may not encode a foreign protein) can be inserted into the E1 or E3 region with or without an operatively-linked eukaryotic transcriptional regulatory sequence. The recombinant expression cassette is

contacted with a PAV genome and, through homologous recombination or other conventional genetic engineering methods, the desired recombinant is obtained. In the case wherein the expression cassette comprises the E1 region or some other essential region, recombination between the expression cassette and a PAV 5 genome can occur within an appropriate helper cell line such as, for example, an E1-transformed cell line. Restriction fragments of the PAV genome other than those comprising the E1 or E3 regions are also useful in the practice of the invention and can be inserted into a cloning vehicle such that heterologous sequences can be inserted into the PAV sequences. These DNA constructs can 10 then undergo recombination *in vitro* or *in vivo*, with a PAV genome either before or after transformation or transfection of an appropriate host cell.

The invention also includes an expression system comprising a porcine adenovirus expression vector wherein a heterologous nucleotide sequence, e.g. DNA, replaces part or all of the E3 region, part or all of the E1 region, part or all 15 of the E2 region, part or all of the E4 region, part or all of the late region and/or part or all of the regions occupied by the pIX, DBP, pTP, pol, IVa2, 52K, IIIA, pIII, pVII, pV, pX, pVI, and 33K genes. The expression system can be used wherein the foreign nucleotide sequences, e.g. DNA, are optionally in operative linkage with a eukaryotic transcriptional regulatory sequence. PAV expression 20 vectors can also comprise inverted terminal repeat (ITR) sequences and packaging sequences.

The PAV E1A, E1B, pIX, DBP, pTP, pol, IVa2, 52K, IIIA, pIII, pVII, pV, pX, pVI, and 33K genes are essential for viral replication. Therefore, PAV 25 vectors comprising deletions in any of these genes, or which lack functions encoded by any of these genes, are grown in an appropriate complementing cell line (*i.e.*, a helper cell line). Most, if not all, of the open reading frames in the E3 and E4 regions of PAV-3 are non-essential for viral replication and, therefore, deletions in these regions can be constructed for insertion or to increase vector capacity, without necessitating the use of a helper cell line for growth of the viral 30 vector.

In another embodiment, the invention provides a method for constructing a full-length clone of a PAV genome by homologous recombination *in vivo*. In this embodiment, two or more plasmid clones, containing overlapping segments of the PAV genome and together covering the entire genome, are introduced into an appropriate bacterial host cell. Approximately 30 base pairs of overlap is required for homologous recombination in *E. coli*. Chartier *et al.* (1996) *J. Virol.* **70**:4805-4810. Through *in vivo* homologous recombination, the PAV genome segments are joined to form a full-length PAV genome. In a further embodiment, a recombinant plasmid containing left-end sequences and right-end sequences of the PAV genome, separated by a unique restriction site, is constructed. This plasmid is digested with the restriction enzyme recognizing the unique restriction site, to generate a unit-length linear plasmid, which is introduced into a cell together with a full-length PAV genome. Homologous recombination within the cell will result in production of a recombinant plasmid containing a full-length PAV genome.

15 Recombinant plasmids will also generally contain sequences specifying replication in a host cell and one or more selective markers, such as, for example, antibiotic resistance.

Suitable host cells include any cell that will support recombination between a PAV genome and a plasmid containing PAV sequences, or between two or more plasmids, each containing PAV sequences. Recombination is generally performed in prokaryotic cells, such as *E. coli*, while transfection of a plasmid containing a viral genome, to generate virus particles, is conducted in eukaryotic cells, preferably mammalian cells, most preferably porcine cell cultures. The growth of bacterial cell cultures, as well as culture and maintenance of eukaryotic cells and mammalian cell lines are procedures which are well-known to those of skill in the art.

In one embodiment of the invention, a defective recombinant PAV vector is used for expression of heterologous sequences. The defective vector will be deleted in all or part of the E1 region. Construction of a deletion in the E1 region 30 of PAV is described in Example 3, *infra*. Heterologous sequences can be inserted

so as to replace the deleted E1 region, and/or can be inserted at other sites in the PAV genome, preferably E3, E4 and/or the region between E4 and the right end of the genome. Defective vectors with E1 deletions are grown in helper cell lines, which provide E1 function.

5        Accordingly, in one embodiment of the invention, a number of recombinant helper cell lines are produced according to the present invention by constructing an expression cassette comprising an adenoviral E1 region and transforming host cells therewith to provide complementing cell lines or cultures providing E1 functions. The terms "complementing cell," "complementing cell line," "helper cell" and "helper cell line" are used interchangeably herein to denote a cell line that provides a viral function that is deficient in a deleted PAV, preferably E1 function. These recombinant complementing cell lines are capable of allowing a defective recombinant PAV, having a deleted E1 gene region, wherein the deleted sequences are optionally replaced by heterologous nucleotide sequences, to replicate and express one or more foreign genes or fragments thereof encoded by the heterologous nucleotide sequences. PAV vectors with E1 deletions, wherein heterologous sequences are inserted in regions other than E1, can also be propagated in these complementing cell lines, and will express the heterologous sequences if they are inserted downstream of a PAV promoter or are 10      inserted in operative linkage with a eukaryotic regulatory sequence. Preferred helper cell lines include VIDO R1 cells, as described in Example 1, *infra*. Briefly, the VIDO R1 cell line is a porcine retinal cell line that has been transfected with DNA from the human adenovirus type 5 (HAV-5) E1 region, and which supports 15      the growth of PAV E1A deletions and HAV-5 E1 deletions.

20       Transformation of porcine cells with either PAV or HAV has not been reported due to the fact that exposure of permissive or semi-permissive cells to adenovirus normally leads to lysis of infected cells. Graham *et al.*, *supra*. The approach used in the present study to create a PAV E1-complementing cell line employing the E1 region of HAV-5 is novel as E1A proteins of HAV-5 have been 25      shown for the first time to complement PAV-3 E1 mutants. There are several 30

reasons that the E1 region of HAV-5 was used for transformation of porcine embryonic retinal cells. The E1 region of HAV-5 was shown to transform human retina cells very efficiently. Fallaux *et al.* (1998) *supra*. In contrast to the E1 region of PAV-3, the E1 region of HAV-5 has been thoroughly characterized and 5 the monoclonal antibodies against the E1 proteins are readily available from commercial sources. In addition, the E1A region of HAV-5 was shown to complement the E1A functions of several non-human adenoviruses. Ball *et al.* (1988) *J. Virol.* **62**:3947-3957; Zheng *et al.* (1994) *Virus Res.* **31**:163-186.

More generally, defective recombinant PAV vectors, lacking one or more 10 essential functions encoded by the PAV genome, can be propagated in appropriate complementing cell lines, wherein a particular complementing cell line provides a function or functions that is (are) lacking in a particular defective recombinant PAV vector. Complementing cell lines can provide viral functions through, for 15 example, co-infection with a helper virus, or by integrating or otherwise maintaining in stable form a fragment of a viral genome encoding a particular viral function.

In another embodiment of the invention, E1 function (or the function of 20 any other viral region which may be mutated or deleted in any particular viral vector) can be supplied (to provide a complementing cell line) by co-infection of cells with a virus which expresses the function that the vector lacks.

### **PAV expression systems**

In one embodiment, the present invention identifies and provides means of 25 deleting regions of the PAV genome, to provide sites into which heterologous or homologous nucleotide sequences encoding foreign genes or fragments thereof can be inserted to generate porcine adenovirus recombinants. In preferred 30 embodiments, deletions are made in part or all of the nucleotide sequences of the PAV E1, E3, or E4 regions and/or the region between E4 and the right end of genome. E1 deletion is described in Example 3; E3 deletion and insertion of heterologous sequence in the E3 region are described in Example 4 and 5; and

insertion of a heterologous sequence between the E4 region and the right end of the PAV genome, as well as expression of the inserted sequence, is described in Example 6, *infra*.

In another embodiment, the invention identifies and provides additional 5 regions of the PAV genome (and fragments thereof) suitable for insertion of heterologous or homologous nucleotide sequences encoding foreign genes or fragments thereof to generate PAV recombinants. These regions include nucleotides 145-13,555; 15,284-19,035; 22,677-24,055; 26,573-27,088; and 10 31,149-34,094 and comprise the E2 region, the late region, and genes encoding the pIX, DBP, pTP, pol, IVa2, 52K, IIIA, pIII, pVII, pV, pX, pVI, and 33K proteins. These regions of the PAV genome can be used, among other things, for insertion of foreign sequences, for provision of DNA control sequences including transcriptional and translational regulatory sequences, or for diagnostic purposes 15 to detect the presence, in a biological sample, of viral nucleic acids and/or proteins encoded by these regions. Example 7, *infra*, describes procedures for constructing insertions in these regions.

One or more heterologous sequences can be inserted into one or more 20 regions of the PAV genome to generate a recombinant PAV vector, limited only by the insertion capacity of the PAV genome and ability of the recombinant PAV vector to express the inserted heterologous sequences. In general, adenovirus genomes can accept inserts of approximately 5% of genome length and remain 25 capable of being packaged into virus particles. The insertion capacity can be increased by deletion of non-essential regions and/or deletion of essential regions whose function is provided by a helper cell line.

In one embodiment of the invention, insertion can be achieved by 25 constructing a plasmid containing the region of the PAV genome into which insertion is desired. The plasmid is then digested with a restriction enzyme having a recognition sequence in the PAV portion of the plasmid, and a heterologous sequence is inserted at the site of restriction digestion. The plasmid, 30 containing a portion of the PAV genome with an inserted heterologous sequence,

in co-transformed, along with a plasmid (such as pPAV-200) containing a full-length PAV genome, into a bacterial cell (such as, for example, *E. coli*), wherein homologous recombination between the plasmids generates a full-length PAV genome containing inserted heterologous sequences.

5        Deletion of PAV sequences, to provide a site for insertion of heterologous sequences or to provide additional capacity for insertion at a different site, can be accomplished by methods well-known to those of skill in the art. For example, for PAV sequences cloned in a plasmid, digestion with one or more restriction enzymes (with at least one recognition sequence in the PAV insert) followed by 10 ligation will, in some cases, result in deletion of sequences between the restriction enzyme recognition sites. Alternatively, digestion at a single restriction enzyme recognition site within the PAV insert, followed by exonuclease treatment, followed by ligation will result in deletion of PAV sequences adjacent to the restriction site. A plasmid containing one or more portions of the PAV genome 15 with one or more deletions, constructed as described above, can be co-transfected into a bacterial cell along with a plasmid containing a full-length PAV genome to generate, by homologous recombination, a plasmid containing a PAV genome with a deletion at a specific site. PAV virions containing the deletion can then be obtained by transfection of mammalian cells (such as ST or VIDO R1 cells) with 20 the plasmid containing a PAV genome with a deletion at a specific site.

Expression of an inserted sequence in a recombinant PAV vector will depend on the insertion site. Accordingly, preferred insertion sites are adjacent to and downstream (in the transcriptional sense) of PAV promoters. The transcriptional map of PAV, as disclosed herein, provides the locations of PAV 25 promoters. Locations of restriction enzyme recognition sequences downstream of PAV promoters, for use as insertion sites, can be easily determined by one of skill in the art from the PAV nucleotide sequence provided herein. Alternatively, various *in vitro* techniques can be used for insertion of a restriction enzyme recognition sequence at a particular site, or for insertion of heterologous 30 sequences at a site that does not contain a restriction enzyme recognition

sequence. Such methods include, but are not limited to, oligonucleotide-mediated heteroduplex formation for insertion of one or more restriction enzyme recognition sequences (see, for example, Zoller *et al.* (1982) *Nucleic Acids Res.* **10**:6487-6500; Brennan *et al.* (1990) *Roux's Arch. Dev. Biol.* **199**:89-96; and 5 Kunkel *et al.* (1987) *Meth. Enzymology* **154**:367-382) and PCR-mediated methods for insertion of longer sequences. See, for example, Zheng *et al.* (1994) *Virus Research* **31**:163-186.

It is also possible to obtain expression of a heterologous sequence inserted at a site that is not downstream from a PAV promoter, if the heterologous 10 sequence additionally comprises transcriptional regulatory sequences that are active in eukaryotic cells. Such transcriptional regulatory sequences can include cellular promoters such as, for example, the bovine hsp70 promoter and viral promoters such as, for example, herpesvirus, adenovirus and papovavirus promoters and DNA copies of retroviral long terminal repeat (LTR) sequences.

15 In another embodiment, homologous recombination in a prokaryotic cell can be used to generate a cloned PAV genome; and the cloned PAV-3 genome can be propagated as a plasmid. Infectious virus can be obtained by transfection of mammalian cells with the cloned PAV genome rescued from plasmid-containing cells. Example 2, *infra* describes construction of an infectious plasmid 20 containing a PAV-3 genome.

The invention provides PAV regulatory sequences which can be used to regulate the expression of heterologous genes. A regulatory sequence can be, for example, a transcriptional regulatory sequence, a promoter, an enhancer, an upstream regulatory domain, a splicing signal, a polyadenylation signal, a 25 transcriptional termination sequence, a translational regulatory sequence, a ribosome binding site and a translational termination sequence.

### **Therapeutic genes and polypeptides**

The PAV vectors of the invention can be used for the expression of 30 therapeutic polypeptides in applications such as *in vitro* polypeptide production,

vaccine production, nucleic acid immunization and gene therapy, for example. Therapeutic polypeptides comprise any polypeptide sequence with therapeutic and/or diagnostic value and include, but are not limited to, coagulation factors, growth hormones, cytokines, lymphokines, tumor-suppressing polypeptides, cell 5 receptors, ligands for cell receptors, protease inhibitors, antibodies, toxins, immunotoxins, dystrophins, cystic fibrosis transmembrane conductance regulator (CFTR) and immunogenic polypeptides.

In a preferred embodiment, PAV vectors will contain heterologous sequences encoding protective determinants of various pathogens of swine, for 10 use in subunit vaccines and nucleic acid immunization. Representative swine pathogen antigens include, but are not limited to, pseudorabies virus (PRV) gp50; transmissible gastroenteritis virus (TGEV) S gene; porcine rotavirus VP7 and VP8 genes; genes of porcine respiratory and reproductive syndrome virus (PRRS), in particular ORF 5; genes of porcine epidemic diarrhea virus; genes of 15 hog cholera virus, and genes of porcine parvovirus.

Various foreign genes or nucleotide sequences or coding sequences (prokaryotic, and eukaryotic) can be inserted into a PAV vector, in accordance with the present invention, particularly to provide protection against a wide range of diseases. Many such genes are already known in the art; the problem 20 heretofore having been to provide a safe, convenient and effective vaccine vector for the genes or sequences.

A heterologous (*i.e.*, foreign) nucleotide sequence can consist of one or more gene(s) of interest, and preferably of therapeutic interest. In the context of the present invention, a gene of interest can code either for an antisense RNA, a 25 ribozyme or for an mRNA which will then be translated into a protein of interest. A gene of interest can be of genomic type, of complementary DNA (cDNA) type or of mixed type (minigene, in which at least one intron is deleted). It can code for a mature protein, a precursor of a mature protein, in particular a precursor intended to be secreted and accordingly comprising a signal peptide, a chimeric 30 protein originating from the fusion of sequences of diverse origins, or a mutant of

5 a natural protein displaying improved or modified biological properties. Such a mutant can be obtained by deletion, substitution and/or addition of one or more nucleotide(s) of the gene coding for the natural protein, or any other type of change in the sequence encoding the natural protein, such as, for example, transposition or inversion.

A gene of interest can be placed under the control of regulatory sequences suitable for its expression in a host cell. Suitable regulatory sequences are understood to mean the set of elements needed for transcription of a gene into RNA (ribozyme, antisense RNA or mRNA), for processing of RNA, and for the 10 translation of an mRNA into protein. Among the elements needed for transcription, the promoter assumes special importance. It can be a constitutive promoter or a regulatable promoter, and can be isolated from any gene of eukaryotic, prokaryotic or viral origin, and even adenoviral origin. Alternatively, it can be the natural promoter of the gene of interest. Generally speaking, a 15 promoter used in the present invention can be chosen to contain cell-specific regulatory sequences, or modified to contain such sequences. For example, a gene of interest for use in the present invention is placed under the control of an immunoglobulin gene promoter when it is desired to target its expression to lymphocytic host cells. There may also be mentioned the HSV-1 TK (herpesvirus 20 type 1 thymidine kinase) gene promoter, the adenoviral MLP (major late promoter), in particular of human adenovirus type 2, the RSV (Rous Sarcoma Virus) LTR (long terminal repeat), the CMV (Cytomegalovirus) early promoter, and the PGK (phosphoglycerate kinase) gene promoter, for example, permitting expression in a large number of cell types.

25 Alternatively, targeting of a recombinant PAV vector to a particular cell type can be achieved by constructing recombinant hexon and/or fiber genes. The protein products of these genes are involved in host cell recognition; therefore, the genes can be modified to contain peptide sequences that will allow the virus to recognize alternative host cells.

Among genes of interest which are useful in the context of the present invention, there may be mentioned:

- genes coding for cytokines such as interferons and interleukins;
- genes encoding lymphokines;
- 5 - genes coding for membrane receptors such as the receptors recognized by pathogenic organisms (viruses, bacteria or parasites), preferably by the HIV virus (human immunodeficiency virus);
  - genes coding for coagulation factors such as factor VIII and factor IX;
  - genes coding for dystrophins;
- 10 - genes coding for insulin;
- genes coding for proteins participating directly or indirectly in cellular ion channels, such as the CFTR (cystic fibrosis transmembrane conductance regulator) protein;
  - genes coding for antisense RNAs, or proteins capable of inhibiting the activity of a protein produced by a pathogenic gene which is present in the genome of a pathogenic organism, or proteins (or genes encoding them) capable of inhibiting the activity of a cellular gene whose expression is deregulated, for example an oncogene;
  - genes coding for a protein inhibiting an enzyme activity, such as  $\alpha_1$ -antitrypsin or a viral protease inhibitor, for example;
    - genes coding for variants of pathogenic proteins which have been mutated so as to impair their biological function, such as, for example, trans-dominant variants of the *tat* protein of the HIV virus which are capable of competing with the natural protein for binding to the target sequence, thereby preventing the activation of HIV;
    - genes coding for antigenic epitopes in order to increase the host cell's immunity;
    - genes coding for major histocompatibility complex classes I and II proteins, as well as the genes coding for the proteins which are inducers of these genes;
- 15
- 20
- 25
- 30

- genes coding for antibodies;
- genes coding for immunotoxins;
- genes encoding toxins;
- genes encoding growth factors or growth hormones;
- 5 - genes encoding cell receptors and their ligands;
- genes encoding tumor suppressors;
- genes coding for cellular enzymes or those produced by pathogenic organisms; and
- suicide genes. The HSV-1 TK suicide gene may be mentioned as an example. This viral TK enzyme displays markedly greater affinity compared to the cellular TK enzyme for certain nucleoside analogues (such as acyclovir or gancyclovir). It converts them to monophosphorylated molecules, which can themselves be converted by cellular enzymes to nucleotide precursors, which are toxic. These nucleotide analogues can be incorporated into replicating DNA molecules, hence incorporation occurs chiefly in the DNA of dividing cells. This incorporation can result in specific destruction of dividing cells such as cancer cells.

This list is not restrictive, and any other gene of interest can be used in the context of the present invention. In some cases the gene for a particular antigen can contain a large number of introns or can be from an RNA virus, in these cases a complementary DNA copy (cDNA) can be used. It is also possible that only fragments of nucleotide sequences of genes can be used (where these are sufficient to generate a protective immune response or a specific biological effect) rather than the complete sequence as found in the wild-type organism. Where available, synthetic genes or fragments thereof can also be used. However, the present invention can be used with a wide variety of genes, fragments and the like, and is not limited to those set out above.

30 Recombinant PAV vectors can be used to express antigens for provision of, for example, subunit vaccines. Antigens used in the present invention can be either native or recombinant antigenic polypeptides or fragments. They can be

partial sequences, full-length sequences, or even fusions (e.g., having appropriate leader sequences for the recombinant host, or with an additional antigen sequence for another pathogen). The preferred antigenic polypeptide to be expressed by the virus systems of the present invention contain full-length (or near full-length) sequences encoding antigens. Alternatively, shorter sequences that are antigenic (i.e., encode one or more epitopes) can be used. The shorter sequence can encode a "neutralizing epitope," which is defined as an epitope capable of eliciting antibodies that neutralize virus infectivity in an *in vitro* assay. Preferably the peptide should encode a "protective epitope" that is capable of raising in the host a "protective immune response;" i.e., a humoral (i.e. antibody-mediated), cell-mediated, and/or mucosal immune response that protects an immunized host from infection.

The antigens used in the present invention, particularly when comprised of short oligopeptides, can be conjugated to a vaccine carrier. Vaccine carriers are well known in the art: for example, bovine serum albumin (BSA), human serum albumin (HSA) and keyhole limpet hemocyanin (KLH). A preferred carrier protein, rotavirus VP6, is disclosed in EPO Pub. No. 0259149, the disclosure of which is incorporated by reference herein.

Genes for desired antigens or coding sequences thereof which can be inserted include those of organisms which cause disease in mammals, particularly porcine pathogens such as pseudorabies virus (PRV), transmissible gastroenteritis virus (TGEV), porcine rotavirus, porcine respiratory and reproductive syndrome virus (PRRS), porcine epidemic diarrhea virus (PEDV), hog cholera virus (HCV), porcine parvovirus and the like. Genes encoding antigens of human pathogens are also useful in the practice of the invention.

### **Therapeutic applications**

With the recombinant viruses of the present invention, it is possible to provide protection against a wide variety of diseases affecting swine, cattle, humans and other mammals. Any of the recombinant antigenic determinants or

recombinant live viruses of the invention can be formulated and used in substantially the same manner as described for the antigenic determinant vaccines or live vaccine vectors.

The present invention also includes pharmaceutical compositions comprising a therapeutically effective amount of a recombinant vector, recombinant virus or recombinant protein, prepared according to the methods of the invention, in combination with a pharmaceutically acceptable vehicle and/or an adjuvant. Such a pharmaceutical composition can be prepared and dosages determined according to techniques that are well-known in the art. The pharmaceutical compositions of the invention can be administered by any known administration route including, but not limited to, systemically (for example, intravenously, intratracheally, intraperitoneally, intranasally, parenterally, enterically, intramuscularly, subcutaneously, intratumorally or intracranially) or by aerosolization or intrapulmonary instillation. Administration can take place in a single dose or in doses repeated one or more times after certain time intervals. The appropriate administration route and dosage will vary in accordance with the situation (for example, the individual being treated, the disorder to be treated or the gene or polypeptide of interest), but can be determined by one of skill in the art.

The vaccines of the invention carrying foreign genes or fragments can be orally administered in a suitable oral carrier, such as in an enteric-coated dosage form. Oral formulations include such normally-employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin cellulose, magnesium carbonate, and the like. Oral vaccine compositions may be taken in the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations, or powders, containing from about 10% to about 95% of the active ingredient, preferably about 25% to about 70%. An oral vaccine may be preferable to raise mucosal immunity (which plays an important role in protection against pathogens infecting the gastrointestinal tract) in combination with systemic immunity.

In addition, the vaccine can be formulated into a suppository. For suppositories, the vaccine composition will include traditional binders and carriers, such as polyalkaline glycols or triglycerides. Such suppositories may be formed from mixtures containing the active ingredient in the range of about 0.5% to about 10% (w/w), preferably about 1% to about 2%.

Protocols for administering to animals the vaccine composition(s) of the present invention are within the skill of the art in view of the present disclosure. Those skilled in the art will select a concentration of the vaccine composition in a dose effective to elicit antibody, cell-mediated and/or mucosal immune responses to the antigenic fragment. Within wide limits, the dosage is not believed to be critical. Typically, the vaccine composition is administered in a manner which will deliver between about 1 to about 1,000 micrograms of the subunit antigen in a convenient volume of vehicle, *e.g.*, about 1-10 ml. Preferably, the dosage in a single immunization will deliver from about 1 to about 500 micrograms of subunit antigen, more preferably about 5-10 to about 100-200 micrograms (*e.g.*, 5-200 micrograms).

The timing of administration may also be important. For example, a primary inoculation preferably may be followed by subsequent booster inoculations, for example, several weeks to several months after the initial immunization, if needed. To insure sustained high levels of protection against disease, it may be helpful to readminister booster immunizations at regular intervals, for example once every several years. Alternatively, an initial dose may be administered orally followed by later inoculations, or vice versa. Preferred vaccination protocols can be established through routine vaccination protocol experiments.

The dosage for all routes of administration of *in vivo* recombinant virus vaccine depends on various factors including, the size of patient, nature of infection against which protection is needed, carrier and the like and can readily be determined by those of skill in the art. By way of non-limiting example, a dosage of between approximately  $10^3$  pfu and  $10^8$  pfu can be used. As with *in*

*vitro* subunit vaccines, additional dosages can be given as determined by the clinical factors involved.

A problem that has beset the use of adenovirus vectors for immunization and gene therapy in humans is the rapid development of an immunological response (or indeed in some cases existing immunity) to human adenoviruses (HAVs). Recombinant PAV vectors are likely to be less immunogenic in humans and, for this and other reasons, will be useful either as a substitute for HAV vectors or in combination with HAV vectors. For example, an initial immunization with a HAV vector can be followed by booster immunizations using PAV vectors; alternatively, initial immunization with a recombinant PAV vector can be followed by booster immunizations with HAV and/or PAV vectors.

The presence of low levels of helper-independent vectors in the batches of helper-dependent human adenoviruses that are grown in complementing human cell lines has been reported. Fallaux *et al.* (1998) *supra*. This occurs as a result of recombination events between the viral DNA and the integrated adenoviral sequences present in the complementing cell line. Hehir *et al.* (1996) *J. Virol.* **70**:8459-8467. This type of contamination constitutes a safety risk, which could result in the replication and spread of the virus. Complete elimination of helper-dependent adenoviruses in the batches of helper-dependent vectors can be achieved using two approaches. The first is by developing new helper cell lines and matched vectors that do not share any common sequences. Fallaux *et al.* (1998) *supra*. The second approach is to take advantage of possible cross-complementation between two distantly related adenoviruses such as HAV-5 and PAV-3. VIDO R1 cells contain the E1 coding sequences of HAV-5. Although there is no significant homology between the E1 regions of HAV-5 and PAV-3 at the nucleotide sequence level, the proteins produced from the region can complement each others' function(s). Thus, the problem of helper-independent vector generation by homologous recombination is eliminated when VIDO R1 cells are used for the propagation of recombinant PAV-3.

The invention also encompasses a method of treatment, according to which a therapeutically effective amount of a PAV vector, recombinant PAV, or host cell of the invention is administered to a mammalian subject requiring treatment. The finding that PAV-3 was effective in entering canine, sheep and 5 bovine cells in which it does not replicate or replicates poorly is an important observation. *See Example 8, infra.* This may have implications in designing PAV-3 vectors for vaccination in these and other animal species.

### **PAV Expression Systems**

10 Recombinant PAV vectors can be used for regulated expression of foreign polypeptides encoded by heterologous nucleotide sequences. Standard conditions of cell culture, such as are known to those of skill in the art, will allow maximal expression of recombinant polypeptides. They can be used, in addition, for regulated expression of RNAs encoded by heterologous nucleotide sequences, as 15 in, for example, antisense applications and expression of ribozymes.

When the heterologous sequences encode an antigenic polypeptide, PAV 20 vectors comprising insertions of heterologous nucleotide sequences can be used to provide large quantities of antigen which are useful, in turn, for the preparation of antibodies. Methods for preparation of antibodies are well-known to those of skill in the art. Briefly, an animal (such as a rabbit) is given an initial subcutaneous injection of antigen plus Freund's complete adjuvant. One to two subsequent 25 injections of antigen plus Freund's incomplete adjuvant are given at approximately 3 week intervals. Approximately 10 days after the final injection, serum is collected and tested for the presence of specific antibody by ELISA, Western Blot, immunoprecipitation, or any other immunological assay known to one of skill in the art.

Adenovirus E1 gene products transactivate many cellular genes; therefore, 30 cell lines which constitutively express E1 proteins can express cellular polypeptides at a higher levels than other cell lines. The recombinant mammalian, particularly porcine, cell lines of the invention can be used to prepare and isolate

polypeptides, including those such as (a) proteins associated with adenovirus E1A proteins: *e.g.* p300, retinoblastoma (Rb) protein, cyclins, kinases and the like; (b) proteins associated with adenovirus E1B protein: *e.g.* p53 and the like; growth factors, such as epidermal growth factor (EGF), transforming growth factor (TGF) and the like; (d) receptors such as epidermal growth factor receptor (EGF-R), fibroblast growth factor receptor (FGF-R), tumor necrosis factor receptor (TNF-R), insulin-like growth factor receptor (IGF-R), major histocompatibility complex class I receptor and the like; (e) proteins encoded by proto-oncogenes such as protein kinases (tyrosine-specific protein kinases and protein kinases specific for serine or threonine), p21 proteins (guanine nucleotide-binding proteins with GTPase activity) and the like; (f) other cellular proteins such as actins, collagens, fibronectins, integrins, phosphoproteins, proteoglycans, histones and the like, and (g) proteins involved in regulation of transcription such as TATA-box-binding protein (TBP), TBP-associated factors (TAFs), Sp1 binding protein and the like.

15

### **Gene Therapy**

The invention also includes a method for providing gene therapy to a mammal, such as a porcine, human or other mammal in need thereof, to control a gene deficiency. In one embodiment, the method comprises administering to said 20 mammal a live recombinant porcine adenovirus containing a heterologous nucleotide sequence encoding a non-defective form of said gene under conditions wherein the recombinant virus vector genome is incorporated into said mammalian genome or is maintained independently and extrachromosomally to provide expression of the required gene in the target organ or tissue. These kinds 25 of techniques are currently being used by those of skill in the art to replace a defective gene or portion thereof. Examples of foreign genes, heterologous nucleotide sequences, or portions thereof that can be incorporated for use in gene therapy include, but are not limited to, cystic fibrosis transmembrane conductance regulator gene, human minidystrophin gene, alpha-1-antitrypsin gene and the like.

In particular, the practice of the present invention in regard to gene therapy in humans is intended for the prevention or treatment of diseases including, but not limited to, genetic diseases (for example, hemophilia, thalassemias, emphysema, Gaucher's disease, cystic fibrosis, Duchenne muscular dystrophy, 5 Duchenne's or Becker's myopathy, *etc.*), cancers, viral diseases (for example, AIDS, herpesvirus infection, cytomegalovirus infection and papillomavirus infection) and the like. For the purposes of the present invention, the vectors, cells and viral particles prepared by the methods of the invention may be introduced into a subject either *ex vivo*, (*i.e.*, in a cell or cells removed from the 10 patient) or directly *in vivo* into the body to be treated. Preferably, the host cell is a human cell and, more preferably, is a lung, fibroblast, muscle, liver or lymphocytic cell or a cell of the hematopoietic lineage.

### **Diagnostic applications**

15 The PAV genome, or any subregion of the PAV genome, is suitable for use as a nucleic acid probe, to test for the presence of PAV nucleic acid in a subject or a biological sample. The presence of viral nucleic acids can be detected by techniques known to one of skill in the art including, but not limited to, hybridization assays, polymerase chain reaction, and other types of amplification 20 reactions. Suitable labels and hybridization techniques are well-known to those of skill in the art. See, for example, Kessler (ed.), *Nonradioactive Labeling and Detection of Biomolecules*, Springer-Verlag, Berlin, 1992; Kricka (ed.) *Nonisotopic DNA Probe Techniques*, Academic Press, San Diego, 1992; Howard (ed.) *Methods in Nonradioactive Detection*, Appleton & Lange, Norwalk, 1993; 25 Ausubel *et al.*, *supra*; and Sambrook *et al.*, *supra*. Diagnostic kits comprising the nucleotide sequences of the invention can also contain reagents for cell disruption and nucleic acid purification, as well as buffers and solvents for the formation, selection and detection of hybrids.

Regions of the PAV genome can be inserted into any expression vector 30 known in the art and expressed to provide, for example, vaccine formulations,

protein for immunization, *etc.* The amino acid sequence of any PAV protein can be determined by one of skill in the art from the nucleotide sequences disclosed herein. PAV proteins can be used for diagnostic purposes, for example, to detect the presence of PAV antigens. Methods for detection of proteins are well-known to those of skill in the art and include, but are not limited to, various types of direct and competitive immunoassays, ELISA, Western blotting, enzymatic assay, immunohistochemistry, *etc.* See, for example, Harlow & Lane (eds.): *Antibodies, A Laboratory Manual*, Cold Spring Harbor Press, New York, 1988. Diagnostic kits comprising PAV polypeptides or amino acid sequences can also comprise reagents for protein isolation and for the formation, isolation, purification and/or detection of immune complexes.

## EXAMPLES

### **METHODS**

#### **15      Virus and viral DNA.**

The 6618 strain of PAV-3 was propagated in the swine testis (ST) cell line and in E1-transformed porcine retinal cells (VIDO R1, see below). Porcine embryonic retinal cells were obtained from the eyeballs of piglets delivered by caesarian section two weeks before the parturition date. Uninfected cells were grown in MEM supplemented with 10% fetal bovine serum (FBS). MEM with 2% FBS was used for maintenance of infected cells. Viral DNA was extracted either from infected cell monolayers by the method of Hirt (1967) *J. Mol. Biol.* **26**:365-369, or from purified virions as described by Graham *et al.* (1991) in "Methods in Molecular Biology" Vol. 7, Gene transfer and expression protocols, ed. E.J. Murray, Humana Press, Clifton, NJ, pp. 109-128.

#### **Plasmids and genomic DNA sequencing.**

Selected restriction enzyme fragments of PAV-3 DNA were cloned into pGEM-3Z and pGEM-7Zf(+) plasmids (Promega). Nucleotide sequences were determined on both strands of the genome by the dideoxy chain-termination

method using Sequenase® enzyme (U.S. Biochemicals) and the dye-terminator method with an Applied Biosystems (Foster City, CA) DNA sequencer.

#### **cDNA library.**

5 A cDNA library was generated from polyadenylated RNA extracted from PAV-3 infected ST cells at 12 h and 24 h post infection. Double stranded cDNAs were made with reagents from Stratagene and cloned into Lambda ZAP vector. Plaques which hybridized to specific restriction enzyme fragments of PAV-3 DNA were plaque purified twice. Plasmids containing cDNAs were excised from 10 the Lambda ZAP vector according to the manufacturer's protocol. The resulting plasmid clones were characterized by restriction endonuclease analysis and by sequencing of both ends of the cDNA insert with T3- and T7-specific primers. Selected clones were sequenced with internal primers. cDNA sequences were aligned with genomic sequences to determine the transcription map.

15

#### **Viral transcript mapping by nuclease protection**

Transcript mapping was conducted according to the method of Berk *et al.* (1977) *Cell* 12:721-732.

20

#### **Example 1: Development of an E1-complementing helper cell line (VIDO R1)**

25

Primary cultures of porcine embryonic retina cells were transfected with 10 µg of plasmid pTG 4671 (Transgene, Strasbourg, France) by the calcium phosphate technique. The pTG 4671 plasmid contains the entire E1A and E1B sequences (nts 505-4034) of HAV-5, along with the puromycin acetyltransferase gene as a selectable marker. In this plasmid, the E1 region is under the control of the constitutive promoter from the mouse phosphoglycerate kinase gene, and the puromycin acetyltransferase gene is controlled by the constitutive SV40 early promoter. Transformed cells were selected by three passages in medium 30 containing 7 µg/ml puromycin, identified based on change in their morphology

from single foci (*i.e.*, loss of contact inhibition), and subjected to single cell cloning. The established cell line was first tested for its ability to support the growth of E1 deletion mutants of HAV-5. Subsequently the cell line was further investigated for the presence of E1 sequences in the genome by PCR, expression 5 of the E1A and E1B proteins by Western blot, and doubling time under cell culture conditions. E1 sequences were detected, and production of E1A and E1B proteins was demonstrated by immunoprecipitation (Figure 3). Doubling time was shorter, when compared to that of the parent cell line. Example 3, *infra*, shows that this cell line is capable of complementing a PAV E1A deletion mutant.

10 To assess the stability of E1 expression, VIDO R1 cells were cultured through more than 50 passages (split 1:3 twice weekly) and tested for their ability to support the replication of E1-deleted HAV-5. Expression of the E1A and E1B proteins at regular intervals was also monitored by Western blot. The results indicated that the VIDO R1 line retained the ability to support the growth of 15 E1-deleted virus and expressed similar levels of E1 proteins during more than 50 passages in culture. Therefore, VIDO R1 can be considered to be an established cell line.

**Example 2: Construction of a full-length infectious clone of PAV-3.**

20 A plasmid clone containing a full-length copy of the PAV-3 genome (pPAV-200) was generated by first constructing a plasmid containing left- and right-end sequences of PAV-3, with the PAV-3 sequences bordered by *PacI* sites and separated by a *PstI* restriction site (pPAV-100), then allowing recombination between *PstI*-digested pPAV-100 and an intact PAV-3 genome. Left- and right- 25 end sequences for insertion into pPAV-100 were produced by PCR amplification, as follows.

The plasmid p3SB (Reddy *et al.*, 1993, *Intervirology* **36**:161-168), containing the left end of PAV-3 genome (position 1-8870) was used for amplification of the first 433 bp of the PAV-3 genome by PCR. Amplification 30 primers were oligonucleotides 1

(5'-**GC GGATC CTTAATTAACATCATCAATAATAACCGCACACTTT**-3')

**(SEQ ID NO.: 2)** and 2

(5'-**CACCTGCAGATAACACCCACACACCGTCATCTCG**-3') **(SEQ ID NO.: 3)**.

5 In the sequences shown here, adenoviral sequences are shown in bold and  
engineered restriction enzyme sites are italicized.

For amplification of sequences at the right end of the PAV-3 genome, the plasmid p3SA (Reddy *et al.*, 1993, *supra*) was used. This plasmid was used as template in PCR for amplification of the terminal 573 bp of the genome using oligonucleotide 1 (above) and oligonucleotide 3

10 (5'-**CACCTGCAGCCTCCTGAGTGTGAAGAGAGTGTCC**-3') **(SEQ ID NO.: 4)**. The primers were designed based on the nucleotide sequence information described elsewhere (Reddy *et al.*, 1995c, *supra*; and Reddy *et al.*, 1997, *supra*).

15 For construction of pPAV-100, the PCR product obtained with oligonucleotides 1 and 2 was digested with *Bam*HI and *Pst*I restriction enzymes and the PCR product obtained using primers 1 and 3 was digested with *Pst*I and *Pac*I enzymes. Modified bacterial plasmid pPolyIIsn14 was digested with *Bam*HI and *Pac*I enzymes. This plasmid was used based on its suitability for homologous recombination in *E. coli*. The two PCR products described above were cloned 20 into pPolyIIsn14 by three way ligation to generate the plasmid pPAV-100 which carries both termini of PAV-3, separated by a *Pst*I site and bordered by *Pac*I restriction enzyme sites.

25 Plasmid pPAV-200, which contains a full length PAV-3 genome, was generated by co-transformation of *E. coli* BJ 5183 *recBC sbcBC* (Hanahan, 1983, *J. Mol. Biol.* **166**:557-580) with *Pst*I-linearized pPAV-100 and the genomic DNA of PAV-3. Extensive restriction enzyme analysis of pPAV-200 indicated that it had the structure expected of a full-length PAV-3 insert, and that no unexpected rearrangements had occurred during recombination in *E. coli*.

30 The infectivity of pPAV-200 was demonstrated by lipofectin transfection (Life Technologies, Gaithersburg, MD) of ST cells following *Pac*I enzyme digestion of the plasmid to release the viral genome from the plasmid. Viral

plaques were evident 7 days following transfection, and titers were equivalent to, or higher than, those obtained after infection with wild-type PAV. The plaques were amplified and the viral DNA was extracted and analyzed by restriction enzyme digestion. The viral DNA obtained by cleavage of pPAV-200 with *PacI* contained an extra 3 bases at each end; but these extra bases did not substantially reduce the infectivity of the PAV genome excised from pPAV-200. In addition, the bacterial-derived genomes lacked the 55-kDa terminal protein that is covalently linked to the 5' ends of adenoviral DNAs and which enhances infectivity of viral DNA.

10

**Example 3: Generation of E1 deletion mutants of PAV-3.**

A plasmid (pPAV-101) containing the left (nucleotides 1-2,130) and the right (nucleotides 32,660-34,094) terminal *NcoI* fragments of the PAV-3 genome was constructed by digesting pPAV-200 with the enzyme *NcoI* (which has no 15 recognition sites in the vector backbone, but many sites in the PAV insert), gel-purifying the appropriate fragment and self-ligating the ends. *See Figure 4.* The E1A sequences of pPAV-101, between nucleotides 407 and 1270 (PAV genome numbering), were deleted by digestion of pPAV-101 with *NotI* (recognition site at nucleotide 407) and *AseI* (recognition site at 1270), generation 20 of blunt ends, and insertion of a double-stranded oligonucleotide encoding a *XbaI* restriction site to create a plasmid, pPAV-102, containing PAV left- and right-end sequences, separated by a *NcoI* site, with a deletion of the E1A region and a *XbaI* site at the site of the deletion. *See Figure 5.* Plasmid pPAV-201, containing a full-length PAV-3 genome minus E1A sequences, was created by co- 25 transformation of *E. coli* BJ 5183 with *NcoI* linearized pPAV-102 and genomic PAV-3 DNA. The resulting construct, when transfected into VIDO R1 cells following digestion with *PacI* restriction enzyme, produced a virus that had a deletion in the E1 region. In similar fashion, construction of a virus with deletions in E1 and E3 was accomplished by transformation of BJ 5183 cells with *NcoI* 30 linearized pPAV-102 and genomic PAV-3 DNA containing an E3 deletion. These

ELA deletion mutants did not grow on either ST (swine testis) cells or fetal porcine retina cells and could only be grown in the VIDO R1 cell line.

**Example 4: Generation of E3 inserts and deletion mutants.**

5 To systematically examine the extent of the E3 region that could be deleted, a E3 transfer vector was constructed. The vector (pPAV-301) contained a PAV-3 segment from nucleotides 26,716 to 31,064 with a green fluorescent protein (GFP) gene inserted into the *Sna*BI site (located at nucleotide 28,702) in the same orientation as E3. The GFP gene was obtained from the plasmid pGreen 10 Lantern-1™ (Life Technologies), by *Not*I digestion followed by purification of a 732-nucleotide fragment. Similarly, another construct was made with GFP cloned into the *Sac*I site located at nucleotide 27,789. *Kpn*I-*Bam*HI fragments encompassing the modified E3 regions were then isolated from these E3 transfer 15 vectors and recombined in *E. coli* with pPAV-200 that had been linearized at nucleotide position 28,702 by *Sna*BI digestion. Virus were obtained with a construct that had the GFP gene cloned into the *Sna*BI site.

To delete the non-essential portion of E3 from the transfer vector, a PCR approach was used. In this approach, the region of the PAV genome between nucleotides 27,402 and 28,112 was amplified using the following primers:

20 5'-GACTGACGCCGGCATGCAAT-3' **SEQ ID NO: 5**  
5'-CGGATCCTGACGCTACGAGCGGTTGTA-3' **SEQ ID NO: 6**

In a second PCR reaction, the portion of the PAV genome between nucleotides 28,709 and 29,859 was amplified using the following two primers:

25 5'-CGGATCCCATACGTACAGATGAAGTAGC-3' **SEQ ID NO: 7**  
5'- TCTGACTGAAGCCGACCTGC-3' **SEQ ID NO: 8**

In the oligonucleotides designated SEQ ID NO: 6 and SEQ ID NO: 7, a *Bam*HI recognition sequence is indicated by underlining. The template for amplification was a *Kpn*I-*Bam*HI fragment encompassing nucleotides 26,716-31,063 of the PAV genome, inserted into the plasmid pGEM3Z (Promega), and 30 *Pfu* polymerase (Stratagene) was used for amplification. The first PCR product

(product of amplification with SEQ ID NO: 5 and SEQ ID NO: 6) was digested with *Bam*HI and gel-purified. The second PCR product (product of amplification with SEQ ID NO: 7 and SEQ ID NO: 8) was digested with *Bam*HI and *Spe*I and gel-purified. They were inserted into *Sma*I/*Spe*I-digested pBlueScript II SK(+) (Stratagene) in a three-way ligation reaction to generate pPAV-300. See Figure 6. pPAV-300 contains the portion of the PAV-3 genome extending from nucleotides 27,402 to 29,859, with 594 base pairs (bp) between nucleotides 28,113 and 28,707 deleted from the E3 region. A virus with such a deletion was constructed as follows. A *Sph*I-*Spe*I fragment from pPAV-300, containing part of the pVII gene, a deleted E3 region, and part of the fiber gene was isolated (see Figure 6). This fragment was co-transfected, with *Sna*BI-digested pPAV-200 (which contains a full-length PAV-3 genome) into *E. coli*. Homologous recombination generated a plasmid, pFPAV-300, containing a full-length PAV genome with a deletion in the E3 region. pFPAV-300 was digested with *Pac*I and transfected into VIDO R1 cells (Example 1) to generate recombinant virus with a deletion in the E3 region of the genome.

**Example 5: Construction of a PAV recombinant with an insertion of the PRV gp50 gene in the PAV E3 region and expression of the inserted gene**

To construct a recombinant PAV expressing pseudorabies virus (PRV) gp50, the PRV gp50 gene was inserted at the *Sna*BI site of pPAV-300 to create plasmid pPAV-300-gp50. A *Sph*I-*Spe*I fragment from pPAV-300-gp50, containing part of the pVII gene, a deleted E3 region with the PRV gp50 gene inserted, and part of the fiber gene, was purified and co-transfected, along with *Sna*BI-digested pFPAV-300 (E3-deleted) into *E. coli*. In the bacterial cell, homologous recombination generated pFPAV-300-gp50, a plasmid containing a PAV genome with the PRV gp50 gene replacing a deleted E3 region. Recombinant virus particles were obtained as described in Example 4.

Expression of the inserted PRV gp50 was tested after infection of VIDO R1 cells with the recombinant virus, by  $^{35}\text{S}$  labeling of infected cells (continuous

label), followed by immunoprecipitation with an anti-gp50 monoclonal antibody and gel electrophoresis of the immunoprecipitate. Figure 7 shows that large amounts of gp50 are present by 12 hours after infection, and expression of gp50 persists up to 24 hours after infection.

5

**Example 6: Expression of the Chloramphenicol acetyltransferase gene from a region that lies between the promoter of the E4 region and the right ITR.**

The right terminal fragment of the PAV genome (encompassing 10 nucleotides 31,054-34,094) was obtained by *Xba*I digestion of pPAV-200 and cloned between the *Xba*I and *Not*I sites of pPolyIIasn14. A Chloramphenicol acetyltransferase (CAT) gene expression cassette, in which the CAT gene was flanked by the SV40 early promoter and the SV40 polyadenylation signal, was inserted, in both orientations, into a unique *Hpa*I site located between the E4 15 region promoter and the right ITR, to generate plasmids pPAV-400A and pPAV-400B. The modified terminal fragments were transferred into a plasmid containing a full-length PAV-3 genome by homologous recombination in *E. coli* between the isolated terminal fragments and *Hpa*I-digested pPAV-200. Recombinant viruses expressing CAT were obtained following transfection of 20 VIDO R1 cells with the plasmids. PAV-CAT2 contained the CAT gene cassette in a leftward transcriptional orientation (*i.e.*, the same orientation as E4 region transcription), while, in PAV-CAT6, the CAT gene cassette was in the rightward transcriptional orientation.

These recombinant viruses were tested for expression of CAT, after 25 infection of VIDO R1 cells, using a CAT Enzyme Assay System from Promega, following the instructions provided by the supplier. *See*, Cullen (1987) *Meth. Enzymology* 43:737; and Gorman *et al.*, (1982) *Mol. Cell. Biol.* 2:1044. The results are shown in Table 3.

30

**Table 3: CAT activity expressed by recombinant PAV viruses**

Sample	<sup>3</sup> H cpm
Mock-infected	458
CAT positive control*	199,962
PAV-CAT2	153,444
PAV-CAT6	63,386

\* - the positive control sample contained 0.1 Units of purified CAT.

These results show that recombinant PAV viruses, containing an inserted  
5 gene, are viable and are capable of expressing the inserted gene.

**Example 7: Construction of replication defective PAV-3 expressing GFP**

A 2.3 kb fragment containing the CMV immediate early promoter, the  
10 green fluorescent protein (GFP) gene and the bovine growth hormone poly(A)  
signal was isolated by digesting pQBI 25 (Quantum Biotechnology) with *Bgl*II and *Dra*III followed by filling the ends with T4 DNA polymerase. This fragment was inserted into the *Srf*I site of pPAV-102 in both orientations to generate pPAV-102GFP (Figure 8). This plasmid, digested with *Pac*I and *Smal* enzymes, and the fragment containing part of the E1 sequence and the GFP gene was gel purified. This fragment and the *Srf*I digested pFPAV-201 were used to transform *E. coli* BJ 5183 to generate the full-length clone containing GFP in the E1 region (pFPAV-201-GFP) by homologous recombination. The recombinant virus, PAV3delE1E3.GFP was generated following transfection of VIDO R1 cells with  
15 *Pac*I restricted pFPAV-201-GFP that had the GFP transcription unit in the opposite orientation to the E1. A similar virus with the GFP in the same orientation as E1 could not be rescued from transfected cells. Presence of the GFP gene in the viral genome was confirmed by restriction enzyme analysis. The recombinant virus replicated in VIDO R1 cells two logs less efficiently than the  
20 wild type PAV-3.

**Example 8: Virus entry and replication of PAV-3 in human and animal cells.**

To initially characterize the host species restriction of PAV *in vitro*, monolayers of 11 cell types from 6 different mammalian species were infected 5 with wild type PAV-3 or PAV3del.E1E3.GFP. ST, VIDO R1 (porcine), 293, A549 (human), MDBK, VIDO R2 (bovine), C3HA (mouse), COS, VERO (monkey), sheep skin fibroblasts or cotton rat lung cells were incubated with 1 pfu/cell of wild type PAV-3 or helper-dependent PAV-3 expressing GFP. The cells infected with wild type PAV were harvested at 2 h and 3 days post-infection, 10 subjected to two cycles of freeze-thaw, and virus titers were determined on VIDO R1 cells. Cells that were infected with the recombinant virus expressing GFP were observed with the aid of a fluorescent microscope for green fluorescence.

A ten-fold increase in virus titers in Vero and COS cells, and a hundred-fold increase in cotton rat lung fibroblasts and VIDO R2 cells, was noticed. No 15 increase in the virus titers was observed with 293, A549, MDBK, sheep skin fibroblasts, dog kidney and C3HA cells. All of these cell types showed bright green fluorescence when infected with PAV3delE1E3.GFP except human cells, which showed a weak fluorescence. In addition, low levels of GFP expression were achieved in human cells with recombinant PAV-3. These observations 20 suggest that virus entry into human cells is limited and/or the human cells are non-permissive for the replication of the virus. These results also demonstrated that GFP was expressed by the PAV-3 vector in cells which are semi-permissive (VERO, COS, Cotton rat lung fibroblasts and VIDO R2), or non-permissive (Sheep skin fibroblasts, MDBK and human cells) for virus replication.

25

**Example 9: Insertions in the regions of the PAV-3 genome defined by nucleotides 145-13,555; 15,284-19,035; 22,677-24,055; 26,573-27,088; and 31,149-34,094**

Insertions are made by art-recognized techniques including, but not limited 30 to, restriction digestion, nuclease digestion, ligation, kinase and phosphatase

treatment, DNA polymerase treatment, reverse transcriptase treatment, and chemical oligonucleotide synthesis. Heterologous nucleic acid sequences of interest are cloned into plasmid vectors containing portions of the PAV genome (which may or may not contain deletions of PAV sequences) such that the foreign 5 sequences are flanked by sequences having substantial homology to a region of the PAV genome into which insertion is to be directed. Substantial homology refers to homology sufficient to support homologous recombination. These constructs are then introduced into host cells that are co-transfected with PAV-3 DNA or a cloned PAV genome. During infection, homologous recombination 10 between these constructs and PAV genomes will occur to generate recombinant PAV genome-containing plasmids. Recombinant virus are obtained by transfecting the recombinant PAV genome-containing plasmids into a suitable mammalian host cell line. If the insertion occurs in an essential region of the PAV genome, the recombinant PAV virus is propagated in a helper cell line 15 which supplies the viral function that was lost due to the insertion.

**Deposit of Biological Materials**

The following materials were deposited and are maintained with the Veterinary Infectious Disease Organization (VIDO), Saskatoon, Saskatchewan, Canada.

5 The nucleotide sequences of the deposited materials are incorporated by reference herein, as well as the sequences of the polypeptides encoded thereby. In the event of any discrepancy between a sequence expressly disclosed herein and a deposited sequence, the deposited sequence is controlling.

10	<u>Material</u>	<u>Internal Accession No.</u>	<u>Deposit Date</u>
<b>Recombinant plasmids</b>			
	pPAV-101	VIDO 98-1	April 10, 1998
	pPAV-102	VIDO 98-2	April 10, 1998
	pPAV-200	VIDO 98-3	April 10, 1998
15	pPAV-300	VIDO 98-4	April 10, 1998
	pPAV-400A	VIDO 98-5	April 10, 1998
	pPAV-400B	VIDO 98-6	April 10, 1998

**Recombinant cell lines**

20 Porcine embryonic retinal cells transformed with HAV-5 E1 sequences:  
VIDO R1 VIDO 98C-1 April 10 1998

25 While the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be apparent to those skilled in the art that various changes and modifications may be practiced without departing from the spirit of the invention. Therefore the foregoing descriptions and examples should not be construed as limiting the scope of the invention.

30

CLAIMS

What is claimed is:

1. A nucleotide sequence that is substantially homologous to the genome of porcine adenovirus type 3 (PAV-3), or a fragment thereof.
- 5 2. A nucleotide sequence that is substantially homologous to a portion of the genome of porcine adenovirus type 3, said portion selected from the group consisting of nucleotides 145-13,555; 15,284-19,035; 22,677-24,055; 26,5732-27,088; and 31,149-34,094 of the PAV-3 genome, or a fragment thereof.
- 10 3. A nucleotide sequence that is substantially homologous to a PAV-3 gene or fragment thereof, wherein the gene is selected from the group consisting of E1A, E1B, E4, pIX, DBP, pTP, pol, IVa2, 52K, IIIA, pIII, pVII, pV, pX, pVI, and 33K.
- 15 4. A nucleotide sequence according to claim 3 comprising a PAV-3 coding sequence from a region of the PAV-3 genome selected from the group consisting of E1A, E1B, E4, pIX, DBP, pTP, pol, IVa2, 52K, IIIA, pIII, pVII, pV, pX, pVI, and 33K, and fragments thereof.
5. A nucleotide sequence that is substantially homologous to the nucleotide sequence of claim 4.
- 20 6. A nucleotide sequence comprising an intergenic region of the PAV-3 genome.
7. A nucleotide sequence that is substantially homologous to the nucleotide sequence of claim 6.
- 25 8. A nucleotide sequence encoding a PAV-3 regulatory sequence.
9. The nucleotide sequence of claim 8, wherein the regulatory sequence is selected from the group consisting of a transcriptional regulatory sequence, a promoter, an enhancer, an upstream regulatory domain, a splicing signal, a polyadenylation signal, a transcriptional termination sequence, a translational regulatory sequence, a ribosome binding site and a translational termination sequence.
- 30 10. A vector comprising the nucleotide sequence of claim 1.

- 11.** A vector comprising the nucleotide sequence of claim 2.
- 12.** A vector comprising the nucleotide sequence of claim 3.
- 13.** A vector comprising the nucleotide sequence of claim 8.
- 14.** A defective recombinant PAV vector, comprising ITR sequences, packaging sequences, and at least one heterologous nucleotide sequence, wherein the PAV vector lacks E1 function.  
5
- 15.** A defective recombinant PAV vector according to claim 14, wherein the vector is deleted in the E1 region.
- 16.** A defective recombinant PAV vector according to claim 15, 10 wherein the vector is additionally deleted in a region selected from the group consisting of E2, E3, E4, L1, L2, L3, L4, L5, L6 and the region between E4 and the right end of the genome.
- 17.** A defective recombinant PAV vector according to claim 16, 15 wherein the vector is additionally deleted in more than one region selected from the group consisting of E2, E3, E4, L1, L2, L3, L4, L5, L6 and the region between E4 and the right end of the genome.
- 18.** A defective recombinant PAV vector according to claim 14, wherein the heterologous nucleotide sequence encodes a therapeutic polypeptide.  
20
- 19.** A defective recombinant PAV vector according to claim 18, wherein the therapeutic polypeptide is selected from the group consisting of coagulation factors, growth hormones, cytokines, lymphokines, tumor-suppressing polypeptides, cell receptors, ligands for cell receptors, protease inhibitors, antibodies, toxins, immunotoxins, dystrophins, cystic fibrosis transmembrane conductance regulator (CFTR) and immunogenic polypeptides.  
25
- 20.** A recombinant PAV vector comprising a PAV genome and at least one heterologous nucleotide sequence, wherein the heterologous sequence is inserted in a region selected from the group consisting of the E1 region, the E3 region, the E4 region and the region between E4 and the right end of the genome.
- 21.** The recombinant PAV vector of claim 20, comprising two or more 30 heterologous nucleotide sequences.

22. The recombinant PAV vector of claim 21, wherein the two or more heterologous nucleotide sequences are inserted at different sites.

23. The recombinant PAV vector of claim 20, wherein the heterologous nucleotide sequence encodes a therapeutic polypeptide.

5 24. The recombinant PAV vector of claim 23, wherein the therapeutic polypeptide is selected from the group consisting of coagulation factors, growth hormones, cytokines, lymphokines, tumor-suppressing polypeptides, cell receptors, ligands for cell receptors, protease inhibitors, antibodies, toxins, immunotoxins, dystrophins, cystic fibrosis transmembrane conductance regulator 10 (CFTR) and immunogenic polypeptides.

25. A method for obtaining a recombinant PAV comprising a heterologous nucleotide sequence inserted into an insertion site, the method comprising the steps of:

- (a) providing a PAV genome;
- 15 (b) providing a heterologous nucleotide sequence;
- (c) linking the heterologous nucleotide sequence to guide sequences, the guide sequences being substantially homologous to PAV sequences flanking the insertion site, such that guide sequences are present at both ends of the heterologous sequence;
- 20 (d) introducing the construct from step (c) into a cell together with the PAV genome;
- (e) allowing homologous recombination to occur between the two sequences from step (d) to generate a recombinant PAV genome;
- (f) purifying the recombinant PAV genome;
- 25 (g) inserting the recombinant PAV genome into a mammalian cell;
- (h) culturing the mammalian cell under conditions wherein the recombinant PAV genome is replicated and packaged; and
- (i) collecting the recombinant PAV from the cell or the culture 30 medium.

**26.** The method according to claim 25 wherein the insertion site is located in a region of the PAV genome selected from the group consisting of the E1 region, the E3 region, the E4 region and the region between E4 and the right end of the genome.

5       **27.** The method according to claim 26 wherein the PAV genome is deleted in a region selected from the group consisting of the E1 region, the E3 region, the E4 region and the region between E4 and the right end of the genome.

10      **28.** A method for producing a recombinant PAV that comprises introducing the PAV vector of claim 14 into an appropriate helper cell line and recovering virus from the infected cells.

**29.** The method according to claim 28 wherein the helper cell line provides E1 function.

**30.** A host cell comprising the vector of claim 10.

**31.** A host cell comprising the vector of claim 11.

15      **32.** A host cell comprising the vector of claim 12.

**33.** A host cell comprising the vector of claim 13.

**34.** A host cell comprising the vector of claim 14.

**35.** A host cell comprising the vector of claim 20.

20      **36.** A recombinant porcine cell line comprising an adenovirus E1 gene region, said recombinant cell line thereby providing E1 function and allowing replication of a PAV vector having a deletion in the E1 region.

**37.** A method for producing a recombinant PAV, the method comprising:

25      (a) introducing, into the cell line of claim 36, a vector comprising ITR sequences, PAV packaging sequences, and at least one heterologous nucleotide sequence, wherein the vector is deleted in the E1 region and the vector is additionally deleted in one or more regions selected from the group consisting of the E2 region, the E3 region, the E4 region, and the region between E4 and the right end of the genome;

(b) culturing the cell line under conditions whereby virus replication and packaging occurs; and

(c) recovering virus from the infected cells.

38. A method for producing a recombinant PAV polypeptide, the  
5 method comprising:

(a) providing a population of host cells according to claim 31;  
and

(b) growing said population of cells under conditions whereby  
the PAV polypeptide is expressed.

39. A method for producing a recombinant PAV polypeptide, the  
10 method comprising:

(a) providing a population of host cells according to claim 32;  
and

(b) growing said population of cells under conditions whereby  
15 the PAV polypeptide is expressed.

40. A method for producing a recombinant polypeptide, the method  
comprising:

(a) providing a population of host cells according to claim 33,  
and

(b) growing said population of cells under conditions whereby  
20 the polypeptide is expressed.

41. A method for producing a recombinant polypeptide, the method  
comprising:

(a) providing a population of host cells according to claim 34,  
25 and

(b) growing said population of cells under conditions whereby  
the polypeptide is expressed.

**42.** A method for producing a recombinant polypeptide, the method comprising:

(a) providing a population of host cells according to claim 35, and

5 (b) growing said population of cells under conditions whereby the polypeptide is expressed.

**43.** A PAV polypeptide encoded by the nucleotide sequence of claim 2.

**44.** A PAV polypeptide encoded by the nucleotide sequence of 10 claim 3.

**45.** A PAV polypeptide produced by the method of claim 38.

**46.** A PAV polypeptide produced by the method of claim 39.

**47.** A recombinant polypeptide produced by the method of claim 40.

**48.** A recombinant polypeptide produced by the method of claim 41.

15 **49.** A recombinant polypeptide produced by the method of claim 42.

**50.** A method for detecting the presence of PAV nucleotide sequences in a biological sample comprising:

(a) providing a biological sample; and

(b) subjecting the sample to hybridization using a labeled probe

20 comprising at least ten continuous nucleotides of the sequence according to claim 1.

**51.** A method for detecting the presence of PAV nucleotide sequences in a biological sample comprising:

(a) providing a biological sample; and

25 (b) subjecting the sample to hybridization using a labeled probe comprising at least ten continuous nucleotides of the sequence according to claim 3.

**52.** A method for detecting the presence of PAV nucleotide sequences in a biological sample comprising:

- (a) providing a biological sample; and
- (b) subjecting the sample to a polymerase chain reaction using

5 primers comprising at least ten continuous nucleotides of the sequence according to claim 1.

**53.** A method for detecting the presence of PAV nucleotide sequences in a biological sample comprising:

- (a) providing a biological sample; and

10 (b) subjecting the sample to a polymerase chain reaction using primers comprising at least ten continuous nucleotides of the sequence according to claim 3.

**54.** A kit for detecting the presence of PAV nucleotide sequences in a biological sample comprising one or more probes, said probes comprising at least 15 ten continuous nucleotides of the sequence according to claim 1.

**55.** A kit for detecting the presence of PAV nucleotide sequences in a biological sample comprising one or more probes, said probes comprising at least ten continuous nucleotides of the sequence according to claim 3.

**56.** A method for detecting the presence of PAV antibodies in a 20 biological sample comprising:

- (a) providing a biological sample; and
- (b) subjecting the sample to immunoassay using the polypeptide of claim 43.

**57.** A method for detecting the presence of PAV antibodies in a 25 biological sample comprising:

- (a) providing a biological sample; and
- (b) subjecting the sample to immunoassay using the polypeptide of claim 44.

**58.** A method for detecting the presence of PAV antibodies in a biological sample comprising:

- (a) providing a biological sample; and
- (b) subjecting the sample to immunoassay using the 5 polypeptide of claim 45.

**59.** A method for detecting the presence of PAV antibodies in a biological sample comprising:

- (a) providing a biological sample; and
- (b) subjecting the sample to immunoassay using the 10 polypeptide of claim 46.

**60.** A kit for detecting the presence of PAV antibodies in a biological sample comprising one or more polypeptides according to claim 43.

**61.** A kit for detecting the presence of PAV antibodies in a biological sample comprising one or more polypeptides according to claim 44.

15 **62.** A kit for detecting the presence of PAV antibodies in a biological sample comprising one or more polypeptides according to claim 45.

**63.** A kit for detecting the presence of PAV antibodies in a biological sample comprising one or more polypeptides according to claim 46.

20 **64.** A method for obtaining antibodies to PAV, the method comprising:

- (a) providing a PAV polypeptide according to claim 43;
- (b) immunizing a mammalian host with the polypeptide; and
- (c) collecting antibody from the immunized host.

25 **65.** A method for obtaining antibodies to PAV, the method comprising:

- (a) providing a PAV polypeptide according to claim 44;
- (b) immunizing a mammalian host with the polypeptide; and
- (c) collecting antibody from the immunized host.

30 **66.** A method for obtaining antibodies to PAV, the method comprising:

- (a) providing a PAV polypeptide according to claim 45;
- (b) immunizing a mammalian host with the polypeptide; and
- (c) collecting antibody from the immunized host.

67. A method for obtaining antibodies to PAV, the method comprising:

- (a) providing a PAV polypeptide according to claim 46;
- (b) immunizing a mammalian host with the polypeptide; and
- (c) collecting antibody from the immunized host.

5 68. A method for detecting the presence of a PAV antigen in a biological sample, the method comprising:

- (a) providing a biological sample; and
- (b) subjecting the sample to immunoassay using an antibody according to claim 64.

10 69. A method for detecting the presence of a PAV antigen in a biological sample, the method comprising:

- (a) providing a biological sample; and
- (b) subjecting the sample to immunoassay using an antibody according to claim 65.

15 70. A method for detecting the presence of a PAV antigen in a biological sample, the method comprising:

- (a) providing a biological sample; and
- (b) subjecting the sample to immunoassay using an antibody according to claim 66.

20 71. A method for detecting the presence of a PAV antigen in a biological sample, the method comprising:

- (a) providing a biological sample; and
- (b) subjecting the sample to immunoassay using an antibody according to claim 67.

25 72. A method for detecting the presence of an antigen in a biological sample comprising:

- (a) providing a biological sample; and
- (b) subjecting the sample to immunoassay using the polypeptide of claim 47.

73. A method for detecting the presence of an antigen in a biological sample comprising:

- (a) providing a biological sample; and
- (b) subjecting the sample to immunoassay using the

5 polypeptide of claim 48.

74. A method for detecting the presence of an antigen in a biological sample comprising:

- (a) providing a biological sample; and
- (b) subjecting the sample to immunoassay using the

10 polypeptide of claim 49.

75. A kit for detecting the presence of an antigen in a biological sample comprising one or more polypeptides according to claim 47.

76. A kit for detecting the presence of an antigen in a biological sample comprising one or more polypeptides according to claim 48.

15 77. A kit for detecting the presence of an antigen in a biological sample comprising one or more polypeptides according to claim 49.

78. A pharmaceutical composition capable of inducing an immune response in a mammalian subject, said composition comprising a nucleotide sequence according to claim 2.

20 79. A pharmaceutical composition capable of inducing an immune response in a mammalian subject, said composition comprising a nucleotide sequence according to claim 3.

80. A pharmaceutical composition capable of inducing an immune response in a mammalian subject, said composition comprising a polypeptide according to claim 43.

25 81. A pharmaceutical composition capable of inducing an immune response in a mammalian subject, said composition comprising a polypeptide according to claim 44.

**82.** A pharmaceutical composition capable of inducing an immune response in a mammalian subject, said composition comprising a polypeptide according to claim 45.

5 **83.** A pharmaceutical composition capable of inducing an immune response in a mammalian subject, said composition comprising a polypeptide according to claim 46.

**84.** A pharmaceutical composition capable of inducing an immune response in a mammalian subject, said composition comprising a polypeptide according to claim 47.

10 **85.** A pharmaceutical composition capable of inducing an immune response in a mammalian subject, said composition comprising a polypeptide according to claim 48.

15 **86.** A pharmaceutical composition capable of inducing an immune response in a mammalian subject, said composition comprising a polypeptide according to claim 49.

**87.** A pharmaceutical composition comprising the defective recombinant PAV vector of claim 14.

20 **88.** A pharmaceutical composition capable of inducing an immune response in a mammalian subject, said composition comprising a defective recombinant PAV vector according to claim 87, wherein the vector encodes an immunogenic polypeptide.

**89.** A pharmaceutical composition comprising the vector of claim 10.

**90.** A pharmaceutical composition comprising the vector of claim 11.

**91.** A pharmaceutical composition comprising the vector of claim 12.

25 **92.** A pharmaceutical composition comprising the vector of claim 13.

**93.** A pharmaceutical composition comprising the vector of claim 20.

**94.** A pharmaceutical composition comprising a recombinant PAV obtained according to the method of claim 25.

30 **95.** A pharmaceutical composition comprising a recombinant PAV obtained according to the method of claim 37.

96. A pharmaceutical composition comprising the host cell of claim 30.

97. A pharmaceutical composition comprising the host cell of claim 31.

5 98. A pharmaceutical composition comprising the host cell of claim 33.

99. A method for eliciting an immune response in a mammalian host to protect against an infection comprising administering a pharmaceutical composition comprising a recombinant PAV vector capable of expressing a 10 protective antigen.

100. A method of gene therapy in a mammalian host comprising administering to the host the vector of claim 11.

101. A method of gene therapy in a mammalian host comprising administering to the host the vector of claim 13.

15 102. A method of gene therapy in a mammalian host comprising administering to the host the defective recombinant PAV vector of claim 14.

103. A method of gene therapy in a mammalian host comprising administering to the host the recombinant PAV vector of claim 20.

20 104. A method of gene therapy in a mammalian host comprising administering to the host a recombinant PAV vector obtained according to the method of claim 25.

105. A method of gene therapy in a mammalian host comprising administering to the host a recombinant PAV obtained according to the method of claim 37.

25 106. A method of gene therapy in a mammalian subject comprising administering to the subject the host cell of claim 31.

107. A method of gene therapy in a mammalian subject comprising administering to the subject the host cell of claim 32.

30 108. A method of gene therapy in a mammalian subject comprising administering to the subject the host cell of claim 33.

**109.** A method of gene therapy in a mammalian subject comprising administering to the subject the host cell of claim 34.

**110.** A method of gene therapy in a mammalian subject comprising administering to the subject the host cell of claim 35.

5           **111.** An antibody that specifically binds the polypeptide of claim 43.

**112.** An antibody that specifically binds the polypeptide of claim 44.

**113.** An antibody that specifically binds the polypeptide of claim 45.

**114.** An antibody that specifically binds the polypeptide of claim 46.

10           **115.** A composition comprising a full-length genomic clone of a PAV genome.

**116.** The composition of claim 115 wherein the PAV genome is the genome of PAV-3.

**117.** A method for obtaining a full-length genomic clone of a PAV genome, the method comprising:

15           (a) providing two or more cloned segments of the PAV genome, wherein the cloned segments of the PAV genome, taken together, represent the entire PAV genome;

         (b) introducing the two or more cloned segments of the PAV genome into a cell;

20           (c) allowing homologous recombination to occur within the cell between the two or more cloned segments of the PAV genome to generate a full-length PAV genome; and

         (d) purifying the full-length PAV genome from the cell.

**118.** A full-length PAV genome produced by the method of claim 117.

FIG.- 1-1

2 / 14

GCTCGTCTTCCCAGCTGGGCCGGCGTCGTCAGGGAGTGGCCGGGACGAATGTGAACGGCGGAGTG  
 GTGGGCGCCCCCTGCCAGAGCGGGGTGCTGGCCTACTCCGCTTCGTTCACGCAACAGCAGCAG  
 CCGGGGACGGCGGGCAGCGGGTCTGTGTTCCGGGCGGTGTTCCATCGGTGGATCTGAGCGCGGAG  
 GTGGGCATGATGCAGCGGGCTGGCGAGCTGCGGAGCAGCTGAGGAGCTGCGGGAGGTGGT  
 GAGATAACAGCTGCAGGGCCACGGCCTCGGAGGCGCCAGGGAGGAAGAGGAGGAGGAGATTGTGGT  
 GACGAGGAGGTGGCGCCGGCGTGGAGCGAACACCATGGAAGAGGAGGAGGAGGATGAGATGGTCTG  
 ACGATGACTGTGGTGGGGGACCTGAGCCTGCTGGAGTGGAAAGGCCAGCCGCCACCACCA  
 CCGGAGAGCGACCCCTGCGGTGCTGCTACTACCAACTACCCGAAGCGGCTCAGCTACGGCGCAGC  
 AAGAGGAGCGGTCCATGCGCGAGGACAACGTACGCGGACTGTGGGGGAAGAAGGGGAGGAGGA  
 AAGAAGACCATGGAGACGGGTGTTGTCTTTCCAGCCAACTTTATTGAGAATAATAAAAGC  
 TTATGGATGTTGGAACGATAATAGCGTGTCCAGCGTTCTGTCTTGCAAGGGTCTTGTATCTT  
 CTCGAGGCACCGTAGACCTGGTGTGGACGTTGAAATACATGGCATGACTCCCTCGCGGGGTG  
 CAGGTAAAGCCACTGGAGGGCTGGGTGCGGGGGCAGGGCAGTGCAGTAGATGATCCAGTCATAGGCGTT  
 CTGGTTGCGGTGGTGGTGGAAAATGTCCTTGAGGAGCAGGCTGATGGCGGTGGCAGACCTTGGT  
 GTAGGCATTGATGAACCGGTGACCTGGCGGCTGCATGAGGGGGACATGATGTGGTACTTGGC  
 CTGGATCTTGAGGGTGGAGATGTTGCCGCTCTGGTCGCGGCGGGGTTCATGTTGTGGAGGACGAC  
 GAGGACGGCGTAGCCGGTGCAGCGGGGAAGCGGGCGTGCAGCTGGAGGGGAAGGCGTGGAAAGAA  
 CTTGGCGACCCCTTGTGTCCGCCAGGTCCATGCACTCGTCAGGACGATGGCGATGGTCC  
 GCGGCGGCGGCGCGGGCGAAGACGTTGCGTAGTCAGTACATGAGTTGTGCTCCTGCATGAG  
 GTCCTGGTAGCTCATGCGGACAAAGTCTGGCATGAGGGTGGCGGTCTGGGGATTAGGGTGTGGT  
 CGGACCGCTGCGGTAGTTGCCCTCGCAGATCTGGTCTCCAGGGCAGTACCTCCTGCGGGGGGAT  
 CATGTCCACCTGCGGGGTGATGAAGAAAACAGTCTCCGGCGGGGGAGAGGAGTTGGGAGGAGAT  
 GAGGTTGCGGAGCAGCTGGGACTTGCCGGAGCCGGTGGGACCGTAGATGACAGCGATGACTGGCTG  
 GACCTGGTAGTTGAGGGAGCGGCAGGTGCCAGCGGGGGTGGAGGAAGGGCATGCAAGCGTTGAGGGT  
 GTCGCGCAGGTTGCGGTTCTCTGGACGAGGTCTGCAGGGTGTGGCCTCCAGGGAGAGGAG  
 GTGGGAGAGGGAGGCAGGGCTTGAGGGGCTTGAGGCCCTCGGGTAGGGCATGTCCTGCGAGGGC  
 CTGGTGGAGCACCGCATGCGCTCCAGAGCTCGTTACATGTCCTCCAGGTATGTCCTCCAGCAG  
 GTCTGGTTGTTCTCGGGTTGGGTTGCGTAGGTTACGGAAACGAGGCGGTGGCGTGGCAGCGGG  
 TGGAGGGTCCGGTCTTCCAGGGCCGGAGGGCCCGTGGAGGGTGTGGTCTCGGTGACGGTGAAGGGG  
 GCGGTCTGGGCTGCTCGGTGGCCAGGGTCTTGAGGCTGAGGCGTGGTGTGCTGAAGGTGGCG  
 CTTCCGAGCTGCGCTGTTCAAGTAGCAGTCGGAGGAGGTCTGGAGCTGTGGCGTCTGCGCAGC  
 TGGCCCTTGGCGCGAGCTTGCCGGGCGCGTGGCGATGGGGTGGCGCGTGGCG  
 GCGTAGAGCTTGGGGCGAGCAGGACCGTCTGGAGCTGGAGCTGGCGTCTGCGCAGC  
 TGGGTCTCGCACCGACAGCCAGGTGAGCTGGGGTTCTGGGATCGAAGACGAGGGGCCCCCG  
 TTCCGCTTGAGGCGGTGTTACCTTGGTCTCCATGAGCTCGCTCCGGCGGGTGGAGGAAGAGG  
 CTGTCGGTGTCCCCGTAGACGGAGCGCAGGGCCGGTGGCGATGGGGTGGCGCGTGGCG  
 TAGAGGATGAGGGCCACTCGGAGATGAAGGCACGCCAGGCAGGACGAAGCTGGCGACCTGC  
 GAGGGGTAGCGGTGTTGGGCACTAATGGCGAGGCCTGCTCGAGCGTGTGGAGACAGAGGTCTCG  
 TCGTCCCGCTCCAGGAAGTGGATTGGTGCCTAGTGGTAGTCCACGTGACCGGCTTGCGGGTGGGG  
 GGTATAAAAGGCGCGGGCCGGGTGCGTGGCCGTCAAGTGTGGCTCGCAGGCCTCGTACCGGAGTCC  
 GCGTCTCCGGCGTCTCGGCTCGGCTGCATCTGTTGGTCCCAGGTCTCAGGTGGGTACGCTACG  
 ACAAAAGTCCGGGGTGACCTCAGCGCTGAGGGTGTCTGTTCTATGAAGGCGGAGGAGCGGAGGGAG  
 AGGTGCGCGGGCGATGGCTTCGGTGGTGCAGGGCGTCCATCTGGCTGGCGAAGACACCTTCTTA  
 TTGTCGAGGCAGTGTGGCGAAACTGCCGTAGAGGGCGTGGAGAGAAGCTTGGCGATGCTGCGGAGC  
 GTTGGTTCTGTCGGTGGCCCTTTCCTGGCAGCGATGTTGAGCTGCACTGAGCTGACGTAGTCTCGGGCG  
 AGGCAGCGCCACTCGGGGAAGATGCTGTTGCGCTCGTCCGGCAGGGAGGCGCACGGCCAGCCACGG  
 TTGTGGAGGGTGACCACTGCTCCACGGAGGTGGCTACCTCGCCGGAGGGCGTGGTGGCG  
 AGGCAGGCCCTTGGGGAGCAGTGGGGGAGGACGTCCAGCTGGTCTCGTGGGGGGTGGCG  
 GCGTCGATGGTGAAGAGGGCGGGCAGGAGGTGGGGTGTGAAGTAGCTGAGGGGCTCGGGCG  
 AGGCAGGCGCTGCCAGCGGGGGCGCCAGGGCGCGTGAAGGGGTTGGAGGGGTTGGCG  
 AAGGGGTGGGTGAGGGCGCTGGCATACATGCCGAGATGTATAGACGTAGAGGGGCTCGTGGTCCAGCAG  
 AGGCCGATGAAGTGGGTAGCAGCGGCCGCCGCAGGCTCTCGCGGACGTAGTCATACAGCTC  
 GTGGGAGGGCGCGAGGAGGTTGGCCGAGGTGCGGCGCTGGGGCGCTGGCGCGTAGAGGAGG  
 TGCTTGAAGATGGCGTGGGAGTTGGAGCTGATGGTGGGCCTCTGGAGACATTGAAGGCGGCGTGG  
 GGAAGGCCGGCTCGGTGTGGACGAAGGCGCGTAGGACTCTTGCAGCTGCGGACCAAGACGGCG  
 GTGACGACGACGGTCTGGCGCAGTAGCGCAGGGTGGCCTGGACGATGTCGTAAGCGTCCCCCTGG

**FIG.\_ 1-2**

SUBSTITUTE SHEET (Rule 26)

CTCTCCTTCTTCCACAGGTCTTGTGAGGAGGTACTCCTGATCGCTGTCCCAGTACTTGGCGTGT  
 GGGAAAGCCGTCTGATCGCGTAAGTAGTACTCCCCGTGCGGTAGAACACTCGTTCACGGCATCGTAGGGG  
 CAGTGTCCCTGTCCACGGCCAGCTCGTAGGCCGCGGCCCTGCGGAGGCTGGTGTGCGTGAGG  
 GCGAAGGTGTCCCGACCAGAACCTGACGTACTGGTGTCTGGGGTCTCGGGGCCATGACGCC  
 TCCTCCCAGTCCCGTAGTCGCGGCCGGAGGGGGTTGGCAGGTTGAAGCTGATGTCA  
 TTGAAGAGGATGCCGCCGGTGCAGGATGAAGGTGCGGGTGACCAGGAAGGAGGGGGCACCTCG  
 CGCGGTGGCGAGCACCTGCGCGGCCAGGACGATCTCATCGAAGGCCAGATGTTGTGGCCACG  
 ATGTAGACCTCCAGGAAGAGGGCGGCCGCGCAGGCCGCGGCCAGCTGGGCATAGGCCAGG  
 GGGTCTCGGGGTCTGGCAGGCCGGGCCCTGCGCCAGCTGGGCTGGGCGAGGTCTGGGTTG  
 TGGGCCAGCAGGTGCTGCCAGAGGGTGTGGTGAAGGCCGCTGCGAGGGCGTGCAGGGCCTG  
 AAGGCCGCCGATGGCGCCTCTGCGGGCAGAGCATGTTAGAAGGTGTGGCTCGGGCTCCAGC  
 GCTGCAGGCCGCTCTGGACGCCACACCTGCAAGCGCGCTCAGCAGCTCTCGTCCCCGAG  
 AGGTGGAAGACCAGCAGGAAGGGCACAGCTGCTTCCGAAGGCCGTGCCAGGTGAGGTCTCC  
 AGGTCACTAGGTGAGGAAGAGGCCGGGTGCCCTCGGGGAGGCCGATGGGCCAGGCGATGGTC  
 TGCCACCAGTCGGCCGCTGGCGCTGAACGTTGGAAGTAGAAGTCCCAGGCCACGGAGCAG  
 GTGTGGCGGTCTGGAAGATGCCGCCAGTGCCTCGCACTTCTGGGCTCTGGATGCTTGTATG  
 AGGTGGCAGCGGCCCTGGGTGAAGAGCAGGCCGGAGGGGAAGGGGAGGCCGGGCCCTCG  
 GGCGGGGGTCCCAGCGCACGTGGTGCAGGTGGTGTGCTGGCGGTGACCACCTGGACGAAGGTG  
 GGCGCGGGCGCCAGCTCCACCGCGCTGGGGTAGCCTGCAAGGAGGTGGGGGGGGCGGG  
 CGCAGGAGGTGAGCTGGAGGTTGGCCAGGGCGCTGCTCCAGTGGCGGTGGTAGGTGATGCTC  
 CAGCTCTCCCGTCTGGGTGGTGCCCTGGAGGCCGGGGTGGCGCGCTCGAGCAGGAGCCC  
 CGCGTCCGGCCTCCGCGCCTCGCGGCCGGCGCTCAGGCCAGCTGGGCCAGGGCA  
 CGGGCGCGTTGAGCTCGGGCAGCGGGAGGTGGTGCAGGCCAGACGCGAGGCCGTGGCGATGACG  
 GGCAGGTTGATGTTCTGGATCTGGGTTCCCGAGAACGACACGGGCCGGTGAACGGTCTG  
 AAGAGAGTTCCACGGAATCAATGTCGGCATCGTGGGTGGCACCTGGCGAGGATCTGGACACGT  
 CCCCCTGTTTCGCGGTAGCGATGTCCTGCACTGACGCTCGAGCTCGTCTCGTCCAGGTCCC  
 CGTGGCGCGCTCCACGGTGGGCCAGGTGACGGTGTGCGGTTCATGATGCCACAGGG  
 CGTCTCTCGTTCTCGTCCACACCGCAGTGTAGACAGCTGGCGTGGCGTCCCGCGCGCA  
 TGAACACTGGCCAGGTGAGGCCACCAGGCCGGTGAAGGCCCTGCAAGGCCAGGGCGTGGT  
 GCAGGTAGTTGAGGTGGTGGCGATGTCCTCGCAGAGGAAGAAGTTATGACCCAGGGCGCAGGG  
 TCAGCTCGTTGATGTCGCCAGGTCTCGAGGCCAGGTGAGCTCTCTTCCAGGGCGGATGCCCTGGCCA  
 GAAAAAAACTCGTGCCTGGGGGGCGAGACCGTGAAGGCCACAGGCCGGTGCAGGCCAGGGCGTGGT  
 CCGCCTGCCGCACCTCCCTTAAGGAGGGCGGGGGCGTGTGGGTCCGGCCACCGCCCTCTT  
 CTTCCCTCTCCCTCCAGGGTGGCATCTCCCTCGTCTTCTTCTCTGCTGCTGCTCCCTCCG  
 GGACGGGGGGCGCAGGCCGGGGACGGCGCCGGCGCAAGGGCAGCCGGTCCAGAAGCGCTCGATGA  
 CCTCGCCCCGCACTGCCGATGGTCTCGGTGACGCCGGCCCTCCGGGGCGCAGCTCGA  
 AGGCCCCCCCGCGCAGCGCGGTGCCGCTGCAGAGGGCGAGGCTGAGCGCACTGATGAGCGTGC  
 TCAACTCTCTCGTAGGTACCTCTGTTGCAAGCGCTTCGGCAAACCTCGCGCACCTGCTCTCGG  
 ACCCGCGAAGCGTTGACGAAGGCCGCTAGCCAGCAACAGTCGAAGGTAAGTTGAGCGCGGTGT  
 GCGTCGGGAGCCGGAGGTGCCGGCTGACGAGGAAGTGAAGTAGGCCGTCTGAGCTGCCGGATGG  
 CGCGCAGGAGGGTGAGGTCTTGGCGCCGGCGCTGCAGGCCGATGCCGCGTGGCCATGCCCGAG  
 CCTCCCTGCTGGCAGCGGCCGATGTCCTGAGCTGCTCTGCAGCAGATGTGCCACGGCACGTCCC  
 GGTGGCGTCCAGGTGGGTGCGACCGTAGCCCCGCAAGGGGGCGCAGCAGGCCAGGTGGCCACCA  
 CGCGCTCGGCCAGGATGCCCTGCTGCAGGCCGAGGGAGTCTGAGAAGTCATCCAGGTCCAGGA  
 ACCGGTGGTAGGCCCGTGTGATGGTAGGAGCAGTTGCCAGCACGGACCAGTTGACCACCT  
 GGTAGTGGGGCTGGATGACCTCGGTGAGCGCAGTCGACTGTAGGCCGCGTGTCAAAGATGTAAT  
 CGTTGCAGAGGCCGAGCGAGGTGCTGGTAGGCCACGAGCAGGTGGGGCGGAGGGTAGAGGTAGAGGG  
 GCCAGTGTCCCGTGGCGGTTGGCGGGGGAGAGGTTCATGAGCATGAGGCCGTTGAGCGGTAGCGGTAGA  
 TGAAGCGGGACATCCAGGCCGATGCCGACGCCGGAGACGGAGGCCGGTCCACTGGTGGCGCG  
 TCCAAATGTTGCGCACGGCGGAAGAGGCTCCACGGTGTAAATGGATTGCCCGTGGAGCGATCTATCTT  
 AGTCGAGGGCGCTCTGTCAAAAGAACCGGGTGTGGTGGTGTGGTAGCGATCTATCTT  
 CTTGTGATCTGGTAGTGAAGCCTGCCAGGCTCCAGCAGGGCGTCCGCTTCTGCG  
 CCCTATCTGGAGGTGTGCTCTGTTCTTCTTCTTCTGAGCTGAGGCCATGCATCCCGTCTGCG  
 AGATGAAGCCGCCGGCGCCCTGGCGCGAGGGGGAGGGCGACGCCGCTCGGTGCCCTGCCGT  
 CGCTGACGCCGGCGCGAGGAGGGGGAGGGCGTGGCGCGCTGTCGGGCCGGCGCCCCCGAGC  
 GGCACCCACGGGTGCAAGCGAGAGGCCATGGAGGCCTATGTGCCGAGGCCAGAATGCGTCC

**FIG.\_ 1-3**

4 / 14

FIG. - 1-4

**SUBSTITUTE SHEET (Rule 26)**

5 / 14

GCACCATCAAGCCCCCTGAAGCAGGACAGCAAGGGTCGCAGCTACCACGTGGGCAGGACCCCGAGG  
 CGGGGGACACCTTACCTACTACCGCAGCTGGTACCTGGCCTACAACACTACGGGGACCCGGCACGG  
 GCACCGCCTCCCAGACGCTGCTGGTCTCCCCGGACGTAACCTGCCAGTGGAGCAGGTCTACTGGA  
 GCCTGCCGGACCTGATGCAGGACCCGGTGACCTTCCGGGCCAGCCAGACGCCAGCAACTACCCGG  
 TGGTAGCCACGGAGCTACTGCCGCTGCGCTCCGGGCCCTCTACAACACCCAGGCCGTGACTCCC  
 AGCTCCTGCAGCAGGCCACCAACAACACCCCTGGTCTTTAACCGCTCCGGAGAACAGATCCTCC  
 TGCGCCGCCAGAGTCCACCATCACCTCATCAGCGAGAACGTGCCCTCGCTGACGGACCACGGCA  
 CGCTGCCGCTGCGTAACAGCATCCCCGGGTGCAGCGGTAAACCGTACCGACGCCGGCGCCCG  
 TGTGTCCTATGTGTACAAGAGTCTCGGGGTGGTACCCCGAGGGTGTCAAGCAGCCGAACCTTCT  
 AACCGACAGCCCTACCGTCACAGGGAGACAGAGAAAAGACAGCCAGCCCCGCCATGCCATCCT  
 CGTCTGCCAGCAACACTTGGCTGGGACTGGGCTGCGCTCATGTACGGGGCGCCCG  
 CCTGTCCCCGGATCACCCGTGATCGTCCGACGCCACTACCGGGCAACTGGGCCAGTCTGAAGGG  
 AC CGTGGCCCCCAGCACCATAGCGACAACGGATGACCTGTGGCGACGTGGTCAACCGCAGTC  
 CGGCCACCCGCCGGCGCCATCGTCAGCTGGAGGGCGCGGTCTCCTCCGG  
 CGTCACCGGGGACCCGGTGGCGATGTGGTCAACCGGGTGGAGGGCGGTAGCCGGCGCCGCC  
 CGGGGCCGGTCTTCGCGATGCGACACCAGGGGACCCGGGGCGAGGGCGCTCCGGCCATCCTGG  
 AGCGGTGGCGCGCCGGAGGGAGCACCCGGGGCGAGGGCGCTCCGGCCATCCTGG  
 GGTGCGCCGCAGCCGCCCTCGCAAACGACCTCGTCTGAGATTGGTGTGTTTCT  
 GCCTCCCGTGGGTGAACAAAGTCCATCCATCCACATCCACATCCGCGCTGCTGTGTTTCT  
 CTTTGCCTTGCGCCCCAGTTGAGCCGGCACCGACCGCCTGGCCATGCCATCTCGCGCCGCGTGA  
 AAAAGGAGCTGCTGCAGGGTTGGCGCCGGAGGTGTACGGGGCGCTAAGAAGGAGGAGAACG  
 TCAAAGAGGAGTCAAAGCTGACCTAAACCGCTGAAGAACGGCGCAAGGCCAACGGGGTTGA  
 GCGACAGCGACGAGGTGCTGGTCTGGCACCGGCCAGGCGCCGCTGGACGGGGCGCGTGC  
 GCGCCACCTACCGCCGGTGCACGCTCGCTACGTCCGGTCTTCGGAGGTGAGCGCCACCA  
 AGCGCTCTCGGGACGAGTTGATGCGACACGGACATCCTGCAGCAGGGTCCCAGGCCCTGAACG  
 AATTGCTTATGCAAGAGAGCCGGCGAGCGCGGGCCCTCGCGACCCCCCGCTCC  
 CGGGCCGGACCACCAAGCGCTTTATGACGAGGTGCTGGCAGACAGTGAACATCCTGCAGCAACTG  
 GATCCGGGACCGCTCCAATGAGTTCTCTATGGCAAGCGGTGCTGGGGAGTCAGGAGACA  
 CCGTCCGGCTGGCGTCCCGCTGGAGGAAGGCAGGAACCACACCCAGCCTGCAGCCGCTCA  
 CCGAGCCCAGTCCCCCTGGTGTCCCCCTCGCACGGCGTCAAGCGCGGGGCCGCGACGAGCCA  
 CCGCCTACTGGCCCCACCGTGCAGGTCTGGCCCCCAAGCGTCGTGCAAGGAGGTGGTGG  
 AGCCGCCCCTCCAGCACCCACGCCCTAGCCCCCGGGCGGTCCAGCGCGCATCATTCTGG  
 CTCCCGCCGG  
 AGCGGGCGGG  
 CTGTCGCCGCGCCCGAGGTGCTGCCACGCCAGCCTCCATCATGCCGCCACGCCACGGAGG  
 TGGCCCTGCCCGTACAGACCCCAGTGCCTGGGGTGGCCGTTCCAGTCCTGGAGGCGCCCTGGTGGCCATGC  
 TCCGCGCGTGTGGCACCGAGCGGGTGGCTGAGTCCATCACGGTCAAGCGGTAAAGCGCCTGACCA  
 CGTGGGGGTGGGACCGAGCCGGTGGTGCAGTCATCACGGTCAAGCGGTAAAGCGCCTGACCA  
 AGCACCATCGGGGTGAGACCATCGACGTACCGTGCCTCGCACTGTCAGCGTGGGACC  
 AACACGCCCGGCTGAGGAGCGCCTCGGTGGCGTCCAGACCGCTCCCGAGACCCGCTCCAGGGGG  
 GTGCAGGTGGCTTCCAACCAGCGTGTAGCCCACCGCAGACCCAGGGAGGTGCGGCTGACGGCG  
 TGGTCCCCCCCACCCCGCGGCCGGTGGTTCCGGTGGCCGCGCCGCGGGTCCGGTGC  
 TCCCCCAGCCCCCTCCAGCCCCCGCGCGCGCGTGCCTCGGCCCTCGGCCCTCGCGT  
 CCGCCGTACCCCGTGGCGGTGGCAGCGCCGCCCGCAGCGGGCGGTCCCCCGCCCTCGCGTGC  
 CGAGGGGGCCCATCGTGTGCCGGGTGCGCTATCATCCCAGTCAGGCCATGGCTCCACCGGCC  
 AACGGCGTCACTGGCGTTGATTTATTTGGAGACCTGACTGTTGTTCTAAATTTTAT  
 CCTCCTCCTCTGCTGAAGCCAGACGATGCTGACCTACCGGTTGCGGCTGCCGTGCGGATGCG  
 GAGACCGAGACTCCCGCGGGTGGCTCCCGCGTGGCGCAGCGGGCGGAGGCCGGTACCG  
 CGGGGGCGATGAGGGGTGGCATCTGCCGGCGTGGTGCCTGAGACAAACGCAATTAAACGGCGCTGCTGTATG  
 CATCCCCGGCATCGCCTCGGTGGCGATGAGTGCTAGACAAACGCAATTAAACGGCGCTGCTGTATG  
 TGTGTCTTCCATGTGCCTTCTCTCGTCCCTAACGGAACAGCAGCAGCACCGTCTCCATGGAGGAC  
 CTAAGCTTTCCCGCGTGGCTCCACGCTTGGCACGCCGGTGTGGGACTTGGAGCGAAATC  
 GGCACGAGTCAGATGAACGGCGCGCTCAGCTGGAGCAATATCTGGAGCGGGCTGAAGAGCTT

**FIG.\_ 1-5**

SUBSTITUTE SHEET (Rule 26)

GGTAGTTCTCTGGCCTCCACGGCCAACAAGGCCCTGGAACAGCGGGACGGTGACGAGCGTGCGCAAC  
 AAGTTGAAGGATGCCGACGTGCAAGGGGAAGATAGGTGAGGTATTGCCTCCGGGTCCACGGTGCC  
 CTGGACGTGGCCAACCAGGCCGTCTCCACGCCGTGGACCGCCGGTGCAACAGCAGCAGCTGCGGC  
 AGCAGCAGCTCCTCCGCCAGCAGCAACAGATGGGCCCTCGTGAACCCCTCTATGAGATGGAGA  
 CAGACGAGCTGCCTCCCTCCCCCGAGGACCTTGCCTCTCCTCCGCCGCTGCCCTCG  
 CCACTCCCAGGCCAATCCCGGGGACGTCCCGCCAAGCGCCGCCGCCAGGAGATCATCA  
 TCCGCTCCGACGAGCCCCCTCCCTATGAAGAGCTGTATCCGACAAGGCCGGATCCCCGCCACCT  
 TGGAGCTCGTCCCAGACCAAACAGCCCTGAGGCCACAATAAGATGCCCCCCCGCCGCC  
 TCACCAACCAACCTCCGCTGCCGCCGCCGCCGCCGCCGCCGCCGCC  
 GGCCTCCGGCCGGCTCCGGCGGGCTCCGGCGAGTCCAAAGGCCGCCAGGTGGGGTCCGC  
 GCGCCGGGGTGGCAAAACAAACTCACACCAATTGTGGACTGGGTGTCCGCACATGCAAGGCC  
 CGTTGTTACTGAGAGAGACAGCATGGAGAAACAACAATGTCTGGATTCAAATAAGACACGCC  
 TCTTCAACGGCTGTTCTTTGCATCTGTGCCATC  
 GCGCCACGGGAATTCCGCAAGGATGGCAGCCGTCGATGATGCCGAGTGGTCTTATGCACAT  
 CTCCGGCAGGACGCGTCCGAGTACCTGCTCCGGCTGGTGCAGTTCTCCAGGCAGGGAGAC  
 CTACTTTAACCTGAACAACAAGTTAGGAACCCCACCGTCGCCACCCACGATGTGACGAC  
 GCGCTCGAGCGCTGCAGCTGCGCTCGTCCCGTGAGACAAGGAGGACACTCAGTACACATACAA  
 GACCCGCTTCCAGCTGGCGGTGGCGACAACCGCGTGTGGACATGGCAGCACCTTGTGACAT  
 CCGGGGAACGCTGGACCGGGGACCCCTCTCAAACCGTACTCGGGCACCGCGTACAACATCATGGC  
 TCCCAAGAGCGCTCCAAACAACCTGTCATATCTAGACCCCTAAAGGTGAAACTGAGGCTGGCAAAGT  
 TAATACCATTGCTCAAGCAAGTTGTGGGCTCTATTGATGAAACACCGGGAGACATTAAATTAC  
 AGAAGAAGAAGACGAAGAGACCACTCGATCCTTGTATGAGGCCAACCCAGCTGGTCCAAG  
 CTCGTGGTCAGACAATATACCTCTGCACTAGCGGAGCTGGAAGAGTTCTCAAACAGACCA  
 GCGTCAACCTTGTACGGTCTTATGCCTCTCGACAAATATTACGGTGGCAAACGAAGGATGA  
 CAAGGTTACACCAATTGTAACAAACAATCCGCCACCGAAGCCGAAGCAACTCGAAGAAAATGG  
 ATTAAAGCCAATGTCAACCTATAACTCAGAGGATGTTGACCTAAAGCACCAGATACTCATCTGGT  
 CTATGCTGTGAATCAAACCCAGGAATTGCTCAATATGGACTTGGACAACAGGCCGCTCCAAACAG  
 GGCAATTACATCGGCTTCAGGGACAACCTTATGGGTGTTGACTACAACAGCAATGGCAACCA  
 GGGCATGCTAGCCGGTCAGGCCTCTCAGCTCACGCGTGGTGCACCTGCAGGACAGGAATCACCG  
 AACTAGCTACCAAGCTTCTCGATAGCCTCTATGACAGGTGAGGTACTTTAGCCTGTGGAACCA  
 GGCCATCGATTCTTATGCAAGGATGTGCGTGTGCTGGAAAACAATGGGTGGAGGACGAGATGCC  
 CAACTTTGCTTCCCATCGGCCATCGAGACCAACATGACATTACACAGCTCAAAGAGTGA  
 GAATGGTGGCTCAAGAGCCACAACCTGGACAAAGGAGAATGGGATGATGGCGGAAACGGAGCGGA  
 GCAACTACCTGGCATCGGCAACCTCAACGCCATGGAGATCAATCTCACGGCCAACCTCTGGCG  
 CTTCCCTACAGCAACGTGGCGCTGTACCTGCCTGACAAGTACAAGTTCCCCCTCAACAAACCTATTGA  
 CATCGACCCCAACACGCACTCCTATGACTACATCAACAAGCGCTGCCCTGACCTCAACCA  
 TACCTTGTCACATCGGGCGCGTGGTCCCCGGATGTCATGGACAACTCAACCCCTCAACCA  
 CCACCGCAACTACGGCCTCGCTACCGCTCCAGCTCTGGCAACGGCGCTACTGCAAGTTCCA  
 CATCCAGGTGCCGCAAAAGTTCTTGCCTCAAGAGCCTGCTGCTCCGCCGGGGGCGACCTACAC  
 CTACGAGTGGCTCTCCGCAAGGACGTCAACATGATCCTCCAGTCCACGCTGGCAACGACCTCCG  
 CGCGACGGGGCAAAATCAACATCGAGAGCGTCAACCTCTACGCCAGCTCTTCCATGGCCA  
 CAACACCGCTCCACCGTGGAGGCCATGTCGCAACGACACCAACCAACAAACCTTATTGACTT  
 CCTCTCCTCCGCCAACATGCTCTACCCCATCCCGCCAACGTCAACCTGCCATCTCCATTCC  
 CAGCCGCAACTGGCCGCTTCCGCGCTGGAGCTCACGCGGCTGAAGCACAACGGAGACCCCG  
 CCTGGGCTGCCCTCGACCCCTACTTACCTACTCGGGCTCCATCCCCCTACCTGGACGGACCTT  
 CTACCTGGGCCACACCTCCGCCATCAGCATCCAGTTCGACTCCTCCGCTGGCTGGCG  
 TGACCGCCTGCTCACTCCCAACGAGTTCGAGGTCAAGCGCACCGTGGACGGGGAGGGCTACACGGT  
 GGCCAGACCAACATGACCAAAGACTGGTCTGGTGCAGATGCTGCCACTACAACATCGGCTA  
 CCAGGGATAACCAACTGCCAGAGGGCTACCGCAACCAACAAAGATGAGTACCTGGAGGTGCC  
 CATGTGCCGCCAGGTGCCGACTACGCCAACCAACAAAGATGAGTACCTGGAGGTGCCACCA  
 CCAGTTCAACAGCAGCGGCTTTGTATCCGCCCTTCACCGCCGGCATGCCGAGGGGACCCATA  
 CCCCCGCAACTGGCCCTACCGCTCATCGGCCAGAGCGCCACCTACTCCTCTCGC  
 CCTCTCGACCGCACGCTCTGGCGCATCCCCCTCTCTCCAAACTTCACTGTCATGGC  
 CGACCTGGGCCAGAACCTCCTCTACGCCAACCTGGCCACGCCCTCGACATGAC  
 CGCCATGGATGAACCCACCCCTTGTATGTTGAGGTCTTGACGTCTGGCG  
 CGGCCACCGAGGCGTACGAGGCCGTACCTGCGCACGCCCTCTCCGCCGG  
 AACGCCACCA

7 / 14

CTAAGGGGGAGCCGCGCAGGCATGGCAGCACCAGGACGAGCTCGAGGCATGGCGCGGACCTC  
 CAGCTGCCCGCTTCTGGCACCTTGACAAGTCCTTCCGGCTTCTGCAAGAGTCCCAGCG  
 TGCTGCCCATCGTCAACACGGCCGCCACACCGGAGGCCACTGGCTGGCCGTCGCCCTGG  
 GAGCCCGCTCGCGCACCTCTACTCTTGACCCCTTCGGCTTCTCGACCGGGAGCTCGCCAG  
 GTCTATGACTTTGAGTACCAAGCGCTGCTGCGCAAGAGCGCCATCCAGAGCACCCCGGACCGCTGC  
 CTCACGCTCGTCAAGAGCACCCAGAGCGTGCAGGGACCACAGCGCCGCTGCGGACTCTTCG  
 CTCCTCTCGCCCTTGCCCGTACCCGACAGCCCCATGGCCTACAATCCGTATGGAC  
 CTGGTGGAGGGCGTGGACAACGAGCGGCTTCGACGCCAGCTCCAGGCCATCTTCCGCGCCAAC  
 CAGGAGGCCTGCTACCGCTTCTCGCCACTCCGCTACTTCCGCGCCACCGGCCAGGCCATC  
 ATGGAACAGACACACCTGCACAAAGCGCTCGATATGCAATAAAGGCTTTTATTGTAAGTAAAAAA  
 GGCCTTTTATCCCTCGCCCTGGGGGTGATGAGATGGGGGACTAGGTGAACCCGGACCCG  
 CCGTCGGCTCCCCCTCCATCCCTCTCTCTCAAAACAGGCTCTCATCGTCGTCCTCCGTTCCACG  
 GGGAAAGATGGTGTCTGCAACCTGGAACCTGGGCCCCACTTGAACCTGGGACCCGTCAGTGGAGGC  
 CGCGTCTGCATCAGGGCGCCACATCTGTTGGTCAGCTGCAGGGCAGCATCACATGGGGCG  
 CTGATCTGAAATCACAATTCTCTGGGGTGTGCGACAGCAGGGCTTGTAGCAGCAGGGG  
 TGGAACACCAGCACCGCGGGGTGGGTACGCTGCCAGAATCTTGGGGTCTTCCACCAAGCTGGGG  
 TTCAGCGCCGCCGACCCGCTCAGCGCGAAGGGGGTGAATCTTGCAAGGTCTGCCGGCCAGCAGGGG  
 ACCTGGCGCAGCCCCAGCCGAGTCGCACACCAGCGGCATCAGCAGGTGCGTCTCCGCGTTGCC  
 ATCCGGGGTAGCAGGCCCTCTGAAAGCCTGAGCTGCTGCAAGGCCCTGCGCCCTGGAGGCC  
 TCCGAGTAGAACAGAGGCCGAGGACCGCGAGAAGGTGTTGGGGCCACCCACGTCGTGGCTG  
 CAACACATGGCCCCGTCGTTGCGCAGCTGCACACGTTGCGGCCAGCGGTTGGTGAATCTT  
 GCGCGCTGGGGTCTCGCGCAGGGCGCTGCCGTTCTCGCTGTTGAGATCCATCTCACCG  
 TGCTCCTGTTGATCATGGCAGCCGTGCAGGCAGTGCAAGCCCTCCGAGCCGCTGCGGTGCTGC  
 CAGATCACGCACCCCGCAGGGTTCCACTCGGGCTCTCAGACCCGCCCTCACACAAAGTCC  
 AGCAGGAAGCGGGCCATCACTGTCAGCAGGCCTTTGCGTGTGAAGGTCAGCTGCCAGCTGATC  
 TTGCGCTCGTTCAGCCAGGCTTGGGCCCCGCGCGGAAGCAACTCAGGGTGTGCGTCCGGCAGC  
 AGCGTCAGGCCCTGACATCCACCTCAGGGGACCAGCATCTGCACAGCCAGATCCATGGCCCG  
 TGCCACTTCTGCTCTGAGCATCCAGCTGCAGCAGCGCCGGGACCGCCGGCTGGGTCA  
 GGGCGGGGGCGGGCCCCCTCCCTCCCTCCCCATCTGCCCTTCTCCCTCGCGTACAGACACGTCC  
 GTCGCCGCTGCCGTCTCAGCCCTCGTCCACAATCAGCACCCCTCTCCCGCTGTACAGACACGTCC  
 GTCGCGACAGGAGCGTCCACAATCAGCACCCCTCTCCCGCTGTACAGACACGTCC  
 GAATAGCGCGACTCATTGCTTCCCTAGATGGAAGACAGCACAGCGCAGCCAGTGAGCTGG  
 GTCCTCCGCGCCCCGACCCCTCCGCCACACCGCCACCTCCGCCACGTCAACGCCACC  
 TTCACTGCAGCGGCAGCAGGAGCCCACCGAAACCGATGACGCCAGGACACCTGCTCTCGTC  
 CTCCCTGTCCTCCGCTCCAGCGAGTGCTCGTCTCGCCGCTGGAAGACACGAGCTCCGAGGACTC  
 GGC GGACACGGTGTCCCCCTCGAGCCCCGCCGGACGAGGAGGAGCAGGAGGAGGACTCGCCGA  
 CCGCTACATGGACCGGACGTGCTGCAGGCCACCTGCTGCCAGAGTACCATCCCTGCCAGGT  
 CCTGCAGGAGGCCGCCCCCGCGCAGCCGGAGGCCGAGGCCGCCCCCTCGGTGGGGAGCTCAG  
 CGCCCGCTGGAAGCGGCCCTCTCTCCCCGCCACGCCGCCGGCGCAGGAGAACGGAACCTG  
 CGCCCCGGACCCCCGCCCTCAACTTCTACCCGGTCTCATGCTGCCGAGGCCCTGCCACCTACCT  
 CCTCTCTCCACAACCAAAGATCCCCGTCAAGCTGCCGCCACCGCCACGAGCCACGCGCA  
 CTGGCGCTGCCAGTGGGACCCCTTACCTGACTATCCAACCACCGACGAGGTTACAAGATCTT  
 TGAGGGCTGGGGACGAGGAGCCGGCTGCCCAACCCAGGACCTGAAAGAGCGCAGCGTGT  
 AGTCAGCTCAAGCTGGACAACCCCCGCCCTGGCGGTGGTCAGCAGTGCACTGCCGTACCCACTT  
 CGCCTACCCGCCCTGGCGCTGCCACCCAGGTCAAGCTGCCAGGCTACGTCAAGCTAGCTAGCAAGAT  
 CGCGCGCCTCGGAGAGTGCCTCCACTACATGTTCCGCCAGGGCTACGTCAAGCTAGCTAGCAAGAT  
 CGCCAATATGGAACTCTTAACCTGGTCTCTACTTGGGATGCAAGCATGAGGCGAGACCGCAGTCCGGTCA  
 GCACGTGTCCTACCCACACCGTCAAGCATGAGGCGAGACCGCAGTCCGGACCCATTACCT  
 ATACCTGGTCTATACTGGCAGACGCCATGGGGTCTGGCAGGAGCCTGTGGACGGGCTTGTAGGAGCGC  
 GCGCCCTGGAAACGTCCTGGCTCGCGCTGCCAGAGCCTGTGGACGGGCTTGTAGGAGCGC  
 TATCGCGCAGGACCTGCCGCGTTCTTCCCCACCAAGCTGTAGAGACCCCTGCAGCGCTCG  
 CCCCACCTTGCCAGCCAGAGCATGATGCATGCCCTCCGCTCTCGAGCGCTCCGGCAT

**FIG.\_ 1-7**

SUBSTITUTE SHEET (Rule 26)

CCTGCCCGCCGTCTGCAACCGCGTCCCCCTGACTTGTGCCACCCTACCGCGAGTGCCGCC  
 GCCCCCTGGGCTCACTGCTACCTCTGCGCCTGCCAACCTCCTCATGTACCACTGCGACCTCGC  
 CGAGGACACCTCCGGCGAGGGCTCTTGAGTGTACTGCCGCTGCAACCTCTGCGCACCGCACCG  
 CTGCGCTGCCACCAACACCGCCCTCCTCAACGAGGTGCAAGCCATCAACACCTTGAGCTCCAGCG  
 GCCCCCAAGCCCAGGGCACCCCTGCCACCGCCCTCAAGCTGACCCCCGGTCTCTGGACCTCCGC  
 CTTCTCCGCCACTTGTCTCGAGGACTACCAACTCGGACCGCATCCTTCTACGAGGACGTGTC  
 CCGCCCCCCCAGGGTGGAGCCCTCCGCGTACCGCACTCGGCCATTCTCGCGCAATTGCA  
 TGACATCAAAAGGCCAGGGAGTGGTGTGACCAAAGGCCACGGCGTCTACCTAGACCCCCA  
 CACCGGAGAGGAGCTAACACCGCCGCCCCGTCCACCGCCACCATGCCGCCCTCCGGAGGAAGC  
 CCATCCGAGCAGCACCGACAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCTA  
 CGCAGACCGTGTCCGAAGCGAGCTCACGCCAACGGCGTGCAGCCACCGCCGCCACCCAGCT  
 CTCTGGGGATGCTCTGCCAGAGGAACCCACTCCCGCATGCTGCTGAAGAAGAGGCTCTCAGCA  
 GCGAGACCAGCGGAGCTCGAAGGAGTTGCTCAGTACCCCTCAGGAACGGAGGAGGAGGAGG  
 AACCGGTACACCGACGAGGCCATCCAAGCCCTCCTACACCAACAGCAGCAGCAGCAGAGCAGCTA  
 GCCAGGCAGGAACCTCGTCGTCCCCAGCGAGGCTCGTAGATGGAATCAGACATCCATCCACCGA  
 GTAGCCAGCCAGGTAGGACACCTCCGCCCTGGCCGACGCTCCTGGCGCCGCTACCGCCACG  
 ACATCCTCTCGGCCCTGGAGTACTGCGCCGGAGACGGAGCCTGCGTGCAGCAGCAGCAG  
 ACCACAACATCAACATCCCTCCAAGATCATCCGTTACTACAAATCCTCTCCGTTCCAGCGATC  
 TCCAGGAAGGCCAGCGAGCGGGGGAGCAGAACACCAGGCCACGTAGCCAGCTGAGAGCTAAGATC  
 TTCCCCACGCTGTACGCCATCTCCAGCAGGCCGGCCAGGAGCAGCCCTAAAGATCAGGAAC  
 CGCACCTCGCCTCCCTACCAAGAGCTGTGTATCACCGCAGGGAGGCAAGCTGGAACGCACG  
 CTCTCGACGAGCAGACTCTCGAGAAGTACTGCGCTCGCAGCGGAGACCCGGTATT  
 AGGAGCGGACCCCTCGTGCAGCACACCATGAGCAAACAAATCCCCACCCGTACATGTGGCTTA  
 TCAGCCACAATCTGGCGTGCCTGGGGGTGCCTCCGCTGATTACTCCACCCGATGAATTGGCTCAG  
 TGCCGGCCTTCCATGATTGGCCAGGTCAATGACATCCGACACACCAGGAACAGATTCTCATT  
 CCAGGCCCTTATCACCGAGACGCCACCCCCGTCAAAGATCCCCCGTCTGGCCGCCAGCCTGTT  
 GCCTCAGATGACGCAACCGCCCACCCACCTGCACCTGCCGCTAACGAAATTGGAGGAGACT  
 GACTGACGCCGGCATGCAATTAGCCGGGGGGAGCCCTCGCACCCAGAGACTTATATGCCCTGAC  
 CCTCCGCGCAGAGGCATCCAGCTCACAGGACCTACCCCTCTCGCGAGCAGCAGCAG  
 CGGCATCTCCAGCTGGAGGCCGGAGGCCCTCCCTCAACCCACCGACGCCCTACCTGACGCT  
 GCAGAACTCCAGCTCCCTCCCCGAGCGGGCATCGGAGCAGCAATTGTCGGAGTTGCT  
 GCCCACGGTCTACATCAACCCCTCTCCGGACCGCCGGGACCTACCCGACCAGTCACTGCCAA  
 CTACAAACATCTAACGGACTCTGTAGCAGGCTATGACTGACGGTCCCCAGGGTCAGCAGCGGTG  
 GGGAGCTCCTCGACCAGCACGCCAGTGCCCTAACCGCTGCTGCTCCGCCAGGGAAAGGGATT  
 ACCCGGAGTACTTTGCATCACCCCGAGCAGTGTGGAGGCCGAGTCATCCCGACTCTGCAAG  
 AAGGCCACGGTCTCGCCTCAGCCTCCCCACCGCAGCAGGCCACCGCGATGGAGACC  
 GCACCATCCTCACTCGTACTACTGCGGCCCTGCTTCAAAGTTGCTGCTCTCGGCCATC  
 CTGCTCCTCACCCCTTCTCGACCTCTGTGTGAGCTGTACAACCGCTCGTAGCGTCAGCCCC  
 TACACCTCCCTCGCTCCAATTCTGTCCGACATAGAACAGACTCTGACTCTTACTCGGGCTCT  
 GGCTCTGGGAGCATGAAGATTATGAATATGAGCTGGCTACCAACACACCGAACGAAGACATT  
 GGCAGCATAGTCATCAACACCGATCGGGCCAAGACCCCTGGCCCTGGGATACTTTATGCCGCC  
 ATGCAGTTGTTCTCTTGCCATCATCATCGTCTCATCCCTACTACCGCCGCTACGTGCTG  
 GCCACCGCCCTCATCGTGCAGCGCAGATGTGGCTCCGAGGGCGCTCGCGAAAACCTCTCG  
 GCCACCGTTGTGGTTACTCCCCAAAACAAGTCACCCCTGCAACTGCTCTGCCGCTCGAGGAG  
 ATGGTGTCTACTACACCACTCCGTCTTCTCATGCCCTGGTGGGCTCATCCTCTGCTCACCGCA  
 TGGTCCGCTGGCCAAGTGATAGGGATCAGATGCCAGCAGAACCGGCCGGCTGCCAC  
 CGCCCTCACCTATGTGGGACCCCTGCGCCGAGGACCATCTACGATGAGCCAACCGTAGGGCAAT  
 ACGTACAGATGAAGTAGCTCCCCCTTTCCATTCCCCATTCTCTATTCAATAAGTTGCT  
 TACCTGAGTTCATCCACACTCGGTCTGCCAGTGCAGTCTATCCATGCCCGTTTCCATACT  
 TAGCGCAGCCGCGCACGCCCTGCCAGGTGACGAAACTGTCGAATGTAACATTGCGCTTCTGTC  
 AGCAGCACCCGTTATAGACCAGTCCACCATGGGACCGAAGAACGAGCAGCGAGCTACCGAG  
 GACTTCGATCCAGTCTACCCCTATGACGTCCCGCAGCTGCAAGATCAATCCACCTCGTCAGCGGG  
 GACGGATTCAACCAATCCGTGGACGGGGTGTCCCTGCACATCGCACCGCCCTCGTTTGAC  
 AACACCAGGGCCCTACCCCTGGCCTCGGGGGAGGTCTACAGCTCTCGGGCAAGCAGCTCGT  
 GCCACCGAGGGCTCGGGCTAACCAACCCGGATGGCAAGCTGGTCTCAAAGTCAGTCCCC  
 ATCACCCCTGACCGCCGAGGGCATCTCCCTGTCCTGGTCCCGGTCTTCTAAACTCAGAGACCGGC

## FIG.\_ 1-8

SUBSTITUTE SHEET (Rule 26)

9 / 14

CTCAGTCTGCAAGTCACAGCTCCCTGCAGTTCCAGGGCAACGCCCTCACTCTTCCCTCGCCGCC  
 GGTCTCCAAAACACCGATGGTGGAAATGGGTGTCAAACGGGGAGCGGTCTCACACGACAACAGT  
 CAGGGCGTGCACCGTTCAAGGTGGAAATGGACTTCAGCTAACGGCAAGGACAACTCACCGTCCCC  
 GCCACGGCCCTTACTAGTCTCAGGGAGCGCAGGCATCTCTTCAACTACTCCAGCAATGACTTCGTC  
 TTAGACAATGACAGTCTCAGTTGAGGCCAAAGGCATCTCTGTCAACCCCTCCGCTGCAGTCCACA  
 GAGGACACAATCTCCCTGAATTATTCTAACGACTTTCTGTGGACAATGGGCCCTCACCTGGCT  
 CCAACTTCAAACCCACACGCTGTGGACTGGCGCTCACCCACAGCAAATGTCAATTCTAACAAAC  
 ACCACCACTCCCAACGGCACCTTTCTCTATGCCTGACACGTGGGGTAGTTGGGTCTC  
 TTTGCCCTGAAATCATCCATCGACCTACTAGTATGACCAAAAGGTCAATTATTGGATGG  
 GCAGGTGGCTTCAGTCAGACTCCACTTATAAAGGGAGATTGGATTTAGATCCAACGACAGCGTA  
 ATTGAACCCACAGCCGAGGACTCAGTCCAGCCTGGTTAATGCCAACCTTATTATCCACGC  
 AACACCTCCGGTCTTCCCTAACATCATTGTATACATTAATCAGACATATGTGCATGTGGACATC  
 AAGGTAACACACTCTAACAAACGGATATAGCCTAGAATTAACTTCAAAACATGAGCTTCTCC  
 GCCCCCTCTCCACCTCCTACGGGACCTTCTGCTACGTGCCCGAAGGACAACTCACCGTCCCCGC  
 CACGGCCCTTACTAGTCTCAGGGAGCGCAGGCATCTTCAACTACTCCAGCAATGACTTCGTC  
 AGACAATGACAGTCTCAGTTGAGGCCAAAGGCATCTGTCAACCCCTCCGCTGCAGTCCACAGA  
 GGACACAATCTCCCTGAATTATTCTAACGACTTTCTGTGGACAATGGGCCCTCACCTGGCTCC  
 AACTTCAAACCCACACGCTGTGGACTGGCGCTCACCCACAGCAAATGTCAATTCTAACAAACAC  
 CACCACTCCCAACGGCACCTTTCTATGCCTGACACGTGGGGTAGTTGGGTCTC  
 TGCCCTGAAATCATCCATCGACCTACTAGTATGACCAAAAGGTCAATTATTGGATGG  
 AGGTGGCTTCAGTCAGACTCCACTTATAAAGGGAGATTGGATTTAGATCCAACGACAGCGTAAT  
 TGAACCCACAGCCGAGGACTCAGTCCAGCCTGGTTAATGCCAACCTTATTATCCACGCAA  
 CACCTCCGGTCTTCCCTAACATCATTGTATACATTAATCAGACATATGTGCATGTGGACATCAA  
 GGTAAACACACTCTAACAAACGGATATAGCCTAGAATTAACTTCAAAACATGAGCTTCTCCGC  
 CCCCTCTCCACCTCCTACGGGACCTTCTGCTACGTGCCCGAGAGTGCCTAGAGAACCTGGCGT  
 CAGCCGGCTCCCCCTTCCAGGCCACCCGTACACCACCGCTCCATGTTCTGTATGTGTTCTC  
 CTCCCGCGCTTGTGCAGCACCCCTCCGCTCGAGCTGAGGATCCGTATGGACACAAAGCC  
 AGGAAGACACATCCTCAGCTCCGTGGGGCGTCAACAACTGTTATGTAAGGAAATAAGACT  
 CAGAGAAAATCAAAGTTCATATGATTCTTATTGATTGGGGATTGATTCAAGGTGGGTGT  
 GCATAATCACAAAATCACATCAGCAGGTACACACACTGAGACATCAGACAGGGTAAGGACAGCGC  
 CTCAGCTCTGGAAACAGACATCAGAAATATTAACTCTGCTGGTAGCTAACACTCTCCCAACACC  
 ATACACTCCTGGAGGGCCCTCTGCCCTCTCCCTCCCCCGCTGCGCCCCGATGGCCTCCGCGCAGCTC  
 TCCCCCTCCGTGAACGTGCTTCTCTCCCCCGCTGCGCCCCGATGGCCTCCGCGCAGCTC  
 AGCCAGTGGCGCAAGCGCTGGCGAGCGCCAGCCACCGGCTCGCTCAGCTCGTGGCAGCGCCGG  
 CACACCAGCACTATGTAATTGGCATAGTCCCCGTACAGTAGATGACCTCCCCCAGTGGAACATG  
 CGCAACAGCTCAGATCACAGTACATGATCTTATGACATCAGGTGGCGCCTCGAACCACAGAAG  
 AACTGCCCACGTACATCACCGCACTCACGCTGGCAGGTTACCGCCTCCCTGAACCACAGAAG  
 ATGCGATTGTAACCGCAGCCCCGGATGATCTCGGCATCAGGGAGCGCATCACCACCTGCCCGCG  
 CGGCACTCCAGACTGGACCTTTCAAGACAGTGGCAATGAAAGTCCACAGCGTCGCCCGCACAG  
 CGTCTCCGGGCTGAAACATATCTGCTCCAGCTCAACCCCCCACAGGGCTGACTGCAGGAAAAT  
 CCATTCTTGTGGAAAGGATGTAAGCGCCAGGGACCACAATCTCAAACAGGGAAACAAACATAC  
 CGCGGGCCGGCTTGTGCACGGCCCCCACCGGATGCAACGTGTCAGGGAGCAGATACTGGGGGG  
 ACAGCGGGCCACGTCTCATAGCAAGTCAAGTCCGGAAGTGGCACGGGTTGCGCACCAGTCTACT  
 GCTGCCGCTGCCACAGCTCCATCGGCTCCTCCATCCTCTCTGTCCATCGGCTGAGGTGCT  
 GCCTCTCTCTCTGCCGCTGCTCCATCATGCTGCTCTGCCGCTCATCAGGAGTAAAAATTCA  
 TTGGCCACCGCAGCAGAGAGAACATGGAGCGCAGGGGCCAGGTGCCGGCGTGCCTCGCT  
 AACCTCCCCAGCAGGTACTCATAGAGATGCTCTCCAAATCCACCGAAACAGGCATGCAGAAAC  
 TCTTCGTTGAGGACGGCCCACGGTAAAGACATAGCCCTCCGCACCTCACCCTGCGCAGCTGC  
 ACGCGCTCATGTCGCTGGAGTACACCCGGACCCGGCTGGATGACTCCAGCACCTGATCGCTC  
 AGACACCTCACAGAGATGCCAGCCGCTGAGCCAGCTCTCATAGAGAGGTGGCTGAATCTGAGCTG  
 AAGCAGCGAGGGCTAGGCACTCCCCGCCCTGGAAACAGGGCGGCCGGTCAAGCCATGGACTTC  
 CTCTACATCCGGGGTCCCTGGCCACCTCACAAACTATCTGGCCAATCGCCTGACCAAGGGTCAACAG  
 GTAAGGATGATGTCGCTGGAGTACAGAGGTGGACTCGGTAGCGTTATCAATCAC  
 GTCCCCAAAGGTCAAAGGTCCCAGTTAGAAGTCAGGTGCTTCAGACCGCAGACACGCCATAGCA  
 ACCAGTGGAAAAGCCAGCAAGAGATCCGTGGCACATGCACCGAAGCTCCGCAGGAATCTCCAC  
 CCACTCCGAGGGTAGACCGTGTAAAGCTACACACCCCGCTCCCGAGTGGAGCAGAAGCATTCTC


**FIG.\_ 1-9**

SUBSTITUTE SHEET (Rule 26)

10 / 14


GCTCAGCCGAAAGAACTTCAGGGTGGCCTGCATATCCTCTTTACTCACTTGTAGCAGCTCCACA  
CAGACCAGGGTTGTGTTGGCGGAATAGGCAGCAGGGTACGTCCCCAGTGAGGGACACCTGGATG  
GGGGCAGAGGATTGATGCCAGGAAGCAGCAGGTACTGGGAAACAGAGACCAGATCCCTCCTCTGA  
AAAATCTCGCTCAGTCGGACAAACACAGCAAACCCAGTGGCACGTAGACTAGCACATTAAAAGG  
ATCACGCTGGCTGTTCTGACGTACGACCAGATGTCGGACGTGCGCAGATGAATGCGGTTCTGA  
TGAATTACCGGAGGCCTCTCACCCGCAGCCAACAGCAGACGGGCTGCTGATGCGGTCCCGCAGAC  
ATATATGAGTTCAATGTGTCTTTCTAAACGTCTAGTGAGTGTGCTCGTCTGCTCTGCCA  
ATCAAAATCCGGGACCAGGGCTGGGGTGGACCCGATGAAGAACGAGGAGAGGCGGCCTCTG  
AGTGTGAAGAGTGTCCCGATCCTGCCACCGCAGGTAGCGAAGTACAGATAGAGCACGGCGAGAAC  
AGTCAGCACCGCGGCCAGCAGCAGTCGGTCGTGGGCATGAGAGGGGCTGATGGGAAGATGGCCG  
GTGACTCCTCTCGCCCCGCTTCGGTTCTCCTCGTCTCGCTCTCAGTGTCTCTCTGTGTACG  
GCCGAGACGAGTGTGAGCGAACACCGCGAGCGGGCCGGTGAATACCCACAGCGGATGTGGCCACG  
CCTGCGGTGGTTAATCAGTACCCCATCGTCCGATCGGAATTCCCCCGCCTCCGCGTTAACGATTA  
ACCCGCCAGAAGTCCCGGAATTCCCGCCAGCCGGCTCGCCGCGACCTGCGACTTGAACCCGC  
CCCTCGGACTTGACCGTTCCACGCCACGTCAATTCCCACGCGACGTACGTTCCCACGCTACG  
TCACACCCCTCTCCACCAATACCAGCCGCCGCCCCAACCTCTCCGCCAATACCCACGCCACAA  
AAGGGGCAATAAAAGTGTGCGGTATATTATTGATGATG

**FIG.\_ 1-10**




12 / 14


1 2 3 4

**FIG.\_3A**



1 2 3 4



**FIG.\_3B**

1 2 3 4 5 6

**FIG.\_7**  
SUBSTITUTE SHEET (RULE 26)

13 / 14

**FIG.\_4****FIG.\_5**

**FIG.\_6****FIG.\_8**

## SEQUENCE LISTING

<110> Reddy, P. Seshidhar  
 Tikoo, Suresh  
 Babiuk, Lorne

<120> PORCINE ADENOVIRUS TYPE 3 GENOME

<130> 293102002440

<140> Unassigned  
 <141> Unassigned

<160> 8

<170> FastSEQ for Windows Version 3.0

<210> 1  
 <211> 34094  
 <212> DNA  
 <213> Porcine Adenovirus Type 3

<220>

<400> 1

catcatcaat	aatataccgc	acacttttat	tgcccccgtt	gtggcgtgg	gattggcgga	60
gagggttggg	ggcggcgggc	ggtgatttgt	ggagaggggt	gtgacgtgc	gtggggacagt	120
gacgtcgcgt	gggaaaatga	cgtgtatgt	cgtcccggtt	gaacgggtca	aagtccaaagg	180
ggaagggggt	gagccctggg	gccccctcc	gcggggcggg	gccgagcggc	ggaaattccc	240
gcacaggtgg	agagtaccgc	gggattttgt	gcctcttgg	ccggacccctc	gccctccgg	300
gtggcacttc	cgcaccacac	gtcccgccgc	cggattttcc	cacctgacga	cggtgacacc	360
actcacctga	gcgggggtgc	cttcgcgtt	agaggccgc	ggccggccgc	cgagatgacg	420
tgtgtgggt	tatttttcc	cctcagtgta	tatagtccgc	gcagcggccg	agagtcacta	480
ctcttgagtc	cgaagggagt	agagtttct	ctcagcgaa	cagaccctcg	acatggcgaa	540
cagacttcac	ctggactggg	acggaaaccc	cgagggtgtt	ccgggtctgg	aatgggaccc	600
ggtggatctg	cgcgaccct	ctccggggga	tgagggttcc	tgtgagccgt	gctgggagag	660
tctggtcgat	ggactgccgg	acgagtgct	ggacagtgt	gacgagggtgg	aggtgattgt	720
gactgagggg	ggtgagtcag	aggacagtgg	tggaggtgcc	gctgggtact	caggtggctc	780
tcaggggggtc	tttgagatgg	accccccaga	agagggggac	agtaatgagg	aggatatcag	840
cgcggtggct	gcggagggtc	tgtctgaact	ggctgatgt	gtgtttgagg	acccacttgc	900
gccaccctct	ccgttgtgt	tggactgccc	cgaggtaact	ggtgtgaact	ggcgtcttg	960
tgattaccat	cgcttcact	ccaaggaccc	caatctgaag	tgcagtctgt	gctacatgag	1020
gatgcatgcc	tttgctgtct	atggtgagtg	ttttggaca	tttggggat	tatgtggaaa	1080
aaaaggaaaa	agtgttgta	agaaatctca	tgtgttattt	ccctttttt	gtcttttttag	1140
aagcttttc	tccagcacct	cacaggtcgg	gttccccggg	acttggagac	ctgccaggac	1200
gcaagaggaa	gtactgctat	gactcatgca	gcgaacaacc	tttggacctg	tctatgaagc	1260
gccccccgca	ttaatcatta	acctaataa	acagcatgt	atgatgactg	attgtctgt	1320
tctctgccta	tatataccct	tgtggtttgc	aggaaaggga	tgtgggtact	gagctattcc	1380
tcagcatcat	catcgctctg	ctttttcta	ctgcaggcta	tttcttgcta	gctcgctgtc	1440
ccttttctt	ttctgtgggc	atggactatc	aacttctggc	caagcttact	aacgtgaact	1500
accttaggaa	ggtgatagta	caggggtctc	agaactgccc	ttgggtggaaa	aagattttt	1560
cggacagggt	tatcaaggta	gtacgagg	ccaggaggca	gtacgggcaa	gagttgatgt	1620
agattttgt	ggagggttag	aggggcttt	gtcctgagtt	cctgcgggaa	gggggactgt	1680
acgaagaggc	cgttctgaaa	gagttggatt	tcagcacctt	gggacgcacc	gtagctatgt	1740
tggctctgt	ctgcttcatt	tttgagaagc	ttcagaagca	cagcgggtgg	actgacgagg	1800
gtattnaa	tcttctgggt	ccgcaactat	gttccctgt	ggaggcgcga	atgatggccc	1860
agcaggtgcg	gcaggggctg	tgcataatca	ggatgccgag	cgcggagcgg	gagatgtgt	1920
tgcccagtgg	gtcatccggc	agtggcagcg	ggccggggat	gcgggaccag	gtgggtcccc	1980
agcgcggcgc	ggagcaggaa	gaggaggagg	aggacgagga	tggatggaa	gcgagcgggc	2040

gcaggctcgaa	agggccggat	ctggttttaga	tcgcccggcg	cccgggggag	cgggtggaga	2100
ggggagcggg	gaggaggcgg	gggggttctc	catggtttagc	tatcagcagg	tgctttctga	2160
gtatctggag	agtctctcg	agatgcata	gcgtacagc	ttttagcaga	ttagggccct	2220
tatgcttcag	ccggggatg	atctgggg	gatgatagcc	cagcacgcca	aggtggagtt	2280
gcagccgggc	acggtgtac	agctgaggcg	cccgtatcacc	atccgcagca	tgtgttacat	2340
catcggaac	ggggccaaga	tcaagattcg	gggaaattac	acggagtaca	tcaacataga	2400
gccgcgttaac	cacatgtgtt	ccattgcggg	catgtggctc	gtgactatca	cggatgttgt	2460
ttttgatcg	gagctaccgg	cccggggtgg	tctgatttt	gccaacacgc	acttcatct	2520
gcacggctgc	aacttcctgg	gctttctgg	ctcgtaata	acggcgaacg	ccgggggggt	2580
ggtgccggga	tgctactttt	tcgcctgta	caaggcgtc	gaccaccggg	gcggcgtgt	2640
gctgacgggt	aacgagaaca	cggttggaaa	gtgtgtgtac	gcgggtgtct	ctgcggggcg	2700
ttgcaggatc	aagtacaact	cctccctgtc	cacccctgc	ttcttcaca	tgagctatac	2760
gggcaagata	gtgggaaca	gcatcatgag	cccttacacg	ttcagcgacg	acccctacgt	2820
ggacctgggt	tgctgccaga	gcgggatgtt	gatgcccctg	agcacacgtc	acatcgctcc	2880
ctcgctctcg	ctgccttacc	ctgagttcc	caagaatgtc	ctcctccgca	gcaccatgtt	2940
tgtggcggc	cgccctggca	gcttcagccc	cagccgtc	tcctacagct	acagctccct	3000
ggtgggtggac	gagcagtct	accggggct	gagtgtgacc	tgctgttgc	atcagacctg	3060
tgagatgtac	aagctgtc	agtgtacgga	ggcggacgag	atggagacgg	atacctctca	3120
gcagtaacgc	tgcctgtcg	gggacaatca	cccttggccg	caggtgcggc	agatgaaagt	3180
gacagacgc	ctgcgggccc	cccggtcc	ggtgagctc	aactggggg	atttcagcga	3240
tgacgatgac	tgaggatgag	tcacccctc	ccctcctt	gcaggtacgt	gcggggcccc	3300
agtggatgg	gctttggatg	ggggaggggt	gttccctata	aaagggggat	gggggtggag	3360
gcatgcaggc	ccacgggaa	gcttggatgg	aggatgtctt	ccgaggggt	gatccggacc	3420
tgcttcattt	cagctcg	tcccagctgg	gccggcgtc	gtcaggaggt	gcggggacg	3480
aatgtgaacg	gcggagtgg	gggcgc	gccagagcg	gggtgttgc	ctactccgc	3540
ttcgttcagc	agcaacagca	gcagccggg	acggcggc	cgggtctgt	gttccggggc	3600
gtgtttccat	cggtggatct	gagcgggag	gtgggcatg	tgccggaggc	gctggcggag	3660
ctgcggcagc	agctgcagga	gctgcggg	gtgggtgg	tacagctgc	gcacccggcc	3720
tcggaggcgg	ccgaggagga	agaggaggag	gagattgtgg	tggacgagga	gttggcgc	3780
ggcgcgtggag	cgaacaccat	ggaagaggag	gaggatgaga	tggtcctgac	gtgactgt	3840
gtgggggacc	ctgagcctc	tggagtggaa	gcccagccg	caccaccacc	cacccggag	3900
agcgaccctg	cggtgcctc	tactaccact	accccgaa	ggctcagcta	ccgcgcgagc	3960
aagaggagcg	gtccatgc	ggaggaca	tgacgcgg	tgtggggg	agaaggggg	4020
ggagggaaaga	agaccatgg	gacgggtgtt	tgtttttt	cagccaa	ttattgagaa	4080
taataataaa	gcttatggat	gttggaaac	ataatagc	gtccagcgtt	ctctgtctt	4140
cagggtctt	tgtatcttct	cgaggcac	gtagacctgg	tgttggacgt	tgaataatac	4200
gggcatgact	ccctcggcg	ggtgcaggta	aagccactgg	agggtgggt	gcggggggca	4260
ggtgcagtag	atgatccagt	cataggcgtt	ctgggtcg	tggtgggt	aaatgtcc	4320
gaggagcagg	ctgatggcg	tggcagacc	cttgggtg	gcattgatg	accgggttgc	4380
ctggggcggc	tgcatgaggg	gggacatgat	gtggtactt	gcctggatct	tgagggttgg	4440
gatgttgcc	ctctggc	ggcggggg	catgttgc	aggacgacg	gcacggcgta	4500
gcccgtgc	cggggaa	ggcgtcg	cttggagg	aaggcgtg	agaacttgg	4560
gaccctt	tgtccgccc	gtcctccat	gcactcg	aggacgatgg	cgatgggtcc	4620
gcggggcggc	gcgcgggc	agacgtgc	ttagtc	acatcatag	tgtgtcc	4680
catgagg	tggtagct	tgcggac	gtctgg	agggtggc	tctgggggat	4740
taggtgtgg	tccggacc	tgcggtagt	gcctcg	atctgg	cccaggcgac	4800
tacctctc	gggggatca	tgtccac	cggggt	aagaaaac	tctccggcg	4860
gggggagagg	agttgggagg	agatgagg	gcggagc	ttggacttgc	cgagccggt	4920
gggaccgt	atgacagcg	tgactgg	gacctgg	ttgagg	gcaggtg	4980
agccgggt	aggaaggcg	tgcaggcg	gagggtgtc	cgcaggt	gttctctt	5040
gacgagg	tgcaggagg	gtcggctc	caggagagg	aggtgg	gggaggcg	5100
ggcctt	ggcttgg	cctcggcg	gggcatgtc	ttggactt	cgagccg	5160
gcgc	tcccagag	cggttacat	tcccacgg	tcgtcctcc	gcaggtct	5220
ttgtttctc	ggttgggg	gtgcgt	tacgg	ggcgg	gtcgagc	5280
tggagggt	ggtcctt	gggcccgg	gcccgcgt	gggtgtct	gtgtacgg	5340
aaggggg	tctgggg	ctcggtgg	agggtc	tgagg	gcgggtgg	5400
ctgaagg	cgctcc	ctgcgtc	ttcagg	actgg	gagg	5460
gagagg	gggtgg	gcgt	gggttgc	gggtt	catag	5520
gcatcg	cggtgtcg	caggcg	cgaggctt	cgggccc	gtgccc	5580
ctgtgg	cgctcg	gac	cgac	gttctcg	cgac	5640
tgggg	ggggatcg	gac	cgagg	gttgc	gggttac	5700

ttggtctcca	tgagctcgcg	tccggcgccgg	gtgaggaaga	ggctgtcggt	gtccccgtag	5760
acggagcgca	ggggccggc	ggcgatgggg	gtccgcgggt	cgtcgccgt	gaggatgagg	5820
gcccactcg	agatgaaggc	acgcgcggc	gcgaggacga	agctggcgac	ctgcgagggg	5880
tagcggtcg	tgggcactaa	tggcgaggcc	tgctcgagcg	tgtggagaca	gaggtcctcg	5940
tcgtccgcgt	ccagaagtg	gattggtcgc	cagtggtagt	ccacgtgacc	ggcttgcggg	6000
tcggggggta	taaaaggcgc	gggcgggggt	gcgtggccgt	cagttgttcc	gcaggcctcg	6060
tcaccggagt	ccgcgtctcc	ggcgctcg	gctcgggctg	catctgtgg	cccgaggtct	6120
tcaggtgggt	acgctacgc	aaagtccggg	gtacactcg	cgctgagg	gtctgtttct	6180
atgaaggcgg	aggagcggac	ggagaggctg	ccgcggggca	tggctcggt	ggtgcggggc	6240
tccatctggc	tggcgaagac	caccccttta	ttgtcgaggc	gtgtggcga	actgcgttag	6300
agggcgttgg	agagaagctt	ggcgatgctg	cgagcggtt	gttttctgtc	ccggctcgcc	6360
ttttccttgg	cagcgatgtt	gagctgcacg	tagtctcg	cgaggcagcg	ccactcgggg	6420
aagatgttgt	tgcgtctcg	ccgcaggagg	cgacggccc	agccacgg	gtggagggtg	6480
accacgtcca	cgaggtggc	tacctcgcc	cgaggggct	cgttggtcca	gcagaggcgg	6540
ccgcccctgc	gggagcagta	ggggggcagg	acgtccagct	ggcctcg	gggggggtcg	6600
gcgtcgatgg	tgaagaggc	gggcaggagg	tcgggtcg	agtagctgag	gggctcg	6660
ccgtcgaggc	ggtctcgca	ggggcggg	gcacgggc	gtcgaaggg	gttgagggt	6720
tggccggcgg	ggaagggtg	gttgaggcg	ctggcataca	tgcgcagat	gtcatagacg	6780
tagaggggt	cccgcaggag	ggcgatgaa	ttgggttagc	agcggccg	gcmcaggc	6840
ttcgcggacg	tagtcataca	gctcg	ggcgcgagg	agttcg	gaggtgcgg	6900
gcctggggcc	ggctggcg	gtagaggagc	tgcgt	tggctgg	gttgagctg	6960
atggtggggc	tctgaaagac	attgaggcg	gcgtggggaa	ggccggc	cgtgtggac	7020
aaggcgcgtt	aggactctt	cagttcg	accagacgg	cgtgacg	gacgtcctt	7080
gcgcagtagc	gcagggtgg	ctggacat	tcgtaa	ccccctgg	ctccttctt	7140
cacaggtcct	tgttggagg	gtactcct	tcgtgt	agacttgg	gtgtggaa	7200
ccgtcctgat	cgcgtaa	gtccccctg	cgttaga	cg	atcgtaggg	7260
cagtgtccct	tgtccacgg	cagctcg	gccggcgg	c	gtgggtgt	7320
gtgagggcga	agggttccc	gaccat	ttgacgt	gtgtgt	gtcctcg	7380
gccatgacgc	cctcc	gtccgc	tcgcggc	ggcgg	gggttgg	7440
aggttgaagc	tgtatgtcatt	gaagaggat	cgccgtt	gcccgt	gtgcgggt	7500
accaggaagg	agggggc	ctcg	ttggcgag	cctgcgc	caggacg	7560
tcatcgaagc	ccgagatgtt	gtggcc	atgtagac	ccagga	ggcgcc	7620
cgcaggcggc	ggcgc	ctgg	gccagggg	c	gtccggc	7680
ccggggcccc	gctc	cagctcg	agg	tgtggcc	cagg	7740
cagaggggt	cggtgagg	ggc	gcgtgc	ggc	gtgcgg	7800
atggcgcgt	tctgcgg	gagcat	aa	ctcg	cagcgt	7860
ggcgggctt	ggacggcc	cac	gcgggt	gcag	gtcccc	7920
aggttgaaga	ccac	ggc	tgcttcc	agc	ccagg	7980
gtctccagg	catagg	gaagagg	cggtgc	gggg	gtgg	8040
aaggcgtt	tctgc	gtcgg	cc	gggg	gatgg	8100
cgccggcgc	cg	gtgg	tc	gg	gtaga	8160
tggcctcct	ggatgtc	gtatgt	gg	gg	gtc	8220
gggaagggg	ggcg	gggg	cc	gg	gtgtc	8280
tgggtgtgt	ggcg	cac	gg	gg	g	8340
accgcgtt	gggg	gtgg	gg	gg	cc	8400
aagaggttgg	ccagg	gtcc	gg	gg	gg	8460
tcctgggtgg	tgcc	g	gg	gg	gg	8520
ccggcctcc	cg	gg	gg	gg	gg	8580
cgggcgcgtt	cg	gg	gg	gg	gg	8640
tgacgcggcg	gtt	gtat	gg	gg	gg	8700
ctcggaa	ctt	gtt	gg	gg	gg	8760
gcaggatctc	gg	cc	gg	gg	gg	8820
cgagctcg	ctcg	cc	gg	gg	gg	8880
cgggtatcg	gtt	cc	gg	gg	gg	8940
tgttagacc	ctgg	cc	gg	gg	gg	9000
ccaccaggcg	gtt	cc	gg	gg	gg	9060
tggcgatgt	ctcg	cc	gg	gg	gg	9120
tgtcgcc	cc	gg	gg	gg	gg	9180
actcg	gtc	cc	gg	gg	gg	9240
ccgcctgc	cac	cc	gg	gg	gg	9300
cctttctt	ctt	cc	gg	gg	gg	9360

ctgcctccgc	ggggacgggg	ggcgcaggcc	ggggacggcg	ccggcgcaag	ggcagccggt	9420
ccacgaagcg	ctcgatgacc	tcgccccgca	tgccggcgcat	ggtctcggtg	acggcgccgc	9480
cgccctcccg	gggcccgcgc	tcgaaggcg	ccccgcgcag	cgccggcgcc	ctgcagaggg	9540
gcaggcgtag	cgcactgtat	atgcagcg	tcaactctct	cgtaggtacc	tcctgctgtt	9600
gcagcgctc	ggcaaactcg	cgcac	cttcggacc	ggcgaagcgt	tcgacgaagg	9660
cgtctagcca	gcaacagtcg	caaggtaat	tgagcgcgg	gtgcgtcggg	agccggaggt	9720
gccggctgac	gaggaagtga	aagttagccg	tctttagctg	ccggatggcg	cgcaggaggg	9780
tgagggtctt	gcccggcg	cgctgcaggc	ggatgcgg	ggccatgccc	caggcctcc	9840
gctggcagcg	gccgatgtcc	ttgagctgt	cctgcagcag	atgtgccac	ggcacgtccc	9900
ggtccggcgtc	cagggtgggt	cgaccgt	cccgccagg	gcccacgc	gccaggtcgg	9960
ccaccacgcg	ctcgccagg	atggccctg	gcatgcgt	caggaggtct	gagaagtcat	10020
ccagggtccag	gaaccgg	taggcggcc	tgtttaggt	gtaggagcag	ttgcccagca	10080
cggaccagg	gaccac	tagtgggct	ggatgac	gtgttagcgc	agtgcactgt	10140
aggcgccgt	gtcaaagat	taatcg	agaggcgcag	cagggtctgg	tagcccacga	10200
gcaggggg	cggagggt	aggtagagg	gcccgtt	cgtggccgt	tggcgggg	10260
agaggttcat	gagcatgagg	cgggtt	gttagatgaa	gcgggacatc	caggcgatgc	10320
cgacggcg	gacggagg	cgggtt	gttgggcgc	tttccaaatg	ttgcgcacc	10380
ggcggaaagag	ctccacgg	taatgatt	gccccgt	gcggg	tcgagggcgc	10440
tctgtcaaaa	agaaccgg	gtgggtt	gtgtgtgt	agcgatctat	cttctt	10500
gatcttggt	gtgaagc	ccaggctt	gcaggggg	tccgg	ttcctt	10560
ccctatctgg	agggtgt	ctgttctt	tttatttca	tgtagccat	catccc	10620
tgccggcagat	gaagccg	gcccgg	tggcgcgg	gggggcac	cgtctcggt	10680
cgccctcgcc	gtcg	cgcccg	aggaggg	ggcctgg	cggctgtc	10740
gcccggcg	ccccg	caccac	tgca	gcgagagg	atggagg	10800
atgtgcgc	gcaga	ttccgc	gaccgg	ggagggg	gagatgagg	10860
acctgcgg	ccgcgcgg	cgggagat	actggacc	ggagc	ctccagccc	10920
aggactt	ggggcgt	gaggagg	ggggagt	cgccgc	gcccacatg	10980
gcccggcc	cctggcc	gcctac	agacgg	cgaggagg	aacttccaa	11040
agaccc	caaca	cgcac	ttggcgg	cgagg	atggactg	11100
tgcac	ttgt	gaggc	tgcag	ccgg	cgctgacc	11160
cgcag	ctgt	cagact	ggacgagg	catgg	gaggcg	11220
tgag	cctgg	cgcc	tggtgg	gtgt	ctccagac	11280
ttgtgt	ggag	atgac	tcgac	ggcgg	aactact	11340
tgccgac	cttgc	ta	atgac	cc	cgccgg	11400
tgaag	gtgt	gaca	actgg	gtat	ctggag	11460
ttgtc	gggg	ctcg	gttgc	gttgc	ccgc	11520
cgccg	ccgg	cg	gggg	gggg	gggg	11580
gaggagg	gggg	cgagg	gggg	gggg	gggg	11640
aggagg	gggg	aggagg	gggg	gggg	gggg	11700
gcagt	cccc	ctgact	gggg	gggg	gggg	11760
tttaaca	aca	acagc	gggg	gggg	gggg	11820
agcgcgg	ccctgg	cgac	gggg	gggg	gggg	11880
gagc	ttgg	agcagg	gggg	gggg	gggg	11940
ttcgc	ggcc	accc	gggg	gggg	gggg	12000
cgcac	ggcc	cgac	gggg	gggg	gggg	12060
gccat	ccgg	cgac	gggg	gggg	gggg	12120
tacaac	aggc	gcaac	gggg	gggg	gggg	12180
atcgcc	cgct	gcaac	gggg	gggg	gggg	12240
ttcatcg	ccgt	ac	gggg	gggg	gggg	12300
agcgc	ggct	gggt	gggg	gggg	gggg	12360
cacac	tgc	gggg	gggg	gggg	gggg	12420
gagaac	ggcc	gggg	gggg	gggg	gggg	12480
tccct	gtca	ccgg	gggg	gggg	gggg	12540
atgaac	ggcc	ctac	gggg	gggg	gggg	12600
gccaact	gtcg	atgt	gggg	gggg	gggg	12660
ggcgac	ggcg	ggcg	gggg	gggg	gggg	12720
cagcgg	ccgt	ggcg	gggg	gggg	gggg	12780
gtcgac	ggcg	gtac	gggg	gggg	gggg	12840
gacgagg	ccgt	ggcg	gggg	gggg	gggg	12900
cgcc	acta	tgc	gggg	gggg	gggg	12960
gtcct	gatgg	cccg	gggg	gggg	gggg	13020
gagcagg	gggg	gggg	gggg	gggg	gggg	

ctcatgtgc	ggtcgcgc	ctcctcagag	ccctcctct	ccttaccc	cctgcccc	13080
accgaggagc	cgccctcg	gccctccacc	ccggccct	cgcgcgtccc	gtcccg	13140
tcctccctgc	tctctctggc	ctctctgg	aagcgggagg	gagggactc	gtctcg	13200
tcgcccggca	cgcccaccta	tggctctcg	tgggctcg	gccgctcc	cctggcc	13260
ggcgcggaca	gcctggagtg	ggacgcgt	ctggccct	ccaaggatgt	gaacgag	13320
ccaggcgccg	ccgcggccg	ccgcgcgc	gcctcc	cctccctgg	ggaggacatc	13380
gacgccatca	gcagccg	gttaccc	cgcacgc	cccaggagat	gggcctg	13440
gtggccagct	tctcccgccg	ccaccagg	cgccccggg	ccctcga	cgacgaggag	13500
gaggaagact	ggcgc	ccggttctt	cgcttcga	cgccccggg	aaaccc	13560
cgccacatcg	cccccaaggg	gctgtatgc	aaaaaaagca	aataaaaaac	ccctccc	13620
ccaactcacc	acggccatgg	ttgtcctgt	gtgcccgt	gatgaggagg	atgatgc	13680
cagcgc	gcagggagcg	tcgcctcc	cgtcctac	gagtgtgg	gggtctt	13740
tcacggagcc	tcttatgt	ccggcgc	acctgggccc	caccgagg	cggaac	13800
tccgttattc	acagctcc	ccgtctac	ataccaca	gatctatct	atcgata	13860
agtcggcg	tatgc	ctgaa	aaaacaacca	cagtactt	ctcacc	13920
tgg	tcagaa	cagcact	acgccc	aggcgag	gcagacc	13980
agcgc	ctggggc	gagtt	aaaaa	gcattct	caccaac	14040
ccc	actat	gttcag	agttcc	tgcc	gagcgc	14100
caa	atgccc	cac	ttgtc	cgagg	gataa	14160
tcg	gggtcat	cgac	tcgc	gat	ggggc	14220
agc	aggggt	caagg	gacat	tgaa	ggggc	14280
gct	atgac	ggag	ctgg	gac	ttccgc	14340
ccg	acgtgt	ggtgc	ccgg	cc	tacc	14400
tgc	ccat	ccgc	tcgact	tttccc	aca	14460
tgg	ggcat	ccgca	tcacc	aggagg	ctg	14520
tgg	gggg	caacat	tcgc	ac	ctat	14580
gcac	ccatcaa	gccc	tcgc	agg	gac	14640
ccg	aggc	ggac	tcgc	actact	actac	14700
acc	ccac	gggc	tcgc	actgtgt	ccgc	14760
tgg	agcgt	ctact	tcgc	tgat	ccgc	14820
gcc	agac	gag	ccgt	ccac	actgc	14880
cct	tacaa	cacc	gtgt	actc	cc	14940
tgg	ttaa	ccgc	tcc	cct	ctcc	15000
cct	ccat	cgaa	cc	tcgc	cc	15060
gc	atcccc	gg	taacc	ccgc	cc	15120
tgt	acaag	tct	gtgac	ccgt	cc	15180
cag	ccct	cc	gggt	ctcg	cc	15240
cgt	tacc	cg	gag	actgg	cc	15300
ccg	ccct	cc	ttgg	cc	cg	15360
cgt	tccg	cc	act	ggcc	cc	15420
ggc	gcgc	cc	tcac	cc	cc	15480
gtt	gggg	cc	ggcc	cc	cc	15540
gggg	acccc	gtgg	ggcc	gg	cc	15600
cac	ccgg	cc	ggcc	gg	cc	15660
cct	ccgaaa	cgca	cct	gggt	cc	15720
tga	acaagt	catcc	tcc	ttt	cc	15780
gtt	gc	ac	gtt	cc	cc	15840
aaa	aggag	gtt	ggc	gg	cc	15900
agg	acgt	gc	gg	gg	cc	15960
agc	gggg	gg	gg	gg	cc	16020
gg	acgg	gg	gg	gg	cc	16080
gtt	tcgg	cc	gg	gg	cc	16140
tc	tcc	cc	gg	gg	cc	16200
agc	gggg	cc	gg	gg	cc	16260
atg	acgt	cc	gg	gg	cc	16320
atg	gtt	cc	gg	gg	cc	16380
tgg	ccgt	cc	gg	gg	cc	16440
ccat	gg	cc	gg	gg	cc	16500
ccgc	cc	gg	gg	gg	cc	16560
tgc	cc	gg	gg	gg	cc	16620
gcat	cc	gg	gg	gg	cc	16680

gcccggccgc	ggcgctggag	cgggcggcgg	ccgcccgtgcc	cctgcaccgc	gacacggagg	16740
acgaccttgt	ggagatggca	gaggctgtcg	ccgcgcggca	ggtgcgtccc	agcctccccc	16800
tctccatcat	gccggccacc	gccacggagg	tggccctgcc	cgtacagacc	caactggcgc	16860
ccgtggcggt	ggccaagagc	tccctgaccc	ccggcctccg	cgcgctgatg	ggcaccgagc	16920
gggtgccggt	tccagtcctg	gaggcgcggc	tggtgccat	gcccgctc	cgggccacca	16980
ccgcccgtgc	cgagcccccg	cgccgctgac	cccgccaggc	cgtgcggac	atccccggca	17040
ggcagccccg	cacgtatcc	ctgcccgtgc	tcacggagcc	cgccccggcc	accgcggctcg	17100
cctccgtgcg	cgcggcagcc	caagtctgc	aggcgcggcc	cgcccggcc	gccaccgtct	17160
ccgtgggggt	gggcaccgag	ccggtggtgc	agtccatcac	ggtcaagcgg	tcaaagcgcc	17220
tgaccaagca	ccatcggggt	gcagaccatc	gacgtcaccg	tgcccaccgt	cgcactgtc	17280
agcgtggcga	ccaacacgc	ccggctgagg	agcgcctcg	tggcgctcca	gaccgctccc	17340
gagaccgc	cccaggggg	gcaggtggct	ttccaaccag	cgtctagcc	caccgcacac	17400
ccagggcagt	gcccgtgac	gcccgtggc	ccccccaccc	gcccggcc	gtgggtccgg	17460
tggccggcg	cccgcggcg	ttccggtgcc	tcccccagcc	cctccagccc	cgccgcgcg	17520
gcgtgcgc	cgcgc	gagcgcctcg	gcgtcgccgc	cgtaccccg	tggcggtggc	17580
agcgcgc	gcccgc	gcccgtggc	ccctctggc	gccgaggcgg	cccatcg	17640
tgcccgggt	gcccgtatcat	cccagtca	ccatggctcc	caccgc	cgcgtcatct	17700
ggcgttgatt	tattttgga	gacgtgact	tgttgcgttc	cttaaattt	ttatcctc	17760
cctccctctgc	tgaagccaga	cgatgctgac	ctaccgggt	cggctcc	tgcggatgc	17820
gagaccgaga	ctccgcgg	gttccgcgt	ggcgcctcg	cgcagggcgg	gcaggcggc	17880
gtaccgcgg	ggccgatga	gggtggcat	cctgcggcg	ctggtgc	tcatcg	17940
atccatctgg	gccatcccc	gatcgcc	ggtggcgt	agtgc	aacgcaatta	18000
acggcgtgc	tgtgtatgt	tgttccat	gtgccttc	tccttc	ccaacggaa	18060
agcagcac	tctccatg	ggaccta	tttccgcgt	tggctcc	c	18120
cggccgg	tgggcact	gagcgaat	ggcacgag	agatgaa	ccgcgc	18180
agctggag	atatctgg	cggtgt	actttgg	gttct	ctccacgg	18240
aacaaggc	ggaacagcg	gacgtgac	agcgtgc	acaagg	gatgccc	18300
gtgcagg	agataggt	gtcatt	tccgggt	acgg	gacgtgg	18360
aaccaggc	tctccac	cgtggacc	cggtgca	gcagc	aggc	18420
agctctcg	ccagcag	caacagat	gcctcg	accct	gagatgg	18480
cagacgag	gcctcc	ccgaggacc	tctgc	tcctc	ccgcgc	18540
cctcgcc	tcccgc	caatccc	ggacgt	ccaag	gcgc	18600
aggagat	catccgc	gacgag	ctcc	agag	ctgac	18660
ccggat	cgccac	gagtcg	ccgag	actgc	gtgg	18720
ataagat	cccc	ccgctc	ccaccac	ctcc	ccgc	18780
ccgccc	cccc	cctgtcg	gggtc	cgcg	ccgc	18840
cgcgag	caaagg	ccaggt	gtcc	gccc	aaaca	18900
aacaccat	tggact	tgtccg	tgaag	gtcg	tgtt	18960
cagcatgg	aaacaaca	gtctgg	aaataa	accgtc	ccac	19020
ctccgc	tgttattt	aacgg	ttcctt	atctct	gtgc	19080
cggg	cgcaggat	cgacgc	gatgat	cgtgt	atatgc	19140
ctccgg	gacgcgt	agtac	tccgg	gtcag	ttccc	19200
ggagac	ttaaac	acaaca	tagga	accgtc	ccagg	19260
tgtgac	gagcgt	agcgg	gctcg	gtccc	gtgg	19320
cactcag	acataca	ccgc	gctgg	ggc	acaagg	19380
catggc	acctt	acatcc	ggat	gac	gggacc	19440
gtactcg	accgcgt	acatcat	tccaa	gctcc	actgt	19500
tctagac	aaagg	ctgagg	caaag	accat	gtc	19560
tgtgg	tct	ccacgg	tat	acatt	gc	19620
gaccac	atgc	atgag	acc	gat	actgc	19680
caata	tctgc	gccc	acc	gttca	atcg	19740
acctt	gtt	ccat	cgt	ccaa	actgt	19800
caagg	tac	ttaca	cc	gac	gttgg	19860
aatgg	aagg	tcacc	ctc	gac	gttgg	19920
tactc	atc	tgc	ca	ggat	gttgg	19980
acagg	cc	ccat	cc	gtca	atcg	20040
gtact	ac	acat	cc	gac	atcg	20100
ggtgg	tc	agg	cc	act	atcg	20160
ctat	gac	ggat	cc	gtt	atcg	20220
tgtgc	tcg	ggat	cc	acc	atcg	20280
cgcc	aaa	atgg	cc	ggat	atcg	20340
ccgc	accatc	gagacca	tgacatt	acag	atcg	

aagagccaca	acctggacaa	aggagaatgg	ggatgatggc	ggaaacggag	cggagcacta	20400
cctgggcattc	ggcaacctca	acgccatgg	gatcaatctc	acggccaacc	tctggcgcaag	20460
cttcctctac	agcaacgtgg	cgctgtacct	gcgtgacaag	tacaagttt	ccccggccaa	20520
cgtccccatc	gaccacaaca	cgcactocta	tgactacatc	aacaagcgcc	tgccccctcaa	20580
caacctcatt	gatacctttg	tcaacatcg	ggcgcgctgg	tccccggatg	tcatggacaa	20640
cgtcaacccc	ttcaaccacc	accgcaacta	cggcctgcgc	taccgctccc	agctcctggg	20700
caacggccgc	tactgcaagt	tccacatcca	ggtgcgcgaa	aagtctttg	ccctcaagag	20760
cctgctgctc	ctgccccggg	cgacctacac	ctacgagtgg	tccttccgca	aggacgtcaa	20820
catgatcctc	cagttccacgc	tgggcaacga	cctccgcgcg	gacggggcca	aatcaacat	20880
cgagagcgtc	aacctctacg	ccagcttctt	tcccatggcc	cacaacaccg	cctccaccct	20940
ggaggccatg	ctgcgcacag	acaccaacaa	ccaaacccctt	attgacttcc	tctccctccgc	21000
caacatgctc	tacccatcc	cggccaacgt	caccaacctg	cccatctcca	ttcccagccg	21060
caactggccc	gccttccgcg	gctggagctt	cacgcggctg	aagcacaacg	agaccccccgc	21120
cctgggctcg	cccttcgacc	cctactttac	ctactcgggc	tccatcccct	acctggacgg	21180
gaccttctac	ctggccaca	ccttccgcgg	catcagcatc	cagttcgact	cctccgtg	21240
ctggccgggc	aatgaccgc	tgctcaactcc	caacgagttc	gaggtaaagc	gcaccgtg	21300
cggggagggc	tacacggtgg	cccagaccaa	catgaccaaa	gactggttcc	ttgtgcagat	21360
gctcgcccac	tacaacatcg	gctaccaggg	ataccacctg	ccagagggt	accgcgaccc	21420
cacctaactcc	ttcctgcgc	actttgagcc	catgtgcgc	caggtgcggc	actacgc	21480
ccacaaagat	gagtacctgg	aggtgcccac	caccaaccag	ttcaacagca	gcggctttgt	21540
atcccgccgc	ttcacccgc	gcatgcgc	ggggcaccca	tacccgc	actggcccta	21600
cccgctcatc	ggcgaagacg	ccgtgcagac	cgtgacccag	cgcaagttcc	tctgcgaccc	21660
cacgctctgg	cgcatccccc	tctcctccaa	cttcatgtcc	atgggcaccc	tcaccgac	21720
gggcccagaac	ctcctctacg	ccaactcggc	ccacgc	gacatgac	ctcgagg	21780
cgcctatggat	gaacccaccc	tcttgtatgt	tctgtcgag	gtcttgac	tctgcggcgt	21840
gcaccagccg	caccgaggcg	tcatcgaggc	cgtctacctg	cgcacccct	tctccgcgg	21900
gaacgcccacc	acctaaggcg	gagccgcg	ggcatggca	gcacccgag	cgagctccg	21960
gccatggcgc	gcaacccctca	gtgccccgc	ttcctggca	ccttgc	acccctccg	22020
ggcttcttc	aagagtccca	gctgctgtc	gccatcg	acacgc	ccgcccacacc	22080
ggaggccgccc	actggctggc	cgtgcctgg	gagccgcct	cgcgcac	ctacttctt	22140
gacccttcg	gtttctccg	ccggagctc	gcccagg	atgacttga	gtaccag	22200
ctgctgcga	agagcgccat	ccagagcacc	ccggacc	gcctc	acgc	22260
acccagagcg	tgcagggacc	gcacagcgc	gcctgcgg	tcttctgc	ccttcc	22320
ggcccttgc	cccgc	cgacagcccc	atggcctaca	atcccgtcat	gacac	22380
gagggcgtgg	acaacgagcg	gctttcgac	gccgacgtcc	agccatctt	ccgc	22440
caggaggcct	gctacgcgtt	cctcgctc	cactccgc	acttccgc	ccacc	22500
gccatcatgg	aacagacaca	cctgcacaaa	gctgcgata	tgcaataaag	gtttttatt	22560
gtaagtcaaa	aaggcctt	ttatcctccg	tcgcctggg	gtgtatgt	atgggggac	22620
taggtgaacc	cgga	gtcg	ctccatcccc	tcttctctca	aaacagg	22680
tcatcgctgt	cctccgttcc	cacgggaa	atgggttct	gcac	ctggggccc	22740
cacttgaact	cgggcaccgt	cagtggaggc	cgcgtctg	tcagg	ccacatctgt	22800
ttggtagat	gcagggccag	catcacatcg	ggggcgt	tctt	gaaatc	22860
tgggggttgc	cgcgcgaccc	gcgttacacc	gggtttagc	actgg	acac	22920
gggtgggtca	cgcgtggcc	aatcttggg	tcttccacca	gctgggg	tttgc	22980
gaccgcgtca	gcgcgaaggg	ggtgatctt	caggtctg	ggccc	acgc	23040
ccgcagccccc	agccgcagtc	gcacacc	ggcatcag	ggtgc	gttgc	23100
atccgggggt	agcaggc	ctggaaagcc	ttgagct	cgaagg	ctgcgc	23160
gagccctccg	agtagaagag	gccc	caggac	cgc	ccgcacccc	23220
acgtcg	tgcaacacat	ggccccgtc	ttgcgc	gac	ccgc	23280
cggttgggtgg	tgatcttgc	gcgtc	gggt	ccgc	ccgc	23340
ctgtttagat	ccatctccac	cagctgtc	ttgtt	gatc	ccgc	23400
tgcagccct	ccgaggcgt	gcgg	gtgt	ccat	ccgc	23460
ggcgttcc	gaccgc	cgtc	cagat	ccgc	ccgc	23520
agcaggc	tttgcgt	gaagg	tggc	acgt	ccgc	23580
gcttgggccc	cgcgcggaa	gcactcc	cagg	ccgg	ccgc	23640
ttgacatcca	ccttc	gtgt	ccgt	cagg	ccgc	23700
ttctgctct	gagcatcc	tgca	gac	ccgc	ccgc	23760
gggcgcgggg	ggcgggccc	ctcc	tcc	ccgc	ccgc	23820
cgcgcgtcg	ccgtgc	ctctt	cagcc	ccgc	ccgc	23880
ttggcacgcg	cgcgttcc	ccgc	tgc	ccgc	ccgc	23940
cccccgcc	ggctgggg	cgc	gac	ccgc	ccgc	24000

ccgctgtcat agtcagacac gtccgaatag cggcgactca ttttgcgttcc cctagatgga 24060  
 agaccagcac agcgcagcca gtgagctggg gtccctccgc gccccgaccc ttccgcccgc 24120  
 accaccgcgc ccacctccgc ccacgtcacc gccaccttca ctgcagcgc ggcagcagga 24180  
 gcccaccgaa accgatgacg cggaggacac ctgctcctcg tcctccctcg cctccgcctc 24240  
 cagcgagtgc ttegtctcgc cgctgaaaga cacgagctcc gaggactcg gggacacggt 24300  
 gctccctcc gagccccgac gggacgagga ggagcaggag gaggactcgc cgcaccgcta 24360  
 catggacgcg gacgtgctgc agcgccaccc gctgcgcag agtaccatcc tgccgcagg 24420  
 cctgcaggag gcccgcgc ggcgcagccg ggaggccgc gaggccct cggtgccgga 24480  
 gtcagccgc cgccctgaaag cggccctctt ctccccccgc acgcccgc ggcgcagg 24540  
 gaacggaacc tgccgcgc gccccccct caacttctac ccgttcttca tgctgcccga 24600  
 gcccctggcc acctacctcc tcttcttca caaccaaaag atccccgtca gtcgcgcgc 24660  
 caaccgcccc cgagccgacg cgcaactgcg gctgcccagt gggacccct tacctgacta 24720  
 tccaaccacc gacgagggtt acaagatctt tgagggcctg ggggacgagg agccggcctg 24780  
 cggcaaccag gacctgaaag agcgcgacag cgtttagtgc gagctcaagc tggacaaccc 24840  
 ccgcctggcg gtggtcaagc agtgcacatcg cgtcaccac ttcgccttacc cggccctg 24900  
 gtcgcaccc aaggtcatga gcacgctcat gcagaccctg ctggtgccgc ggcgcagg 24960  
 actcccccac gaggggcgaga cggccctcgaa ggacccctcg gtggtcagcg acgagcagct 25020  
 gggccgctgg atgcacaccc tggacccca ggtcctggag gaggccgcgca agaccgtcac 25080  
 cggccgcctgc atggtcacgg tgcaacttca ctgcacatcg accttcctca cttccgcga 25140  
 gatggtgccgc cgccctcgag agtgccttca ctacatgttcc cggccaggct acgtcaagct 25200  
 agctagcaag atcgccaata tggaaactctc taacctggtcc tcctacttgg gcatgctgca 25260  
 cggaaaacagg ctggcgtcgc acgtgcctca ccacaccctc aagcatgagg cgagacgcga 25320  
 ctacgtcccg gacaccattt acctataacctt ggtctataacc tggcagaccg ccatgggggt 25380  
 ctggcagcag tgcctcgagg accgaaacctt gcgccctcg gaaacgtctc tggctcgcc 25440  
 tcgccagagc ctgtggacgg gctttatgaa gcgcactatc gcgcaggacc tggccgcgtt 25500  
 cttttccccc accaagctcg tagagaccctt gcagcgctcg ctccccgact ttgccagcca 25560  
 gagcatgatg catgccttcc gtccttcgt ctcgagcgc tccggcatcc tgcccgcgt 25620  
 ctgcaacgcg ctccctctg actttgtgcc caccgtctac cgcgagtgcg cggcccccct 25680  
 ctgggctcac tgctacatcc tgcgcctcg ccaacttctc atgtaccact gcgcacatcg 25740  
 cgaggacacc tccggcgagg gccttttga gtgtactgc cgctgcaacc tctgcgcacc 25800  
 gcaccgctgc ctggccacca acaccgcct cctcaacgcg gtgcaagcca tcaacaccc 25860  
 tgagctccag cggcccccacca agccgcacgg caccctgcca cggcccttca agctgacc 25920  
 cggctctcg acctccgcctt tcctccgcctt cttgtctcc gaggactacc actcggacc 25980  
 catcctcttc tacgaggacg tgccccccccc ccccaagggtg gagccctccg cctgcgtcat 26040  
 cacgcactcg gccattctcg cgcaatttgc tgacatcaaa aaggccagg aagagtttt 26100  
 gtcgacccaa ggcacggcg tctacctaga ccccccacacc ggagaggacg tcaacaccgc 26160  
 cggcccgctcc accgcccacc atgcgccttcc tccggaggaa gcccattccgc agcagcacc 26220  
 gcaccagcag cagccgagcc accgcccgcg ccaccaccgc tccagctacg cagaccgtgt 26280  
 cccaaaggcg acctccgcctt acggcggtgc gaccggttcc tcccgccacc ctgtctctgg 26340  
 cggatgctctt ggcacggaa cccactcccg cgatgctgtc cgaagaagag gctctcagca 26400  
 gggagaccag cggcagctcc gaaggcagtt tgctcagttac cctcgaggaa ctggaggagg 26460  
 aggaggaacc ggtcacaccg acgaggccat ccaagccctc tccacaccaac agcagcagca 26520  
 gcaagagcat cagccagcgc aggaactccg tcgtccccag cgaggctcg agatggaaatc 26580  
 agacatccat ccacccggat agccagccag gtggacacc tccgcctcg gcccgcgc 26640  
 gtcctggcg ccgctaccgc cacgacatcc tctccgcctt ggagtactgc gccggagacg 26700  
 gagcctgcgt ggcgggtac ctactctacc accacaacat caacatccct tccaagatca 26760  
 tccgttacta caaatccctt tcccggttcca gcatcttca ggaaggccgc agcagcggcg 26820  
 gcagcagaac cagccacgt cagccagctg agagctaaatc tcttcccttcc gctgtacgccc 26880  
 atcttccagc agagccgcgg cggccaggac gcctcaaaa tcaggaaccg caccctgcgc 26940  
 tccctccacca agagctgtct gtatcaccgc gaggaggcca agctggaaacg caccgtctcg 27000  
 gacgcagaag ctctcttgcgaa gaaatctgc gctcggcgc ggcagaccgg cccgtattta 27060  
 aggagccggac cctgcgtgcg gacacaccat gagaaacaa atccccccctt cgtacatgtg 27120  
 gtcttatcag ccacaatctg ggcgtccgc cggcccttcc gtcgattact ccaccgcac 27180  
 gaattggctc agtgcgggac cttccatgtatggccaggatc aatgacatcc gacacacc 27240  
 gaaccagatt ctcatttgcg aggcccttccat caccgagacg ccacgccccg tccaaaatcc 27300  
 cccgtcttgg cccgcacgt tggcccttca gatgacgcgaa ccgcggccacc acctgcaccc 27360  
 gcccgcgtac gaaatttgg aaggcagact gactgacgcg ggcacatgc atggccgggg 27420  
 cggagccctc gcacccagag acttatatgc cctgaccctc cggccggcagag gcatccag 27480  
 caacgaggac ctaccctctt cggcggacac tcccgccgg gacggcatct tccagctcg 27540  
 aggccggaggc cgctcttccct tcaacccac ccacgcctac ctgacgctgc agaactccag 27600  
 ctcccttccc cgcacggcg gcatcgccag cgaccaattt gtcggcgagt tcgtgcccac 27660

ggtctacatc aacccttct	ccggaccgcc	cgggacctac	cccgaccagt	tcatcgccaa	27720
ctacaacatc ctaacggact	ctgttagcagg	ctatgactga	cggtccccag	gtcagcagc	27780
ggctgcggga gctccctcgac	cagcaccgccc	gccagtgccc	taaccgctgc	tgcttcgcca	27840
gggaagggat tcacccggag	tacttttgc	tcaccccgca	gcacttttag	gccgagtgca	27900
tccccgactc tctgaagaa	ggccacggtc	tgcgcttcag	cctccccacg	cgctacagcg	27960
accggccgcca cccgcatgg	gaccgcacca	tcctcacttc	gtactactgc	gccctgtctt	28020
ctttcaaagt tcgctgtctc	tgccggccatc	ctgctccctca	ccctcttctt	ctcgacaccc	28080
tgtgtgagct gtacaaccgc	tcgttagcg	agcccctaca	cctccctcg	cggtccaaattt	28140
ctgtccgaca tagaaccaga	ctctgactct	tactcgggct	ctggctctgg	gacgatgaa	28200
gattatgaat atgagctgg	taccaacaca	ccgaacgaaag	acattctagg	cagcatagtc	28260
atcaacaacc agatcgggcc	caagaccctg	gccctgggat	acttttatgc	cgccatgcag	28320
tttgtcttctt ttgcacatcat	catcatcg	ctcatccct	actaccgccc	ctacgtgctg	28380
gccaccgccc tcatcg	gcccagatg	tggtcctccg	aggccgtct	gcccggaaaacc	28440
ttctcgccca cccgtgtgt	tactccccca	aaacaagtca	ccccctgcaa	ctgctccctgc	28500
cgcttcgagg agatgggtt	ctactacacc	acccctcg	tcatgccc	gtgggcctca	28560
tcctcctgtc caccgc	gtccgcctgg	ccaaactggat	agtggatcag	atgcccagca	28620
ggaaccgcgc cccgcgc	ccaccgc	tcacctatgt	gggaccctgc	gccgaggacc	28680
acatctacga tgagccaacc	gtagggcaat	acgtacagat	gaagtagctc	cccctcttc	28740
ccatcccccc atttttctct	attcaataaa	gttgcttacc	ttagttc	cacactcg	28800
ctgccagtgc agtctatcca	tgccgcgtt	tccatactca	catagcgc	ccgcgcacgc	28860
ctcgccagggt gacgaaactg	tgcgaaatgt	acatttcg	cttctgtc	cagcacc	28920
ttatagacca gttccaccat	gggaccgaag	aagcagaagc	gcgagctacc	cgaggacttc	28980
gatccagttt accccat	cgtccgc	ctgcagatca	atccacc	ctgcagcgg	29040
gacggattca accaattccgt	ggacgggg	ctgtccctgc	acatgcacc	ccccctcg	29100
tttgacaaca ccagggcc	caccctggcc	ttcggggag	gtctacagct	ctcgggcaag	29160
cagctcg	ttgcccaccg	gggctgggg	ctaaccacca	accggatgg	29220
ctcaaagtca agtccccat	caccctgacc	gccgagg	tctcc	ctgggtccc	29280
ggtcttcta actcagagac	cggcctc	ctgcagatca	cagcccc	cgagttccag	29340
ggcaacgc	cctcgcc	ggtctccaaa	acaccatgg	tggatgggt	29400
gtcaaactgg ggagcggt	caccacgg	aacagtca	cggtgacc	tcaagg	29460
aatggacttc agtgaacgg	cgaagg	ctcaccgtc	ccgcac	ccctttagtc	29520
tcagggagcg caggcat	tttcaactac	tccagcaatg	acttc	ctt	29580
agtctcagg	tgaggccaa	ggccatct	gtcacc	cgctc	29640
acaatctccc tgaattattc	taacgactt	tctgtggaca	atggc	ccct	29700
ccaacttca aaccctacac	gctgtggact	gggcctc	ccacag	caaa	29760
acaaacacca ccactccaa	ccgcac	ttcctatg	tgacac	gtgtgggtt	29820
gttttgggtt ctttgc	gaaatcatc	atcgac	ctag	tatgac	29880
aattttattt ttgatgggc	aggtcg	cgact	ccacttataa	agggagattt	29940
ggatttagat ccaacgac	cgtaattgaa	cccacag	caggact	tccagc	30000
ttaatgcca	gcac	ttatcc	ac	cc	30060
gtatacat	atc	tgtc	gacat	taaa	30120
ggatata	tagaattt	cttcaaa	atgac	ccgc	30180
tacgggac	tctgtac	gcccc	acaact	cc	30240
agtctcagg	agcgcagg	tctt	ctact	cc	30300
tgacagtctc	agtttgg	caaagg	cat	ctcg	30360
ggacacaatc	ccctg	attct	ctt	gtc	30420
ggctccaact ttcaacc	acacg	gtctgt	gact	ggcg	30480
tctaaca	acc	cc	cc	cc	30540
gttagttt	gttcc	ccctg	atccat	cc	30600
ggtcaattt	atttt	atccat	gttca	cc	30660
atttggattt	agatccaa	ggc	gact	cc	30720
ctggtaat	cca	ttat	ttc	cc	30780
atttgtatac	attaa	catat	tgt	cc	30840
aaacggat	agc	tta	actt	cc	30900
ctcctac	ac	ttc	cc	cc	30960
gcctcc	cc	cc	cc	cc	31020
ctccc	cc	cc	cc	cc	31080
aaagccaga	agac	cc	cc	cc	31140
aaaataaaga	ctc	cc	cc	cc	31200
ttgattcagg	ttgg	cc	cc	cc	31260
atcagacagg	ggta	cc	cc	cc	31320
gttaaggaca	gcgc	cc	cc	cc	

tgctggtagc	taacactcct	tcccaacacc	atacactcct	ggagggccct	ctgcctctcc	31380
tcctcccgct	ccgcgtccct	ctggccggac	caccactccc	cctccgtcaa	ctgctgcttc	31440
ctccccccgccc	gctgcgcccc	gatggcctcc	gcgcgcagct	tcagccagtg	ccgcaagcgc	31500
tgggcgcagc	gcccggccac	cggctcgctc	agtcgtggc	agcgcggca	caccagcact	31560
atgtaattgg	catagtcccc	gtcacagtag	atgacctccc	cccagtggaa	catgcgcaac	31620
agcttcagat	cacagtata	catgatctt	atgtacatca	ggtggcgc	tgcggaaacatc	31680
acactgcccc	cgtacatcac	gcfactcacg	ctgggcaggt	tcaccgcctc	cctgaaccac	31740
cagaagatgc	gattgtactc	gcagccccgg	atgatctcgc	gcatcaggga	gcccgcaccc	31800
acctgcccc	cgcggcactc	cagactggac	ctttcagac	agtggcaatg	aaagttccac	31860
agcgtcgcgc	ccgcacagcg	tctccggct	gaaacatata	tgctccagct	ccaacccccc	31920
acacaggctg	tactgcagga	aaatccattc	ttgatggaa	aggatgtac	gccaggggac	31980
cacaatctcc	aaacagggaa	caaaacatac	cgccggccgg	ctgtgcgc	cgccccccac	32040
cggatgcac	gtgctcacgg	agcagatacg	ggtgggacag	cgccccacgt	ctcatagcaa	32100
gtcaagtccg	gaagtggcac	ggggttcgcc	accactgcta	ctgctgcgc	tgcgcacca	32160
gctccatcg	ctcctccatc	ctcctctgt	tccatcggt	gaggtgctgc	ctcctctcc	32220
tcctgcccgt	gctccatcat	gctcgctgc	ggtcatcagg	agtcaaaaaa	ttcattggcc	32280
accgcacgca	gagagaacat	ggagcgcagg	ggcccgagg	cccggccgt	gcccgcgc	32340
aactccccca	gcaggtaactc	atagagatgc	tcctccaaat	ccaccgcaaa	ccaggcatgc	32400
agaaaactctt	ccgttcgagg	accgcacacg	gtaaagacat	agccctccc	cacccatcacc	32460
gctgccagct	gcacgcgc	atgtcgctgg	gagtagacccc	ggacccggc	ctggatgtac	32520
tccagcacct	gatcgctcag	acacctcaca	gagatgcccag	cctgagccag	tttctcatag	32580
agaggtggct	gaatcttgc	cttgaagcag	cgagcggcta	ggcactcccc	ggccccccttgg	32640
aacaggccgg	ccgggtcagc	catggacttc	ctctacatcc	ggggtcctgg	ccacccatcaca	32700
aactatctgg	ccaatcgcc	gaccacgggt	caccaggtaa	ggatgatgtc	ctttgttgcg	32760
aatgagaatg	ctcagaggtg	actcggtagc	gttatcaatc	acgtccccaa	aggtccaaag	32820
gtcccagtt	gaagtccagg	gtttcagacc	gcagacacgc	ccatagcaac	cagtggaaa	32880
agccagcaag	agatccgtgg	gcacatgcac	cgaagctccc	gcaggaatct	ccacccactc	32940
cgaggcgtag	accgtgtaa	ctacacaccc	cgccctcccga	gtgggagcag	aaggattctc	33000
gctcagccga	aagaacttca	gggtggctg	catatcctct	tttactact	ttttagcagc	33060
tccacacaga	ccagggttgt	gttggcgaaa	ataggcagca	gggttacgtc	cccagtggagg	33120
gacaccttgg	tgggggcag	aggattgtat	ccaggaagca	gcaggtactg	ggaaacagag	33180
accagatccc	tcctctgaaa	aatctcgctc	agtcggacaa	acacagcaaa	cccagtggc	33240
acgttagacta	gcacattaaa	aaggatcact	ctgggctgtt	ctgacgtcag	caccagatgt	33300
cgggacgtgc	gcagatgaat	gcgggcttgc	tgaattaccg	gaggcctctc	acccgcagcc	33360
aacagcagac	cgggctgtc	atgcggtccc	gcagacatat	atgagttcaa	tgtgtgtt	33420
ttttctaaac	gtcttagtgc	tgtgctcg	ctgctcctgc	caatcaaaat	ccgggcacca	33480
gggctgggtgg	ttggacccga	tgaagaagcg	aggagaggcg	gcctcctgag	tgtgaagagt	33540
gtcccgtatcc	tgccacgcga	ggtaggcgaa	gtacagatacg	agcacggcga	gaacagtca	33600
caccgcggcc	agcagcagtc	gtcgtggc	catgagaggg	ggctgatggg	aagatggccg	33660
gtgacttc	tcgccccgt	ttcggttct	cctcgctc	ctctcgtgt	ctctctctgt	33720
gtcagcgcgg	agacagatgt	gagcgaacac	cgcgagcgg	ccgggtat	acccacagcg	33780
gatgtggcca	cgcctgcgt	cgttaatca	gtacccatc	gtccgatcg	attcccccg	33840
cctccgcgtt	aacgattaa	ccgcccagaa	gtccccggaa	ttcccgccag	ccggctccgc	33900
cgcgacactgc	gactttgacc	ccgccccctcg	gactttgacc	gttcccacgc	cacgtcattt	33960
tcccacgcga	cgtcacgttc	ccacgctacg	tcacacccct	ctccaccaat	caccgcggc	34020
cgcggccaaac	cctctccgc	aatcaccac	ccacaaaagg	ggcaataaaa	gtgtgcggta	34080
tattattgt	gtat					34094

<210> 2  
 <211> 44  
 <212> DNA  
 <213> Porcine Adenovirus Type 3

<400> 2

gcggatccctt aatataacatc atcaataata taccgcacac tttt

44

<210> 3  
 <211> 32  
 <212> DNA

<213> Porcine Adenovirus Type 3  
<400> 3  
cacctgcaga tacacccaca cacgtcatct cg 32

<210> 4  
<211> 32  
<212> DNA  
<213> Porcine Adenovirus Type 3  
<400> 4  
cacctgcagc ctcctgagtg tgaagagtgt cc 32

<210> 5  
<211> 20  
<212> DNA  
<213> Porcine Adenovirus Type 3  
<400> 5  
gactgacgcc ggcatgcaat 20

<210> 6  
<211> 27  
<212> DNA  
<213> Porcine Adenovirus Type 3  
<400> 6  
cggatcctga cgctacgagc ggttgt 27

<210> 7  
<211> 27  
<212> DNA  
<213> Porcine Adenovirus Type 3  
<400> 7  
cgatccata cgtacagatg aagtagc 27

<210> 8  
<211> 20  
<212> DNA  
<213> Porcine Adenovirus Type 3  
<400> 8  
tctgactgaa gccgacctgc 20